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Abstract of the Dissertation
The Splice is Not Right: Splice-site-creating Mutations in Cancer Genomes

by
Reyka Jayasinghe
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Genetics and Genomics
Washington University in St. Louis, 2018
Professor Li Ding, Chair

Accurate interpretation of cancer mutations in individual tumors is a prerequisite for
precision medicine. Large-scale sequencing studies, such as The Cancer Genome Atlas
(TCGA) project, have worked to address the functional consequences of genomic
mutations, with the larger goal of determining the underlying mechanisms of cancer
initiation and progression. Many studies have focused on characterizing non-synonymous
somatic mutations that alter amino acid sequence, as well as splice disrupting mutations
at splice donors and acceptors. Current annotation methods typically classify mutations
as disruptors of splicing if they fall on the consensus intronic dinucleotide splice donor,
GT, the splice acceptor, AG. Splice site mutations as a group have been presumed to be
invariably deleterious because of their disruption of the conserved sequences that are
used to identify exon-intron boundaries. While this classification method has been useful,
increasing evidence suggests that splice site mutations can lead to transcriptional
xii

changes beyond disruption and that many exonic mutations that act primarily through
alternative splicing are still being overlooked in cancer genomics. My thesis work focuses
on developing tools to systematically classify and functionally validate splice site and
splice creating mutations using RNA-Seq data, to more accurately understand the
functional consequences of mutations on alternative splicing by integrating DNA and
RNA-Sequencing data.

First we developed SpliceInator, a semi-automated tool to systematically detect splicing
phenotypes using mutation and gene expression data. We interrogated 1,146 conserved
splice site mutations across 19 cancer types revealing a wide range of complex splicing
phenotypes and emphasize the importance of analyzing patient specific RNASequencing. We further explored beyond the splice site by interogating all mutations in a
splicing context using MiSplice for the first large-scale discovery of splice-creating
mutations (SCMs) across 8,656 TCGA tumors. We reported 1,964 originally misannotated mutations having clear evidence of creating novel splice junctions. Mutations
in a subset of genes including PARP1, BRCA1, and BAP1, were experimentally validated
for splice-creating function using a mini-gene splicing assay. Notably, we found
neoantigens induced by SCMs are likely several folds more immunogenic compared to
missense mutations, exemplified by the recurrent GATA3 SCM. Our work highlights
importance of integrating DNA and RNA data for understanding functional and clinical
implications of mutations in human diseases. Finally, to further capture the full landscape
of SCMs, we explored both somatic and germline mutations for splice-site-creating
function using MiSplice. Altogether, we have gathered a set of 2,888 SCMs enabling us
xiii

to effectively compare the landscape of rare and germline SCMs. This compendium of
SCMs has also started to elucidate novel genomic properties of mutations located at the
donor and acceptor splice site and SCM containing exons including an overall decrease
in the size of the novel exon post mutation, mimicking a natural evolutionary selective
pressure but exploited in the cancer genome to maintain proper alternative splicing. To
date, this is the first analysis comparing rare germline SCMs and somatic SCMs revealing
their comparable dysregulation to the splicing code in cancer. Together my thesis work
revealed that splice-site-creating mutants play a much larger role than previously
appreciated in contributing to cancer and further expands our understanding of the
genetic basis by which mutations can alter the mRNA landscape by dysregulating
alternative splicing. More broadly, my work calls for a deeper analysis of seemingly
“silent” mutations in any disease as such mutations may alter gene function via alternative
splicing and integrating RNA and DNA-Seq can allow for accurate evaluation of mutations
in a splicing context.

xiv

Chapter 1: Introduction
1.1 Cancer Cell Fitness

Introduction: Cancer, the second leading cause of death in the US, will cause an
estimated 609,640 Americans deaths in 2018. The scientific community has come to the
conclusion that cancer is a “disease of the genome” but deciphering the origins of cancer
is still an evolving field of research. Over time, cells acquire random mutations, many of
which have no effect, some with deleterious effects, and a few that confer a selective
advantage that allows the cell to grow faster than neighboring cells (Stratton et al., 2009).
After a cell acquires a set of genomic alterations that allow it to grow freely, resist cell
death, escape normal signaling, and acquire the properties of immortality, metastasis and
angiogenesis, the cancer cell can form a malignant mass that is harmful to the host
(Hanahan and Weinberg, 2011).

Type of Mutations: Mutations can be germline or somatic in nature. Germline mutations
are inherited from parents or acquired de novo. Somatic mutations are acquired
throughout an organism’s lifetime in individual cells due to genetic and environmental
factors, such as chemicals and radiation. Most of the damage in the DNA is repaired, but
sometimes the alterations are fixed. Acquired mutations include point mutations (single
nucleotide variants / SNVs), insertions, deletions, larger copy number aberrations (CNA),
1

or large scale structural variation (SV). Mutations in genic and regulatory regions can
affect gene function in several ways by causing loss or gain of function, altering transcript
splicing, and increasing or decreasing gene expression level. Epigenetic changes on
histones and DNA, (such as methylation etc.) have been shown to play a central role in
turning genes on and off, and are known mechanisms of dysregulation in cancer (Chen
et al., 2014; Maunakea et al., 2013; Rajagopal et al., 2014). In combination, such
variations can disrupt normal gene function and alter cellular response to regulation giving
the cell a selective advantage to proliferate autonomously.

Passenger and Driver Mutations: Genomic changes contributing to cancer can be placed
into two categories: driver and passenger events. Driver mutations confer a growth
advantage to the cell (under selective pressure) and are positively selected for during the
development of the tumor. Novel bioinformatic analyses of large scale sequencing data
have helped to infer pathogenic/driver and passenger mutations. Lu et al. analyzed allelic
imbalance to identify potential initiating germline mutations in cancer (Lu et al.). In a study
to identify rare germline truncation variants in 12 cancer types from The Cancer Genome
Atlas (TCGA), variants with a higher variant allele fraction (VAF) in the tumor compared
to the normal tissue were hypothesized to have undergone positive selection in the tumor.
More recently, our lab expanded on this analysis by expanding to a larger cohort of 10,389
samples and expanded the landscape of known pathogenic drivers in a subset of cancer
types (Huang et al.). Passenger mutations are those that are acquired in somatic cells
but do not increase or inhibit cellular growth potential. These mutations can occur prior
to, during, and after tumor initiating mutations but most are present prior to the
2

accumulation of driver mutations (Stratton et al.). Since they are present prior to the driver
event, when the driver mutation does confer a selective advantage to a cancer clone, you
may observe passenger mutations “hitch-hicking” with the driving clone. Alternatively,
initiation mutations are events that confer an advantage to the disease, but require
cooperating mutations for developing disease phenotypes. Xie et al. identified initiation
mutations in DNMT3A, ASXL1, TET2 and other genes associated with myelodysplasic
syndrome (MDS), myeloproliferative neoplasm (MPN), chronic lymphocytic leukemia
(CLL) and acute myeloid leukemia (AML) (Xie et al., 2014). These mutations were
identified in patients without overt hematological malignancies suggesting that they may
initiate clonal expansion but alone are insufficient to result in the development of cancer.
Since this publication, there have been several novel studies that have expanded on this
analysis by evaluating the presence of initiation mutations in the general population, but
at extremely low variant allele fraction. This finding has appropriately initiated an entire
cancer genomics field and spurred the development of novel sequencing technologies to
accurately classify low level variants relative to background noise (Wong et al.; Young et
al.).

Tumor Suppressors and Oncogenes: Cancer drivers can be categorized as tumor
suppressors or oncogenes. In 1979, Oppermann and colleagues linked the neoplastic
transformation of cells by avian sarcoma virus to a phosphoprotein with kinase activity
encoded by src(Oppermann et al.). This report identified the first oncogene, a gene where
an alteration to one allele could contribute to the malignant tumor phenotype and cellular
transformation. In 1984, RB1 was identified as the first tumor suppressor gene (TSG), a
3

gene with suppressor or regulatory function(Murphree and Benedict). TSGs commonly
require mutation or inhibition of both alleles in order for cellular transformation to occur.
According to Knudson’s “two hit hypothesis”, patients carrying a germline mutation in a
tumor suppressor are more likely to develop cancer since a second random somatic
mutation affecting the wildtype allele in any cell is much more likely to occur than two
random mutations in a non carrier(Knudson). The “two hit hypothesis” is a tale as old as
time and is still commonly referred to in the literature as a method to identify putative
cancer predisposition genes in large genomic datasets(Park et al.).

Large Scale Cancer Projects: With the first cancer genome sequenced in 2008, the
amount of sequencing data in cancer genomics has increased dramatically, supplying the
scientific community with a gold mine of data to process, analyze, and refine. Several
large scale projects have taken the initiative to integrate genomic data and genome wide
annotation tracks allowing multiple teams to work together and pour their efforts into
determining key genes and pathways that contribute to cancer. The Cancer Genome
Atlas (TCGA) is a project that collected expression, methylation, RNA and DNA sequence
data for matched tumor and normal samples across 33 distinct cancer types. The
International Cancer Genomics Consortium (ICGC) seeks to provide genomic,
transcriptomic, and epigenomic data across 50 different tumor types. The Pediatric
Cancer Genome Project (PCGP) is a collaboration between St. Jude Children’s Research
Hospital and Washington University School of Medicine in St. Louis whose goal is to
determine genetic changes that give rise to childhood cancers. The Clinical Proteomic
Tumor Analysis Consortium (CPTAC) has expanded off the analyses and projects of the
4

cancer genome atlas to expand the integration of omics data beyond the transcriptome
and to the proteome and phosphoproteome. These projects are just a few of the many
large-scale projects that are aimed at identifying the genetic origins that contribute to the
development and progression of various forms of cancer.

Pan-Cancer Studies: With the accumulation of large-scale genomic data across tissues
types due to the aforementioned large scale-cancer projects, some labs have dedicated
their entire research focus on pan-cancer analyses. The goal of these pan-cancer
analyses is to glean important and relevant signatures and patterns among many patients
to determine and define cancer by molecular subtype in order to expand and properly
design personal therapies across cancer types (Cancer Genome Atlas Research et al.;
Cooper et al.; Hoadley et al.; Huether et al.; Kandoth et al.; Sveen et al.; Vogelstein et
al.). Currently, small sample sizes for individual cancer types limits our statistical power
to identify more infrequently mutated driver genes. To address this problem, TCGA lead
the effort in emphasizing the importance (statistically and biologically) to compare
samples across multiple cancer types to identify infrequently mutated sites that are
potentially driving cancer development. Initial findings from pan-cancer studies included:
the identification of 127 significantly mutated genes across 12 cancer types(Kandoth et
al.), which has more recently been expanded to a list of 299 cancer related genes (Bailey
et al.). The identification of rare germline pathogenic variants including an analysis across
12 cancer types and subsequently 33 cancer types(Huang et al.; Lu et al.). While the
TCGA phase has wrapped up, the upcoming phases, which will expand into the clinic to
guide personalized medicine, is going to be a very exciting new direction for the field and
5

will bring novel genomic applications directly to the clinic. While these aforementioned
pan-cancer analyses have elucidated many differentially mutated regions in the genome,
it is important to remember all sequencing projects are limited by the mutational load of
the tumor of interest.

1.2 Alternative Splicing and Disease

The potential for phenotypic variability within an individual species is encoded and
dictated by the underlying genomic. Understanding how differences in gene architecture
can alter a gene’s function is essential to understanding many biological questions
including disease diagnosis, progression, and treatment. To understand genomic
variability, we will briefly discuss the genomic differences between species, evaluate how
the genome has evolved in multicellular organisms, and discuss how mutations can lead
to disease.

The Splicing Code: One of the characteristic differences between unicellular and
multicellular eukaryotic organisms is the difference in genomes. The central dogma of
biology postulates that DNA is transcribed to RNA which is then translated to proteins
that perform most functions within the cell. This central dogma lead scientists to realize
that certain segments of DNA were not transcribed into RNA or translated in the final
protein structure. Instead, transcribed regions of the DNA (exons) were often interrupted
by longer segments of DNA that were systematically removed from the RNA (introns) to
6

generate the final sequence that is shuttled for protein translation. In 1978, Walter Gilbert
hypothesized different combinations of exons could generate multiple mRNA isoforms
from the same pre-mRNA molecule (Berget et al.; Chow et al.; Gilbert; Modrek and Lee,
2002). This hypothesis has come to be known as alternative splicing, the process of
joining exons or coding sequences, and splicing out introns.

There is still active debate regarding where in our evolutionary history introns arose. The
introns early (IE) hypothesis suggests that introns are ancient structures but were lost in
intron-poor species such as prokaryotes (Irimia and Roy; Roy and Gilbert). In opposition,
the introns late (IL) hypothesis postulates certain species like eurkaryotes gained introns
due to insertion events after the divergence of prokaryotes and eukaryotes. Complicating
this question more, intron-rich and intron-poor species are interspersed throughout the
eukaryotic branch, suggesting massive intron gain or loss could lead to the diversity of
genomic sequences present in eukaryotes.

The average human transcript contains approximately 8 introns. Current studies suggest
that between 70-95% of human genes harbor multiple mRNA transcripts(Johnson et al.,
2003; Matlin et al., 2005; Modrek and Lee, 2002). Alternative splicing expands the
complexity and information content of the eukaryotic genome and allows for tissue,
developmental, or temporally expressed isoforms which can perform alternate functions.

The splicing code is made up of cis-acting elements that help the splicing complex
distinguish between non-coding and coding regions and facilitates the joining of exons
7

and exclusion of introns (Wang and Cooper, 2007). The consensus intronic dinucleotide
GT splice donor and AG splice acceptor flank spliced exons at the 3’ and 5’ ends
respectively, and can be found in 99% of all introns. Intronic and exonic splicing enhancer
(ISE and ESE) and suppressor (ESS and ISS) elements influence the splicing complex
to target true splice sites and pseudo splice sites (Supek et al., 2014b) (Ast; Bonomi et
al.; Faustino and Cooper; Keren et al.; Matlin et al.). The spliceosome is responsible for
joining exons and splicing out introns to form the mature mRNA molecule. The
spliceosome is made of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5
and U6, along with a number of other proteins. The U1 snRNP interacts with the 5’ splice
site (5’ ss), splicing factor 1 (SF1) identifies the branch site, and the U2 auxiliary factory
(U2AF) binds the polypyrimidine tract and the 3’ splice site (3’ ss). Additional proteins that
facilitate the splicing process include SR proteins (SR) which bind to ESEs and interact
with U2AF. Mutations in splices sites and enhancer or suppressor sequences can
ultimately contribute to a pathogenic phenotype by altering the binding affinity for
spliceosomal or associated proteins.

The splicing process is dynamic and occurs co-transcriptionally. For this reason, genomic
context alone cannot begin to describe the efficiency of the splicing code. But we still
need to start somewhere.

RNA polymerase II transcribes DNA to create the nascent mRNA molecule. As the
molecule is transcribed, the spliceosomal machinery is recruited to facilitate the removal
of introns and the joining together of exons. RNA polymerase transcriptional dynamics
8

can be influenced by underlying genetic architecture. For example nucleosomes are
commonly found positioned on exons which have a high GC content. The median length
of exons are coincidently very close in size to the length of genomic DNA that wraps
around histones, suggesting an added selective pressure on maintaining an exon size of
rougly 140 bp. Nucleosomes are made up of 8 core histone proteins which contain histone
tails that have post-translational modifications (PTMs). PTMs can influence both RNA
polymerase transcriptional dynamics and RNA processing by attracting necessary
splicing factors to facilitate proper splicing. For example the H2A.Z histone 2A variant is
known to promote splicing of non-consensus introns in S. cerevisiae (Herzel et al.; Neves
et al.).

Splicing alterations and cancer development: Splice alterations have been shown to affect
the landscape of mRNA isoforms present in both tumor and normal tissues (Wang and
Cooper). Mutations in cis can directly affect the use of a splice site or promote the use of
an alternative splice site facilitating exon/intron inclusion. The production of inappropriate
transcripts in a particular tissue type can result in disease due to its alternate function.
Mutations in canonical splice sites have been linked to several diseases, for instance: A
familial study found in hSNF5, when the consensus GT dinucleotide is mutated to an AT,
a deletion of exon 7 occurs. This germline mutation was observed in both affected and
unaffected family members, but infant brain tumors in affected members showed a loss
of the wild-type allele in the tumor(Taylor et al.; Venables). In colorectal and liver
metastases, a 3’ splice site mutation from AG to AT leads to a loss of the adjacent exon.
Furthermore a loss of the wild type allele in the tumor suggests that this isoform is under
9

positive selection in the tumor (Kurahashi et al.). In another familial study, a single intronic
base change formed a cryptic splice site resulting in the addition of 11 nucleotides to the
tumor suppressor BRCA1 gene creating a truncated protein(Findlay et al.; Hoffman et
al.). Less studied are mutations in less conserved intronic regions. In ATM, a mutation at
the 6th position of an intronic region is linked to breast cancer but only causes a proportion
of transcripts to form a truncated protein(Broeks et al.).

All of the above studies are one-off cases where a resulting phenotypic effect was
observed in an individual which led to the discovery of the mutation inducing the aberrant
splicing pattern. Bioinformatic heavy labs are starting to group similar splicing alterations
to evaluate genomic signatures that can predict the resulting phenotypic changes. Below
we will describe some of the recent novel findings in the field that have started to broadly
characterize the normal and mutation induced splicing landscape across populations.

The global effects of mutations on splicing variation is now being widely studied in largescale RNA-Seq consortia. Rivas et al. predicted the effects of protein-truncating variants
on the transcriptome by utilizing data from the Genotype-Tissue Expression (GTEx) and
Geuvadis projects (Rivas et al., 2015). Both projects allowed the team to quantitatively
evaluate allele specific expression of 13,182 mutations in healthy individuals, primarily
focusing on nonsense and splicing mutations. Their findings identified variants within the
splicing region with significant splice-disruption events and confirmed their findings in a
separate dataset of common variants in Swedish individuals.
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Using the same dataset, a recent publication evaluated the level of “deleterious-ness” of
mutations near the splice-site to determine a more refined definition for the splice-region
(Zhang et al., 2018). In addition to the canonical GT and AG sites, the study found one
base in the exon and four bases into the intron after the canonical GT (donor) and the
first exonic base adjacent to the AG (acceptor) site are mutation intolerant. Additionally,
co-occuring mutations were less likely to occur suggesting one mutation in one of the
aforementioned sites was enough to perturb the splicing pattern. Additional studies
identified synonymous driver mutations in key oncogenes, and found that nearly half of
all synonymous driver mutations affected splicing, specifically last base exonic mutations
(Supek et al., 2014a). Together, these findings suggest that synonymous driver mutations
likely also contribute to cancer through altering alternative splicing.

Shiraishi et al. developed SAVNet to evaluate somatic variants that induced splice altering
variants across 31 cancer types in the TCGA cohort (Shiraishi et al., 2018). The authors
found that the smoking signature (C>A substitutions) contributed largely to the variants
characterizing splicing differences followed by APOBEC.

Cummings et al. used paired transcriptome analyses for patients with undiagnosed
muscle disorders and identified recurrent splice-site-creating variants in collagen VIrelated dystrophy and predicted functional variants in mutation-rich genes such as TTN
(Cummings et al., 2017).
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Several studies have tried to integrate computational predictions and massively parallel
splicing assays to gain new insight into the splicing code. Soemedi et al. evaluated 4,964
single nucleotide variants via a massively parallel splicing assay (MaPSy) (Soemedi et
al., 2017). Approximately 10% of variants were confirmed in vitro and in vivo to disrupt
splicing but their assay is limited in only being able to evaluate mutations in exons that
were less than 100 nucleotides in length.

Mutations in Trans Elements & Cancer: Mutations in trans-acting elements or splicing
factors will affect a larger subset of genes by disrupting the biological machinery that
helps to recognize exons and introns. The most well studied splicing factors include
serine/arginine-rich (SR) proteins and heterogenous nuclear ribonuclear proteins
(hnRNPs)(Kaida et al.; Matlin et al.). SR proteins bind to ESE’s and ISE’s and promote
splicing and inclusion of exons by recruiting spliceosomal proteins. The family of hnRNP
proteins function as splicing silencers by binding to ESS’s and ISS’s. SR proteins in
particular are shown to be differentially regulated in cancer and play a role in
neoplasia(Fregoso et al.; Kaida et al.). These splicing elements have been shown to
function in a position dependent fashion(Lim et al.). SR proteins are usually bound in
exons while hnRNPs are found in introns, but modifications that lead to altering the
splicing elements binding sites has been linked to their opposite function. Cis mutations
that affect binding of hnRNPs and SR proteins can drastically change whether exon
usage is promoted or suppressed. An initial study showed that many disease alleles
should be classified as splicing mutations even though they were mis-classified as
missense mutations because of the motifs that were changed near the splice site(Lim et
12

al.). Using the pan-cancer dataset by TCGA, more motif alterations can be elucidated and
linked to splicing alterations.

Mutations in enhancer and silencer sequences can also affect isoform expression
because of the proteins that associate with them. Variants in BRCA1 (Walker et al.),
SMN1/2, PDHA and GH are known to cause exon skipping by disrupting the ESE
sequence(Woolfe et al.). This same study showed that splice altering variants (SAVs) are
enriched in regions near the splice junctions. Exon skipping SAVs are characterized by a
loss of ESE and a gain of ESS while variants with increased exon inclusion are
characterized by ESS loss. Alternative isoforms are linked to a number of different
diseases which have been shown to contribute to drug resistance, tumor angiogenesis,
metastasis, and misregulation of apoptosis(Woolfe et al.). Tools are still needed to identify
the functional significance of somatic and germline splice altering mutations within the
coding and noncoding regions of a gene.

While the field has made great strides in classifying variants that disrupt alternative
splicing, interpreting all variants in a splicing specific context has still been largely ignored
in large scale sequencing projects. Variant classification and interpretation is fundamental
to understanding the biological consequences of mutations on a gene of interest. If
variants are not properly annotated, the biological interpretation is incorrect. Currently,
mutations are classified based on their changes to the resulting protein. The degenerate
nature of the genetic code whereby 61 codons represent 20 amino acids allows
nucleotide changes to affect the sequence of mRNA while leaving the amino acid
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sequence of the resulting protein unchanged. “Silent” mutations that do not change the
amino acid are still to this day commonly overlooked in cancer genomics. A study
analyzing mutations in the CFTR gene showed that synonymous mutations could alter
splicing by leading to the use of a cryptic splice site or by altering the 3’ splice site of exon
9 which results in a truncated protein product(Niksic et al.; Wang and Cooper; Wilschanski
et al.) Another recent study showed that synonymous mutations were enriched in
oncogenes and some tumor suppressor genes in a cancer type specific manner (Supek
et al., 2014a). Furthermore, this study found many recurrent “synonymous” TP53
mutations are inactivating events that alter canonical splicing of the mRNA. These studies
suggest that some seemingly “silent” mutations can affect gene function by modifying
splicing, transcription factor binding, or other properties that contribute to mRNA
translation(Sauna and Kimchi-Sarfaty, 2011). Using known exonic and intronic mutations
that activate cryptic splice sites, Lee et al. developed a machine learning classifier to
predict whether a mutation would disrupt alternative splicing (Lee et al., 2017).
Interestingly, in analyzing variants in CFTR, 70% of the 47 variants tested, were predicted
to be missense variants suggesting many splicing alterations are mis-annotated in wellknown disease-related genes.

The previously mentioned studies all emphasize the importance of evaluating
synonymous and nonsynonymous mutations across cancer types in order to uncover
potential pseudo or non-canonical splice sites that are currently being overlooked in
cancer genomics.
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My thesis work focused first on generating bioinformatic tools that systematically classify
splice site and splice-site-creating mutations by integrating DNA and RNA sequencing
and experimentally validating the predicted consequences of the variants using a minigene splicing assay. In Chapter 2, I helped develop SpliceInator a semi-automated tool
to systematically detect splicing phenotypes using mutation and gene expression data.
SpliceInator, combines two lines of evidence to assess mutant specific aberrant splicing
events and their implications, one based on interpretation of RNA-Seq fragment mapping
using TopHat and another based on standard statistical hypothesis testing of RSEM
expression values. We interrogated 1,146 conserved splice site mutations across 19
cancer types revealing a wide range of complex splicing phenotypes. 521 variants in our
dataset conferred a measurable splicing alteration, with 69.29% associated with only one
splicing defect, while the remaining were a combination of two to four different splicing
events. Another 624 splice site mutations did not confer any measurable splicing defects
but 75.6% were classified as having a low variant allele fraction, low exon expressivity or
both while 24.8% were undetermined. Furthermore, synonymous and non-synonymous
variants genome-wide were evaluated in a splicing context and we discovered 243
mutations that create and strengthen nearby alternative splice sites, respectively, further
justifying the demand for a tool that can systematically evaluate all mutations in a splicing
context. To meet this demand, in Chapter 3 we developed MiSplice for the first largescale discovery of splice-creating mutations (SCMs) across 8,656 TCGA tumors. We
report 1,964 originally mis-annotated mutations having clear evidence of creating novel
splice junctions. TP53 and GATA3 have 26 and 18 SCMs, respectively and ATRX has 5
from low-grade gliomas. Mutations in 11 genes including PARP1, BRCA1, and BAP1,
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were experimentally validated for splice-creating function. Notably, we found neoantigens
induced by SCMs are likely several folds more immunogenic compared to missense
mutations, exemplified by the recurrent GATA3 SCM. Further, high expression of PD-1
and PD-L1 was observed in tumors with SCMs, suggesting candidates for immune
blockade therapy. Our work highlights importance of integrating DNA and RNA data for
understanding functional and clinical implications of mutations in human diseases.

Finally, to further capture the full landscape of SCMs, in chapter 4 we evaluated both
somatic and germline mutations for splice-site-creating function using MiSplice.
Altogether, we have gathered a set of 2,888 SCMs enabling us to effectively compare the
landscape of rare and germline SCMs. Interestingly, we found mutations overlapping the
splice donor site were sufficient to disrupt the canonical splice site but this phenomenon
doesn’t hold true for acceptor splice site mutations in our dataset. Alternatively acceptor
SCMs needed to not only strengthen the novel splice site to facilitate the novel site usage,
but also disrupt the canonical splice site. This compendium of SCMs has also started to
elucidate novel genomic properties of SCM containing exons including an overall
decrease in the size of the novel exon post mutation, mimicking a natural evolutionary
selective pressure but exploited in the cancer genome to maintain proper alternative
splicing. To date, this is the first analysis comparing rare germline SCMs and somatic
SCMs revealing their comparable dysregulation to the splicing code in cancer. Evaluating
mutation induced events separately from patient specific de novo events can provide a
focused analysis on the genomic features selecting for SCM+ exons relative to leaky
splicing or mutation independent cryptic splice site activation. As tissue type specific
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datasets continue to increase, developing novel tissue specific signatures will help inform
the tissue type specific relevance of mutation induced SCMs. Together my thesis work
revealed that splice-site-creating mutants play a much larger role than previously
appreciated in contributing to cancer and further expands our understanding of the
genetic basis by which mutations can alter the mRNA landscape by dysregulating
alternative splicing. More broadly, my work calls for a deeper analysis of seemingly
“silent” mutations in any disease as such mutations may alter gene function via alternative
splicing and integrating RNA and DNA-Seq can allow for accurate evaluation of mutations
in a splicing context.
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Chapter 2: Complex patterns of splice
site mutations
Contribution: I scripted and developed the full code for the TopHat Module and partial
code to the Expression Level Module and Rule Based Classifier of SpliceInator.

I

manually reviewed all variants validated by our computational tool, performed
downstream analyses and created all Figures other than 2.1A.

2.1 Introduction
Large-scale sequence-based studies are increasingly examining the functional
consequences of human genomic variants(Dees et al.; Ding et al.; Hoadley et al.; Huether
et al.; Kandoth et al.; Wang and Cooper; Xie et al.), with many focusing on characterizing
somatic coding mutations and their amino acid sequence alterations in order to
investigate the underlying mechanisms of cancer. Splice mutations are of particular
interest because of their dramatic modifications of mature RNA products, including
possible retention of large intronic segments and loss of whole exons, coupled with
significant downstream consequences for associated surviving proteins. With respect to
cancer, splicing alterations can affect both tumor and normal tissues(Wang and Cooper),
but determining their functional consequences within and outside of the canonical splice
site is still understudied in cancer genomics(Barbaux et al.; Broeks et al.; Holmila et al.;
Kurahashi et al.; Steffensen et al.; Venables; Woolfe et al.). By one estimate, around 22%
of disease causing alleles are mis-classified as missense mutations because they alter
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motifs near the canonical site utilized by the splicing machinery. Especially relevant to
cancer are synonymous mutations that can be enriched in oncogenes and some tumor
suppressor genes in specific cancer types(Supek et al.). Several recurrent mutations in
cancer-associated genes, such as TP53, were found to be inactivating events, altering
canonical mRNA splicing. Silent and missense mutations can also affect gene function
by modifying splicing, transcription factor binding, or other aspects of mRNA translation
(Sauna and Kimchi-Sarfaty). These studies show that mutations in cis can directly affect
the use of a splice site, or promote the use of an alternative splice site, thereby facilitating
exon skipping or intron inclusion. There is a growing appreciation of the need for reliable
splicing analyses to identify alternative biochemical pathways that are causative in
contributing to the disease state(Dorman et al.; Lim and Fairbrother; Mort et al.; Rivas et
al.; Steffensen et al.). It is likely that many, perhaps most of these pseudo or noncanonical splice sites are currently being overlooked in cancer genomics.

Given the biomedical importance of splice-affecting mutations, a bevy of analysis tools
has been developed over the last few decades. Early entrants, including Gene
Splicer(Pertea et al.), MaxEntScan(Yeo and Burge), Splice Site Finder(Shapiro and
Senapathy), NNSplice(Reese et al.), and Human Splicing Finder(Desmet et al.) sought
mainly to identify splice site mutations, but methods have increasingly added new
analysis capabilities. For example, tools like Skippy(Woolfe et al.), SpliceTrap(Wu et al.),
DEXSeq(Anders et al.) use RNA-Seq data to discern differential exon usage and exonskipping and SpliceSeq(Ryan et al.) added significant visualization aids. Algorithms are
becoming progressively more ambitious, for example SpliceR(Vitting-Seerup et al.) and
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SplicingTypesAnno(Sun et al.) attempt to characterize a broader set of events
encompassing intron retention and various exon extensions and contractions.
Calculations often depend on tally-based heuristics and ad-hoc rules. The overall problem
of comprehensively characterizing splice mutations and their downstream implications
remains unsolved.

Research increasingly suggests that splice architectures are complex and their
implications for cancer are significant(Ast; Bonomi et al.; Faustino and Cooper; Keren et
al.; Matlin et al.; Modrek and Lee; Taylor et al.; Venables; Wang and Cooper) . A number
of specific mechanisms have already been observed. For example, variants in BRCA1,
SMN1/2, PDHA and GH cause exon skipping by disrupting an exonic splicing enhancer
sequence(Walker et al.; Woolfe et al.). Mutations near pseudo splice sites can also result
in activation, for instance the c.190 mutation in BRCA1(Yang et al.), which appears to be
under positive selection in the tumor. This mutation is a clear example of a predicted
“missense” event that actually functions as a modifier of splicing efficiency in vivo and
points to modified alternative splicing as a more important effect in cancer than has been
previously appreciated. Importantly, we found that standard annotation tools did not
properly identify this variant as splice altering.

Given the importance of splice effects in cancer and the lack of a purely algorithmic
solution for finding and characterizing them, we applied a semi-automated approach to
this problem based on large batches of case-control RNA-Seq data that are now
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available. We apply this method here to examine 1,146 candidate mutations over 19
cancer types and describe several novel findings.

Figure 2.1: SpliceInator Workflow. The SpliceInator workflow can be grouped into two main modules
and post processing analyses. In Module 1, case and control RSEM expression values are compared
using standard statistical hypothesis testing to classify intron retention and exon skipping events. In
Module 2, BAMs are processed with TopHat using RNA-Seq fragment mapping to identify mutant specific
alternative splice junctions to classify intron retention, exon skipping, exon shrinkage and exon extension
events. In the post processing steps, a rule based classifier is used to derive support from module 1 and
module 2 to classify variants with associated splicing defects. Second, quantile analysis is performed to
group genes into expression classifications in a tissue specific manner. After processing, users can
compare variants to predicted splicing defects to infer the functional consequences of each variant in a
splicing context. The right-hand column highlights several thresholds and internal tests that are utilized
in SpliceInator that can alter which steps are run for each module. For example, if read count thresholds
are not satisfied in the second module, then only module 1 and the post processing steps will be tested
and reported.
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2.2 Results
SPLICEINATOR – AUTOMATIC PRIORITIZATION OF SPLICE MUTATION EVENTS

Given the difficulty of rigorously characterizing splice mutation events, we instituted a
procedure to automatically prioritize candidates from large lists of inputs (Figure 2.1).
Called SpliceInator, it identifies the most promising members, assigning each a
preliminary assessment of one or more phenotypes. SpliceInator employs 3 forms of
analysis. In the first module, expression levels (units of RPKM) are permutation-tested
against corresponding controls, for example intron x in the case versus intron x in the
control group. If 3’ bias of the case gene is sufficiently low (Spearman rank test), this
between-samples assessment is augmented by a within-sample permutation test, for
instance the subject intron against the other introns in the gene. In this latter scenario, the
probability results would then be combined using Fisher’s chi-square transform method.
The second module uses TopHat(Trapnell et al.) assembly to identify boundaries and
establish read counts. Given some minimal read thresholds, a Fisher exact test is applied
to assess whether patterns of junction coverage are altered between case and controls
due to splice site mutation. A third component of SpliceInator classifies whole gene
expression values based on Tukey’s quartile analysis, including pronouncement of no
expression for values more than 1.5 interquartile ranges below the first quartile. Finally,
using a rule based classification we then prioritized variants from module 1 and module
2 using the following rules: 1) Events are classified as intron retention if found to be
statistically significant by module 1; 2) Exon extension and exon shrinkage events are
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reported if found to be statistically significant by module 2; 3) Exon skipping events are
classified based on a combination approach. If the exon skipping event is found to be
statistically significant in module 1 and module 2, the module 1 pvalue is reported and a
designation of M1;M2 is reported. If module 2 reports a statistically significant pvalue, an
M2 designation is reported. The codebase is available from GitHub (github.com/dinglab/SpliceInator).

DIVERSE SPLICING PHENOTYPES ASSOCIATED WITH SPLICE SITE MUTATIONS

We collected high quality mutation calls with a UCSC conservation score greater than
99% from 19 cancer types derived from The Cancer Genome Atlas (TCGA). A total of
1,146 splice site mutations currently defined as substitutions, deletions, or insertions
overlapped the 2 bp canonical intronic splice donor or acceptor of 624 cancer associated
genes. We predicted mutations located at highly conserved sites in cancer genes would
be associated with measurable splicing defects. The TopHat module identified alternative
junctions near splice site mutations and each prediction was manually reviewed to
produce a high confidence list of mutations and associated splicing defects. Our analysis
revealed TopHat accurately classifies exon extension, exon shrinkage, and some exon
skipping events, but is unable to identify intron retention, another widespread defect
observed in many samples by manual review. The statistical based module using RSEM
data properly identified intron retention and exon skipping events that were missed in the
TopHat alignment analysis.
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45.46% of variants in our dataset conferred measurable splicing alterations. The overall
landscape of splicing phenotypes for 521 variants included: exon skipping (230), 5’ exon
shrinkage (137), intron retention (219), 3’ exon shrinkage (49), multi-exon skipping (32),
3’ exon extension (27), and 5’ exon extension (24) (Figure 2.1a). 69.29% (361) of splice
site mutations had only one associated splicing defect, while the remaining were a
combination of splicing events including 2 events (24.76%, 129), 3 events (4.99%, 26)
and 4 events (0.96%, 5).
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Figure 2.2. Splicing defects associated with splice site mutations. (A) An UpSetR plot highlighting
the distribution of splicing phenotypes associated with splice site mutations across the dataset. The bar
plot on the left hand side reflects the total amount of sites that fall into each splicing phenotype group.
The bar plot at the top depicts the total mutations that are classified as having a corresponding splicing
defect depicted in the bubble’s below. Colors correspond to a separate splicing phenotype. Black lines
between bubbles indicate complex splicing events. (B) For each splicing phenotype, we evaluated how
the splicing defect would alter the reading frame of the protein.

SPLICE SITE MUTATIONS LINKED TO COMPLEX SPLICING EVENTS

Current tools and analyses focus on the primary splicing defect, but 30.6% of mutations
with a measurable splicing phenotype in our dataset have two to four different splicing
alterations linked to the same splice site mutation. The most common complex event
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involves intron retention and single exon skipping in 29 cases. A 2011 study(Ma et al.) in
c.elegans provides evidence that intron retention and exon skipping is regulated by the
identity of the 3’ splice site due this regions interaction with U2AF splicing factors.

Five mutations in KDM6A, KMT2B, CBFB and TP53 presented with 3’ exon shrinkage
and single exon skipping. Two of the mutations sharing this out of frame complex splicing
event are annotated to exon 26 of the H3K27 demethylase, KDM6A, and have lower
expression relative to their BLCA cohort (Figure 2.3a). A closer examination of the RNASeq revealed equal support of the 3’ exon shrinkage and single exon skipping events,
and a lack of reads supporting the canonical junction in both cases. Using MaxEntScan
we scored the canonical and alternative splice sites using a sliding window approach to
evaluate the strongest alternative splice site score with the introduced mutation. Before
the mutations the donor site score is 8.07 but with the introduced mutations the score
changes to -0.33 and -6.43 for the point mutation and larger deletion, respectively.
Although the alternative splice site utilized in the 3’ exon shrinkage event in both cases
has a lower splice score of -0.88, Human Splicing Finder scored the alternative site as a
potential donor site (70.87 out of 100) taking into consideration additional genomic
features such as branch point potential and splice factor protein binding sites(Desmet et
al.). Altogether, these results suggest the donor splice site mutation weakens the
canonical splice site decreasing the overall expression of KDM6A while also utilizing a
nearby alternative donor site leading to a 3’ exon shrinkage and exon skipping event. The
landscape paper on LUAD(Cancer Genome Atlas Research), and two additional
studies(Banka et al.; Cheon et al.) of Korean patients with Kabuki syndrome report the
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presence of frequent mutations in KDM6A, including mutations overlapping the same
splice site, but did not report on the functional consequences of the splice site mutation.

Since the recurrent KDM6A splice site mutations had the same splicing phenotype, we
next evaluated the landscape of recurrent splicing alterations across the cohort. Our
dataset contained 300 recurrent splice site mutations present in two or more samples
overlapping the same splice site. Several highly recurrent mutations in the same cancer
type showed similar splicing patterns including GATA3 in BRCA and MET in LUAD. The
GATA3 simple indel was identified in 12 breast cancer (BRCA) samples and expressed
the same 5’ exon shrinkage event across all 13 samples (Arnold et al.; Dorman et al.).
Four different mutations overlapping the same splice site in MET expressed a similar exon
skipping profile that is well supported in the literature(Drilon).
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Figure 3: Complex Splicing Events
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Figure 2.3. Complex Splicing Events. (A) Heatmap showing the distribution of splicing phenotypes
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Alternatively, many recurrent sites did not show such consistency across samples and
tissue types. TP53 is highly mutated across cancer types and harbors 80 recurrent splice
site mutations across nine splice sites. Evaluating the distribution of splicing phenotypes
for each splice site shows a very different effect. Mutations at p.261_splice are derived
from BRCA, HNSC, KIRC and UCS and while three cancer types share the same intron
retention event, the UCS sample has no measurable splicing alterations. Six of the seven
mutations at p.224_splice are derived from four cancer types and all lack a measurable
splicing defect, but a single mutation in SKCM expresses 3’ exon extension and intron
retention which could be explained by the high tumor VAF (94.44%) for this particular
mutation. This result highlights the importance of having individualized RNA-Sequencing
to complement mutational analysis to evaluate patient specific splicing alterations.

37

LACK OF MEASURABLE SPLICING DEFECT FOR MANY SPLICE SITE MUTATIONS

We next wanted to explore whether there was a relationship between the presence of an
aberrant transcript and the newly formed premature termination codon (PTC). The
Nonsense Mediated Decay (NMD) pathway predominantly degrades PTC’s and
nonsense mutations that differ from the canonical stop codon to reduce expression of
potentially damaging transcripts. The general rule of thumb is that PTC’s located at least
50-55 bp upstream of the last exon-exon junction drive strong NMD, whereas those out
side of this criteria are predicted to escape the degradation process. To evaluate if the
presence of a measurable splice defective product is due to the lack of degradation by
NMD, we translated the aberrantly spliced product and evaluated the position of the PTC
relative to the exon-intron boundary predictions. Our analysis found that X mutations
create a PTC that is predicted to escape NMD while X mutations should hypothetically be
degraded.
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Figure 2.4. Lack of a measurable splicing defect. (A) Mutations which lack a measurable splicing
defect are categorized into bins by quantile gene expression classification into not expressed, low
expression, average expression and high expression based on their tissue type (x axis). Each variant is
then grouped based on exon expression, variant allele fraction and unknown causes to explain the lack
of a measurable splicing defect in each gene expression category. (B) Overall distribution of exon
expressivity between samples found with and without a measurable splicing defect separated by
acceptor and donor site annotation.

Although we identified splicing alterations for 521 variants, 624 splice site mutations were
not associated with any measurable splicing defects suggesting one or more of the
following: (1) a lack of expression of the transcript; (2) low expression of the variant allele
in the tumor; (3) the creation of a highly unstable transcript that is degraded; (4) copy
number aberrations; (5) presence of a subclone; or (6) a false positive. To evaluate lack
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of expression of the case sample relative to the controls, we performed Tukey’s quartile
analysis, including pronouncement of no expression for values more than 1.5 interquartile
ranges below the first quartile (Methods). While 339 sites had high or average expression
relative to their cohort, 14 and 272 genes were considered as not expressed or lowly
expressed, respectively, suggesting the mutation disrupted overall expression of the
transcript. To assess exon expression we evaluated reads supporting the adjacent
annotated exon against control samples and normalized by the length of the transcript
and total mapped reads (Methods). For 116 of the 624 splice site mutations, the transcript
had no expression in the tissue type of interest illuminating the lack of a measurable
splicing defect in the presence of a splice site mutation. Furthermore, the group lacking
splicing defects had an overall lower exon expressivity and lower variant allele fraction
distribution when compared to the group of variants with measurable splicing defects
(Figure 2.4). Altogether, our results suggest 75.6% of highly conserved splice site
mutations lacking a measurable splicing defect can be classified as having low VAF
(<30%), low exon expressivity or both while 24.8% are still undetermined (Figure 2.4).
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IMPACT OF SPLICE SITE MUTATION ON GENE EXPRESSION

Figure 2.5. Splice altering variants with increased expression. 19 predicted splice eQTLs identified
across cohort. Indicated in figure are gene name, sample, cancer, variant allele fraction (VAF), copy
number (CN), purity estimate, and the associated splicing defects indicated by color. Color legend on
right hand side corresponds to associated splicing defect, and a filled in circle indicates predicted out of
frame events.

We next compared cases against cancer specific control cohorts to evaluate the effect of
splice site mutations on gene expression. Overall, around 59% of sites had comparable
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(high or average) expression within their control cohort, while 41% had lower overall
expression (low or not expressed). Interestingly of the 59%, 19% had higher gene
expression, selecting for an altered transcript that escapes RNA degradation pathways.
In the high expression group, we sought to identify splicing expression quantitative trait
loci (eQTLs) where the splice site mutation is associated with higher expression in the
gene of interest. We hypothesized splice eQTL’s would have a measurable splicing
defect, elevated DNA VAF (>50%) and increased overall gene expression of case
samples relative to the associated control cohort. Out of 526 mutations with measurable
splicing alterations, 19 are predicted to be splice eQTLs in our cohort and they reside in
the following cancer associated genes: TP53 (2), PTEN (2), KEAP1 (2), CREBBP, AXIN1,
ACVR2A, TSC1, MGA, CHD4, WAS, CDKN2A, BCORL1, BRIP1, MAP4K3, KMT2C, and
CBLC (Table 1). Interestingly, 10 of these 19 mutations are complex events, having 2 or
more splicing phenotypes associated with the mutation, and 13 are classified as having
a retained intron.
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Figure 2.6. KEAP1 highly expressed splice eQTLs. (A) Lolliplot depicting location of highly expressed
splice site mutations in KEAP1 (p.570). Each domain is highlighted using a different color and each
circle on the lolliplot visualizes the location of the mutation on the exonic sequence and highlights the
complex splicing patterns identified at each site. The resulting consequences of each splicing defect on
the kelch domains is further annotated below the lolliplot revealing crucial structural elements that are
absent under each condition. (B) Protein structure of the kelch domains in the KEAP1 structure. Six kelch
domains form a propellar structure within KEAP1 (gray) that is responsible for interacting with Nrf2
(yellow). The circles in the upper left hand corner of each structure highlight the splicing defects that will
disrupt the associated colored kelch domain in the 3D depiction. The amino acid position where the splice
site mutations fall are highlighted in blue and annotated along with the Nrf2 interacting domain (yellow).

Two highly expressed splice eQTLs were identified in the E3 ubiquitin ligase Kelch-like
erythroid cell derived protein with CNC homology (ECH) associated protein 1 otherwise
known as KEAP1. KEAP1 sequesters and ubiquitinates Nrf2, a nuclear factor erythroid
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2-related factor 2 (NFE2L2). In cancer, many mutants disrupt the binding between KEAP1
and Nrf2. Disrupted binding increases the presence of free Nrf2, thereby activating
downstream genes that are conducive for cell growth and responding to oxidative
stresses. Three LUAD samples in our dataset harbor splice site mutations in KEAP1, two
of which were classified as high expressing splice eQTLs. We hypothesized the two
mutations in KEAP1 are disrupting the binding between KEAP1 and Nrf2. One mutation
was identified at the acceptor site of exon 6 and another at the donor site of exon 5, with
a VAF of 61% and 72%, respectively. Copy number data also suggests the mutant with
72% VAF has undergone a copy number loss, providing further evidence as to the
selection of the mutant case in the tumor. Furthermore, while one mutation occurs within
the last 50 bp of the last exon-exon junction and the other is present in the last exon of
KEAP1, this could explain why the splicing defects are tolerated and escape degradation
by nonsense mediated decay.

When comparing the KEAP1 mutants against the control group, KEAP1 mutants had
higher overall gene expression (wilcox test=0.04) and lower overall NFE2L2 expression
(wilcox test = 0.01). Interestingly, one KEAP1 mutant sample with RPPA data had higher
Nrf2 protein expression relative to the controls and lower KEAP1 protein expression,
providing an answer as to the mechanism by which the splice eQTL could be disrupting
this biological pathway. The discordant relationship between protein and gene expression
in this case could be explained by a negative feedback loop leading to a decrease in gene
expression under conditions of high protein expression.
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Structurally, the mutations occur within the last of the six kelch repeats that fold into a
beta propeller tertiary structure, with each blade compromising four anti-parallel beta
sheets (Figure 2.6b). In Figure 2.6b we highlight the kelch domains that are predicted to
be disrupted due to associated splicing defects. For example, if exon 5 of KEAP1 was
skipped, the fifth kelch domain would be completely absent thus disrupting the overall
propeller structure and the binding pocket for Nrf2. These results lead us to believe the
KEAP1 high expressing splice eQTLs act in a dominant negative manner by disrupting
the binding of KEAP1 to Nrf2 thereby increasing the amount of free Nrf2 in the cell.
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NON-CANONICAL SPLICE SITE MUTATION DISCOVERY

Finally, we wanted to perform a genome-wide investigation on the creation and
strengthening of de novo splice sites by exonic variants. We used two independent
methods to interrogate mutations outside of the splice site in a splicing context. Using the
entropy based method, for each variant the sequences of each 9-mer (donor) and 23-mer
(acceptor) covering the variant position was extracted from the genome for both the
mutant and reference sequence. Their splice score as potential donor or acceptor sites
were estimated using MaxEntScan. The largest scores of the 9-mer or 23-mer windows
were retained for mutant and reference and their difference (mutant - reference) was
calculated. Finally, the scores with largest difference between potential donor site and
potential acceptor site was retained as the final score. A novel splice site is predicted to
be created if the reference score <3 and the mutant score is >8. We further filtered this
list by evaluating nearby junctions in the bam files (reads>10) for predicted novel splice
sites. For the second method, we used the TopHat module of SpliceInator to collect all
alternative junctions within 14 base pairs of the annotated mutations. We manually
reviewed all the predictions to evaluate the efficacy of our method.

For the entropy based method, a total of 243 sites were predicted near a novel junction
but after manual review the method correctly called 9 de novo donor sites, 6 strengthened
alternative acceptor sites, and 7 strengthened alternative donor sites. Of the 22 sites, 15
were specific to the mutated sample and not present in any control samples. For the
TopHat method, a total of 192 alternative acceptor sites and 204 alternative donor sites
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were predicted to fall within 14 bp of a non-splice site mutation. After manual review, 1 de
novo acceptor site, 35 de novo donor sites, 153 strengthened acceptor splice sites, and
145 strengthened donor splice sites were properly detected. Furthermore, 49 of the 154
acceptor sites had no supporting reads supporting the novel junction in the control and
84 of the 180 donor sites were specific to the mutated sample. The MaxEntScan scoring
filtered out many sites that were found using our TopHat method, suggesting using the
splice score alone isn’t sufficient to properly evaluate mutations in a splicing context. Both
methods picked up strengthened acceptor sites in the following genes CTSH, LAMC1
and NUP98; and 4 created donor sites in WDR33, NOP14, RSRC2 and PARP1.

The Poly ADP-ribose polymerase 1, PARP1, is an enzyme involved in recruiting proteins
involved in DNA repair pathways. Both methods identified a silent mutation in PARP1 in
a LUSC patient that acts as a splice altering variant by creating a de novo donor site in
exon 21. RNA-Sequencing data supports the use of the de novo donor site leading to an
11 amino acid deletion, which falls within the PARP1 catalytic regulatory domain. 180
reads in the mutated sample supported the de novo site while 170 controls contained no
supporting reads giving us strong evidence that this “silent” mutation is more appropriately
a splice altering variant. PARP1 inhibitors are commonly used in cancer treatment to
disrupt DNA repair in tumor cells thereby leading to the accumulation of DNA breaks and
ultimately cell death(Malyuchenko et al.).

2.3 Methods
SpliceInator Methods:
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The analysis procedures use RPKM values, which were derived for the full-length exons
and introns of genes using TCGA RNA-Seq bam files. Briefly, bed files were generated
for exon and intron coordinates based on the Ensembl 37.75 database. The SamTools
package counted raw reads for each exon and intron. Finally, RPKM was calculated as
109×R/(N×L), where R is the number of raw reads mapped to each exon or intron, N is the
total number of mapped reads in the project, and L is the length of the exon or intron.
Some analyses also consider ±50 bps and ±2 bps around junctions, for which we use
RPM (# of mapped reads per million reads) to quantify the expression because the
lengths are short and fixed.
The main algorithm, which we call SpliceInator, combines two lines of evidence to assess
aberrant splicing events and their implications, one based on standard statistical
hypothesis testing of RSEM expression values and the other based on interpretation of
RNA-Seq fragment mapping using TopHat. We have found empirically that each of these
components excels at a relatively mutually exclusive subset of the various kinds of
splicing anomalies that have been observed: intron retention and exon skipping for the
statistical method and exon extension and shrinkage for TopHat-based analysis. The
latter also can detect some exon skipping events, for which perform ad hoc interpretation
in light of the statistical evidence. Consequently, we have not found it necessary to
develop any sort of overarching method for combining results of the two calculations.
For the genes of interest, the statistical method takes as input both the gene-wide RSEM
and the individual intron and exon RSEM values for each gene over a set of samples.
Genes reporting RSEMs below a threshold are considered to have expression too low to
properly assess and are skipped. Otherwise, each sample for each gene is processed
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sequentially for the different kinds of possible splicing anomalies. Each of these
calculations proceeds in essentially the same way, the intron retention calculation being
representative, as follows. Preliminary exclusion criteria are evaluated first: the intron’s
RSEM must be above a threshold and must likewise be greater than the average RSEM
over the corresponding introns in the control group, of which there must be at least 50
instances. Assuming these criteria are met, the algorithms then evaluates whether the
subject intron’s RSEM is significantly higher than the average of those in the control group
via simple permutation testing, which returns a “case-control” P-value. The method
attempts to maximize power when possible. Specifically, if 3’ bias within the gene of the
current sample is sufficiently low, a within-sample test is also performed. Potential 3’ bias
is checked via Spearman’s rank test between the introns’ RSEM values and their location
midpoints, both ordered 5’ to 3’. Lack of strong bias is inferred if Spearman’s coefficient
£ 0.3, in which case the algorithm runs a second permutation test to check whether the
subject intron RSEM is significantly greater than the other intron RSEMs within that gene.
This calculation returns the “within-sample” P-value. These tests are essentially
independent, by which we finally combine the case-control and within-sample P-values
using Fisher’s Method. Analysis of exon-skipping is similar. The algorithm is relatively
robust against the heuristic parameters quoted above.

For TopHat-based analysis, TopHat Junction output was used for each splice site
mutation to identify junction ids where mutations are between the start and stop of the
junction feature. Exon intron boundaries were calculated using the overhang value for
each junction feature. We enforced a threshold of at least 10 reads aligned to a particular
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exon-intron boundary. Depths of coverage for each junction for cases and controls were
collected using the TopHat junction output. To obtain total unique reads within the junction
neighborhood, we performed read counts on the in house bam files and used this value
as our total reads for both cases and controls. Reads supporting reference junction versus
alternative junction were compared using Fisher’s 2x2 exact test between cases and
controls to discern altered junction coverage due to presence of the splice site mutation.

Methods Novel splice site mutation discovery:
We propose to use the TopHat Module of SpliceInator to identify all alternative junction
predictions across the entire cancer genome atlas RNA-Seq sample set (>7,000 samples)
and pediatric cancer dataset (>500 samples). To hone in on mutations that are directly
disrupting pseudo splice sites, we will first identify missense and silent variants that are
within a threshold distance of an alternative junction prediction. After identifying the
alternative junction, we searched for nearby donor and acceptor sites that may have been
strengthened or weakened by the introduced mutation. By comparing cases to controls
within the same cancer type, we were able to determine if the novel junction is used within
the cancer type at a low level or only present in the case with the mutation. Finally, each
de novo donor and acceptor site is scored using a scoring algorithm. By using entropy
and information analysis of the consensus base sequences, we can evaluate the strength
of a particular site based on its nucleotide frequencies(Burset et al.). Using a weighted
scoring method for each possible acceptor/donor sequence, we multiplied the information
of each base by the information weight of the site. The acceptor and donor information
and weight is derived from over 25,000 different splice donor/acceptor sites to come up
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with the information weights and content at each position. To be classified as creating or
strengthening a novel acceptor or donor site the mutation fell within 8 bp of the novel
predicted donor site, 14 bp of the novel predicted acceptor site, had supporting reads
from both the positive and negative strand, and create or strengthen a nearby site that
utilizes the canonical GT or AG splice site.
Methods to evaluate exon expression:
Github/Exon-Expressivity
We developed a script which take as inputs a Mutation Annotation File (MAF) and an
RNA bamlist to compare total reads supporting an exon against the total mapped reads
(normalized by length) to evaluate exon expressivity across cancer types and samples in
our dataset.
•

Exon_Expressivity.pl : Inputs 1) RNA-Seq bam locations 2) Mutation Annotation
File (MAF). This script will identify all exons nearest to the splice site mutation of
interest designated in the MAF file and collect exon read count data across
samples in the RNA-Seq bam list and total mapped reads from the flagstat or
alignment stats files in the designated bam directories. The exon expressivity
coefficient (Ei) is calculated by dividing the total reads aligned to exon (E) over the
total mapped reads of the imported bam (B), normalized by the length of the exon
and multiplied by a scaling factor (see equation below). The Ei coefficients are then
averaged across all samples for each cancer type to determine the overall exon
expressivity of the exon of interest. If multiple transcripts share the same exon,
multiple Ei values will be reported for each individual exon.

•
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To determine a cut off for the exon expressivity (Ei) we evaluated Ei scores across all
1,159 mutations in our dataset and associated control samples. We determined Ei of case
samples with detectable splicing alterations to define samples with known “expressed
junctions”.

Alignment guided junction analysis to identify mutations linked to splicing defects: We
propose to identify junctions between two exon-exon boundaries genome wide. A junction
is defined by RNA-Seq reads that are split between two exon-intron boundaries, joining
two exons. TopHat41 reports the number of reads supporting the canonical junction
shared between two exons, or any deviations including exon skipping, intron retention, 5’
exon shrinkage, 3’ exon shrinkage, multi exon skipping, 3’ exon extension, and 5’ exon
extension. The number of reads supporting each junction for cases and controls were
collected for each sample. Controls were defined for each gene based on tissue type and
only include samples lacking mutations in the gene of interest. Reads supporting the
reference junction and alternative junctions were compared using Fisher’s Exact Test
between cases and controls to determine which junctions showed statistically significant
altered junction usage. This calculation indicates whether the altered junction is
potentially due to the mutation in the case, or if a background level of alternative splicing
is occurring at this junction due to a tissue type specific event.
Part 1. SpliceInator: Splice site mutations that lead to aberrant signals have cancer
implications. We developed a tool combining TopHat RNA-seq analysis with case-control
and within-sample statistical testing of expression data to identify and classify such
events.
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RNA-Seq Guided Junction Analysis using SpliceInator to identify mutations contributing
to splicing defects: SpliceInator is a statistical tool that we are developing to classify
variants into the following categories: 1) expression loss, 2) intron retention, 3) exon
skipping, 4) exon extension, 5) exon shrinkage, and 6) unknown, using patient specific
RNA-seq data. It performs permutation based testing on normalized expression data
derived from exons, introns, and splice junctions between mutant and control samples.
Additionally, when there is minimal 3’ bias, within-sample testing is also performed to add
statistical power.
First, reads per kilobase per million (RPKM) are derived for each gene using patient
specific RNA-Seq. Next, mutations are tested for intron retention. Within this test, we first
check for 3’ bias within the given sample according to Spearman’s Rank Correlation test
of each exon across the gene in a 5’ to 3’ manner. Absent significant bias, RPKM of each
intron is tested against all others within the gene to check for elevated expression. Next,
the full intron expression of the mutant sample is tested against the same intron in the
control cases. For exon skipping, the same type of calculations are performed, except full
exon expression is used. After an initial analysis of a highly recurrent GATA3 acceptor
variant, we noted that exon shrinkage and extension events could not be properly
identified when comparing the full exon and intron expression between cases and
controls. For the exon shrinkage and extension tests, we decided to additionally extract
RPKM values associated with +/- 2bp and +/- 50 bp of all defined exon boundaries. This
allowed us to test smaller events that could be occurring near a splice site, such as the 7
bp shrinkage identified in the GATA3 variants, or larger events with the +/- 50 bp data.
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For exon shrinkage and exon extension, the full exon expression, 2 bp expression and
50 bp expression are all compared between cases and controls. This analysis will allow
us to connect our expression analysis with junction-based prediction and identify cases
of intron retention, which are outside of TopHat’s predictive capability.
Intron retention events are common splicing aberrations: SpliceInator identified 104 intron
retention events highlighted in Figure 2.1. An additional 44 exon skipping events were
identified by SpliceInator, further supporting the findings of TopHat predicted exon
skipping events. Our findings emphasize the importance of using both tools in identifying
splicing defects associated with mutations. [add more examples here about interesting
intron retention events].

3.4 Discussion
Splice alterations have been shown to affect the landscape of mRNA isoforms present in
both tumor and normal tissues. Unlike many missense mutations known to disrupt the
protein structure or associated binding sites, an initial review of splice site mutations
quickly revealed position and tissue type alone couldn’t explain observed splicing
patterns. Since looking solely at genomic context could not directly inform whether a
splice site mutation would confer a splicing defect we developed SpliceInator, a semiautomated tool to interrogate mutations in a splicing context.

Evaluating splicing defects associated with highly conserved splice site mutations
revealed diverse splicing patterns. While some well known splicing patterns were
observed, more than 30% of variants with a known splicing defect had a more complex
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phenotype consisting of two or more splicing defects. Although some recurrent splice site
mutations at the same position conferred similar splicing defects, many exhibited different
patterns, suggesting tumor heterogeneity makes predicting the effects of mutations on
the transcriptome very difficult without patient specific RNA-Sequencing data. In
particular, TP53 harbored many recurrent splice site mutations across cancer types and
didn’t show consistent splicing patterns while recurrent mutations in KDM6A did.

Even more interesting was the lack of a measurable splicing defect for 54% of highly
conserved splice site variants. While we were able to classify approximately 75% of
variants from this group into samples having low variant expression and low exon
expressivity, approximately 25% were still unclassified. The unclassified variants could
be creating a highly unstable transcript that is quickly degraded by the cell, but follow up
functional analysis is needed to confirm this prediction revealing the limitation of RNASeq data. We were also able to demonstrate mis-annotated variants by evaluating all
mutations in a splicing context using SpliceInator. By more accurately classifying variants
in genes such as PARP1 and PTEN we can better understand the biological implications
of variants disrupting the splicing process and determine patient specific treatments.

Altogether our findings suggest you can’t predict what to expect due to the complexity of
the splicing process and tumor heterogeneity. While our tool makes a significant
contribution by providing an automated method to determine functionally relevant
mutations using matched RNA-Seq data there is still much to learn about how cancer can
abrogate splicing mechanisms for tumor growth and proliferation. For example, while we
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focused on defining specific defects such as exon skipping, exon shrinkage, exon
extension and intron retention, there were several events that were not easily classified
into one or more of the aforementioned categories. Further developing our tool to
accommodate more complex splicing defects will be a necessity to better gauge the true
landscape of splicing phenotypes in disease.

3.5 References

Uncategorized References
Anders, S., Reyes, A., and Huber, W. (2012). Detecting differential usage of exons from
RNA-seq data. Genome Res 22, 2008-2017.
Arnold, J.M., Choong, D.Y., Thompson, E.R., kConFab, Waddell, N., Lindeman, G.J.,
Visvader, J.E., Campbell, I.G., and Chenevix-Trench, G. (2010). Frequent somatic
mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-,
BRCA2- or sporadic breast tumors. Breast Cancer Res Treat 119, 491-496.
Ast, G. (2004). How did alternative splicing evolve? Nature reviews Genetics 5, 773782.
Banka, S., Lederer, D., Benoit, V., Jenkins, E., Howard, E., Bunstone, S., Kerr, B.,
McKee, S., Lloyd, I.C., Shears, D., et al. (2015). Novel KDM6A (UTX) mutations and a
clinical and molecular review of the X-linked Kabuki syndrome (KS2). Clin Genet 87,
252-258.

56

Barbaux, S., Niaudet, P., Gubler, M.C., Grunfeld, J.P., Jaubert, F., Kuttenn, F., Fekete,
C.N., Souleyreau-Therville, N., Thibaud, E., Fellous, M., et al. (1997). Donor splice-site
mutations in WT1 are responsible for Frasier syndrome. Nat Genet 17, 467-470.
Bonomi, S., Gallo, S., Catillo, M., Pignataro, D., Biamonti, G., and Ghigna, C. (2013).
Oncogenic alternative splicing switches: role in cancer progression and prospects for
therapy. Int J Cell Biol 2013, 962038.
Broeks, A., Urbanus, J.H.M., de Knijff, P., Devilee, P., Nicke, M., Klöpper, K., Dörk, T.,
Floore, A.N., and van't Veer, L.J. (2003). IVS10-6T>G, an ancient ATM germline
mutation linked with breast cancer. Human mutation 21, 521-528.
Burset, M., Seledtsov, I.A., and Solovyev, V.V. (2001). SpliceDB: database of canonical
and non-canonical mammalian splice sites. Nucleic Acids Res 29, 255-259.
Cancer Genome Atlas Research, N. (2014). Comprehensive molecular characterization
of urothelial bladder carcinoma. Nature 507, 315-322.
Cheon, C.K., Sohn, Y.B., Ko, J.M., Lee, Y.J., Song, J.S., Moon, J.W., Yang, B.K., Ha,
I.S., Bae, E.J., Jin, H.S., et al. (2014). Identification of KMT2D and KDM6A mutations by
exome sequencing in Korean patients with Kabuki syndrome. J Hum Genet 59, 321325.
Dees, N.D., Zhang, Q., Kandoth, C., Wendl, M.C., Schierding, W., Koboldt, D.C.,
Mooney, T.B., Callaway, M.B., Dooling, D., Mardis, E.R., et al. (2012). MuSiC:
identifying mutational significance in cancer genomes. Genome Res 22, 1589-1598.
Desmet, F.O., Hamroun, D., Lalande, M., Collod-Beroud, G., Claustres, M., and Beroud,
C. (2009). Human Splicing Finder: an online bioinformatics tool to predict splicing
signals. Nucleic Acids Res 37, e67.
57

Ding, L., Wendl, M.C., McMichael, J.F., and Raphael, B.J. (2014). Expanding the
computational toolbox for mining cancer genomes. Nat Rev Genet 15, 556-570.
Dorman, S.N., Viner, C., and Rogan, P.K. (2014). Splicing mutation analysis reveals
previously unrecognized pathways in lymph node-invasive breast cancer. Sci Rep 4,
7063.
Drilon, A. (2016). MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends
Half-Life. Clin Cancer Res 22, 2832-2834.
Faustino, N.A., and Cooper, T.a. (2003). Pre-mRNA splicing and human disease.
Genes & development 17, 419-437.
Hoadley, K.A., Yau, C., Wolf, D.M., Cherniack, A.D., Tamborero, D., Ng, S., Leiserson,
M.D.M., Niu, B., McLellan, M.D., Uzunangelov, V., et al. (2014). Multiplatform analysis
of 12 cancer types reveals molecular classification within and across tissues of origin.
Cell 158, 929-944.
Holmila, R., Fouquet, C., Cadranel, J., Zalcman, G., and Soussi, T. (2003). Splice
mutations in the p53 gene: case report and review of the literature. Human mutation 21,
101-102.
Huether, R., Dong, L., Chen, X., Wu, G., Parker, M., Wei, L., Ma, J., Edmonson, M.N.,
Hedlund, E.K., Rusch, M.C., et al. (2014). The landscape of somatic mutations in
epigenetic regulators across 1,000 paediatric cancer genomes. Nature communications
5, 3630-3630.
Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q.,
McMichael, J.F., Wyczalkowski, M.A., et al. (2013). Mutational landscape and
significance across 12 major cancer types. Nature 502, 333-339.
58

Keren, H., Lev-Maor, G., and Ast, G. (2010). Alternative splicing and evolution:
diversification, exon definition and function. Nature reviews Genetics 11, 345-355.
Kurahashi, H., Takami, K., Oue, T., Kusafuka, T., Okada, A., Tawa, A., Okada, S., and
Nishisho, I. (1995). Biallelic inactivation of the APC gene in hepatoblastoma. Cancer
Res 55, 5007-5011.
Lim, K.H., and Fairbrother, W.G. (2012). Spliceman--a computational web server that
predicts sequence variations in pre-mRNA splicing. Bioinformatics 28, 1031-1032.
Ma, L., Tan, Z., Teng, Y., Hoersch, S., and Horvitz, H.R. (2011). In vivo effects on intron
retention and exon skipping by the U2AF large subunit and SF1/BBP in the nematode
Caenorhabditis elegans. RNA 17, 2201-2211.
Malyuchenko, N.V., Kotova, E.Y., Kulaeva, O.I., Kirpichnikov, M.P., and Studitskiy, V.M.
(2015). PARP1 Inhibitors: antitumor drug design. Acta Naturae 7, 27-37.
Matlin, A.J., Clark, F., and Smith, C.W. (2005). Understanding alternative splicing:
towards a cellular code. Nat Rev Mol Cell Biol 6, 386-398.
Modrek, B., and Lee, C. (2002). A genomic view of alternative splicing. Nature genetics
30, 13-19.
Mort, M., Sterne-Weiler, T., Li, B., Ball, E.V., Cooper, D.N., Radivojac, P., Sanford, J.R.,
and Mooney, S.D. (2014). MutPred Splice: machine learning-based prediction of exonic
variants that disrupt splicing. Genome biology 15, R19-R19.
Pertea, M., Lin, X., and Salzberg, S.L. (2001). GeneSplicer: a new computational
method for splice site prediction. Nucleic Acids Res 29, 1185-1190.
Reese, M.G., Eeckman, F.H., Kulp, D., and Haussler, D. (1997). Improved splice site
detection in Genie. J Comput Biol 4, 311-323.
59

Rivas, M.A., Pirinen, M., Conrad, D.F., Lek, M., Tsang, E.K., Karczewski, K.J., Maller,
J.B., Kukurba, K.R., DeLuca, D.S., Fromer, M., et al. (2015). Human genomics. Effect of
predicted protein-truncating genetic variants on the human transcriptome. Science 348,
666-669.
Ryan, M.C., Cleland, J., Kim, R., Wong, W.C., and Weinstein, J.N. (2012). SpliceSeq: a
resource for analysis and visualization of RNA-Seq data on alternative splicing and its
functional impacts. Bioinformatics 28, 2385-2387.
Sauna, Z.E., and Kimchi-Sarfaty, C. (2011). Understanding the contribution of
synonymous mutations to human disease. Nature reviews Genetics 12, 683-691.
Shapiro, M.B., and Senapathy, P. (1987). RNA splice junctions of different classes of
eukaryotes: sequence statistics and functional implications in gene expression. Nucleic
Acids Res 15, 7155-7174.
Steffensen, A.Y., Dandanell, M., Jønson, L., Ejlertsen, B., Gerdes, A.-M., Nielsen, F.C.,
and Hansen, T.V. (2014). Functional characterization of BRCA1 gene variants by minigene splicing assay. European journal of human genetics : EJHG 3, 1-7.
Sun, X., Zuo, F., Ru, Y., Guo, J., Yan, X., and Sablok, G. (2015). SplicingTypesAnno:
annotating and quantifying alternative splicing events for RNA-Seq data. Comput
Methods Programs Biomed 119, 53-62.
Supek, F., Miñana, B., Valcárcel, J., Gabaldón, T., and Lehner, B. (2014). Synonymous
mutations frequently act as driver mutations in human cancers. Cell 156, 1324-1335.
Taylor, M.D., Gokgoz, N., Andrulis, I.L., Mainprize, T.G., Drake, J.M., and Rutka, J.T.
(2000). Familial posterior fossa brain tumors of infancy secondary to germline mutation
of the hSNF5 gene. Am J Hum Genet 66, 1403-1406.
60

Trapnell, C., Pachter, L., and Salzberg, S.L. (2009). TopHat: discovering splice
junctions with RNA-Seq. Bioinformatics 25, 1105-1111.
Venables, J.P. (2004). Aberrant and alternative splicing in cancer. Cancer Res 64,
7647-7654.
Vitting-Seerup, K., Porse, B.T., Sandelin, A., and Waage, J. (2014). spliceR: an R
package for classification of alternative splicing and prediction of coding potential from
RNA-seq data. BMC Bioinformatics 15, 81.
Walker, L.C., Whiley, P.J., Couch, F.J., Farrugia, D.J., Healey, S., Eccles, D.M., Lin, F.,
Butler, S.A., Goff, S.A., Thompson, B.A., et al. (2010). Detection of splicing aberrations
caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions:
implications for prediction of pathogenicity. Hum Mutat 31, E1484-1505.
Wang, G.-S., and Cooper, T.a. (2007). Splicing in disease: disruption of the splicing
code and the decoding machinery. Nature reviews Genetics 8, 749-761.
Woolfe, A., Mullikin, J.C., and Elnitski, L. (2010). Genomic features defining exonic
variants that modulate splicing. Genome Biol 11, R20.
Wu, J., Akerman, M., Sun, S., McCombie, W.R., Krainer, A.R., and Zhang, M.Q. (2011).
SpliceTrap: a method to quantify alternative splicing under single cellular conditions.
Bioinformatics 27, 3010-3016.
Xie, M., Lu, C., Wang, J., McLellan, M.D., Johnson, K.J., Wendl, M.C., McMichael, J.F.,
Schmidt, H.K., Yellapantula, V., Miller, C.A., et al. (2014). Age-related mutations
associated with clonal hematopoietic expansion and malignancies. Nat Med 20, 14721478.

61

Yang, Y., Swaminathan, S., Martin, B.K., and Sharan, S.K. (2003). Aberrant splicing
induced by missense mutations in BRCA1: clues from a humanized mouse model.
Human molecular genetics 12, 2121-2131.
Yeo, G., and Burge, C.B. (2004). Maximum entropy modeling of short sequence motifs
with applications to RNA splicing signals. J Comput Biol 11, 377-394.

62

Chapter 3: Discovery of splice-sitecreating mutations
Contribution: I developed 1/3 the code for MiSplice with the other parts developed by
Qingsong Gao and Song Cao. I manually reviewed all variants validated by our
computational tool, performed downstream analyses, created all Figures and performed
entire mini-gene splicing assay for 11 variants tested.

3.1 Introduction
Large-scale sequencing studies, such as The Cancer Genome Atlas (TCGA) project,
have worked to address the functional consequences of genomic mutations in tumors
(Dees et al., 2012; Kandoth et al., 2013; Lawrence et al., 2013; Niu et al., 2016), with the
larger goal of determining the underlying mechanisms of cancer initiation and
progression. Many studies have focused on characterizing non-synonymous somatic
mutations that alter amino acid sequence, as well as splice disrupting mutations at splice
donors and acceptors (Jung et al. 2015). Current annotation methods typically classify
mutations as disruptors of splicing if they fall on either the consensus intronic dinucleotide
splice donor, GT, or the splice acceptor, AG. As a group, splice site mutations have been
presumed to be invariably deleterious because of their disruption of the conserved
sequences that are used to identify exon-intron boundaries.
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While this classification method has been useful, increasing evidence suggests that splice
site mutations can lead to transcriptional changes beyond disruption of the canonical
junction (Lim and Fairbrother, 2012; Mort et al., 2014; Rivas et al., 2015; Sauna and
Kimchi-Sarfaty, 2011; Steffensen et al., 2014). One such example is the c.190 mutation
in BRCA1. Conventional annotation had predicted a missense mutation, p.C64G, but our
analysis of RNA-seq data in ovarian tumors harboring p.C64G and a published mouse
model (Yang et al., 2003) suggested the germline c.190 mutation leads to the creation of
an alternative splice junction, resulting in a truncated null protein. There have been
several case studies reporting observations of missense and silent mutations activating
cryptic splice sites in MLH1 (Nyström-Lahti et al., 1999), LMNA (Woolfe et al., 2010), RB1
(Zhang et al., 2008), RNASEH2A (Rice et al., 2013), MECP2 (Taimoor I Sheikh, 2013),
BAP1 (Wadt et al., 2012), KIT (Chen et al., 2005), as well as other studies relating
missense and silent mutations with splicing changes (Jung et al., 2015; Kahles et al.,
2016; Soemedi et al., 2017; Supek et al., 2014). Despite the broad clinical ramifications
of mutation-induced altered splicing, systematic evaluation of their occurrence and
resulting effects in cancer has yet to be undertaken, nor have there been significant
bioinformatics platforms for doing so.

We applied a newly developed bioinformatic tool called MiSplice, which integrates DNA
and RNA-Seq data across thousands of samples to discover mutations that induce splice
site creation. In our large-scale analysis across 8,656 tumor samples, we report 1,964
such somatic mutations that had originally been mis-annotated. Splice site-creating
mutations (SCMs) are enriched in the new introns, with the highest rate at the -3
nucleotide position of acceptors with two-thirds of such events at aGag and agGag
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repeats by creating an alternative junction 2 nucleotides away. Partial and full splice
creation capabilities across these 1,964 sites are evaluated by measuring the fraction of
reads supporting the alternative junction, which we term the Junction Allele Fraction (JAF)
and which is found to be negatively correlated with distance to the new splice site. In total,
1,607 genes harbor SCMs, with 248 of them having more than one mutation, including
TP53, GATA3, ATRX, and NF1. Recurrent SCMs were found in TP53, GATA3, DDX5,
KDM6A, PTEN, SETD2, SMAD4, BCOR, SPOP, and BAP1, suggesting association with
cancer development. Broadly speaking, integrated DNA and RNA data can furnish a
sound basis for discovering SCMs and for accurately understanding functional
consequences of mutations in cancer and other human diseases.

3.2 Results
SPLICE-SITE-CREATING MUTATION DISCOVERY
We collected high quality mutation calls from 8,656 tumors across 33 cancer types
derived from The Cancer Genome Atlas having available TCGA RNA-Seq data
(Methods). For every mutation, we defined a set of control samples in the same cancer
cohort that lacked the same mutation in the gene of interest. We sought to assess the
landscape of SCMs across cancer genomes by evaluating all mutations already having
conventional annotations and their potential splice site-creating effects (Fig. 3.1A). To
achieve this goal, we conducted analysis using a bioinformatic tool, MiSplice (Mutation
Induced Splicing), which systematically evaluates mutations in a splicing context using
RNA-Sequencing data (Fig. 3.1B).
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Figure 3.1. Splice site-creating mutation discovery. (A) Examples of splice site-creating mutations for
different conventionally annotated mutation types. Splice-in is defined as mutations contained within the
newly created exons and splice-out is when the mutation is present in the newly created intron. (B) The
MiSplice work flow consists of three steps: alternative junction discovery, filtering, and manual review.
First, the user inputs the locations of RNA-Seq BAM files along with a mutation file. MiSplice searches
the BAM file to identify any alternative splice junctions near the mutation of interest, while filtering out
known splice junctions and calculates the number of alternative junction supporting reads for case and
control samples. For the filtering step, the following sites are removed: mutations in HLA genes, low
fraction of reads supporting the alternative splice junction, and sites expressed in controls. Finally we
manually reviewed all sites to validate the in silico predictions. (C) Breakdown of 2,056 manually validated
splice site-creating mutations by conventional annotation.

MiSplice manages large analyses using parallel computation to search for alternative
splice junctions within windows of ±20 bp from the mutation of interest. For example, of
66

the 1,416,566 candidate mutations examined here, 4,448 had 5 or more unique RNASequencing reads supporting the predicted alternative junction in proximity to the
mutation. MiSplice then conducts a series of further evaluations, including Ensemblbased filtering of canonical junctions, establishing observational significance by case
comparison to a matched set of controls, and assessing score and depth of each cryptic
site using MaxEntScan (Yeo and Burge, 2004) and SamTools (Li et al., 2009). From the
resulting subset, MiSplice filters out HLA genes and sites whose junctions have
insufficient difference of expression, as judged from the case-control assessment. Here,
we evaluated promising alternative junctions with at least 5% of paired end RNASequencing reads at the genomic location supporting the alternative junction of interest.
MiSplice processing revealed 2,056 mutations (Table S1) potentially creating an
alternative splice site. Manual review indicated a 2.09% false positive rate, suggesting
high specificity of the MiSplice algorithm for discovering these types of mutation-induced
splicing events. Of these putative splice events, 1.90% and 0.47% are considered
complex and are in highly homologous gene regions, respectively, so they were excluded
from further analyses (Methods).

Of the final 1,964 splice site-creating mutations (SCMs) passing manual review (Table
S1), 52% (1,016) are in annotated splice sites, suggesting disruption of the canonical
splice site and selection of a the alternative splice site nearby (Fig. 3.1C). Importantly,
26% (513) and 11% (208) of the SCMs had previously been mis-annotated as missense
and silent mutations, respectively. In addition, we found 58 insertions or deletions, 46
nonsense, and 123 non-coding region mutations that likewise create cryptic splicing sites.
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MOLECULAR AND BIOLOGICAL PATTERNS OF SPLICE SITE-CREATING MUTATIONS
We next characterized the sequence context for the 1,790 SCMs corresponding to single
nucleotide mutations. The sequences of each 9-mer (donor) and 23-mer (acceptor)
covering the mutation position were extracted for both the mutant and reference
sequences. Their splice scores as potential donor or acceptor sites were then estimated
using MaxEntScan (Table S1).
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Figure 3.2. Sequence contexts and characteristics of splice site-creating mutations. (A)
Frequency distribution of splice site-creating mutations relative to the newly created splice junction,
with high frequency shown at the 3rd nucleotide position in the newly created intron. (B) Comparison of
splicing scores for the newly created splice site, before (reference) and after the mutation (mutant).
Showing larger effect of mutations at the 3rd nucleotide position in the intron (especially for the 3’ splice
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sites). (C) Dominant nucleotide sequence context for splice site-creating mutations at -3 position of the
3’ splice site. Mutation position (red dot) is present 3 base pairs away from the newly created exon. (D)
Transition and transversion rate at the -3 position of the 3’ splice site. Most mutations are G>C
transversions, strengthening the consensus sequence of the splicing factor U2AF1. (E) Comparison of
splicing scores between the nearest canonical splice junction with and without mutation compared to
the newly created splice junction with and without the mutation. Most mutations strengthen the
alternative splice junction relative to the canonical splice junction.

Mutations near the alternative splice junctions show higher mutation rates in the introns
for both 5’ (p<1e-5, binomial test) and 3’ splice site (p<1e-6) (Fig. 3.2A). More
interestingly, we found an enrichment of mutations at the third nucleotide position in the
intron, but depletion at the first and second positions (especially for 3’ splice site) (Fig.
3.2A). Comparison of splicing scores between splice site-creating mutants and reference
forms shows that most mutants have stronger splice signals than the reference (Fig.
3.2B). Mutations that create a G or T to produce an alternative 5’ splice site dramatically
increase splice site strength. For 3’ splice sites, mutations enriched on the third nucleotide
of the newly created intron showed the largest increase of splicing score (Fig. 3.2B).
Further examination of the sequence context around mutations at the third nucleotide of
3’ splice sites shows that 53% have a mutation on aGag repeats and another 16% are
mutated on agGag repeats, all creating alternative junctions 2 nucleotides away from the
annotated ones (Fig. 3.2C). Mutations at the -3 position of the alternative acceptor site
would potentially enhance U2AF1 recognition of the acceptor splice site. Previous studies
have reported S34F U2AF1 mutants preferentially skip exons that contain a T nucleotide
at the -3 position (Okeyo-Owuor et al., 2015). Of the 192 mutations that are located at the
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-3 position from the alternative junction and contain an AG in the -2 and -1 positions, 56%
undergo a G>C transversion (21% G>A, 18% G>T, 3% C>T, 2% A>C, 1% A>T) with C
being the preferred base at the -3 position for U2AF1 binding (Fig. 3.2D).

We also explored the relationship between the alternative and canonical splice junctions.
As expected, mutations at splice sites dramatically reduced splice scores of the canonical
splice junctions, while strengthening those at the alternative splice junctions in most
cases. In contrast, a subset of missense and silent mutations did not drastically alter the
canonical junction, but instead preferentially strengthened a nearby alternative splice site
(Fig. 3.2E). When analyzing the raw splicing scores (canonical and alternative site before
and after mutation), we found that 1,089 out of 1,790 (61%) events showed higher splice
score for the alternative splice site than the canonical site, indicating inclination for the
alternative sites. Further, while 485 (27%) events saw lower post-mutation alternative
splice score, differences between alternative and canonical scores had decreased,
suggesting that these mutations are still likely enhancing the preference for the alternative
site. Only 214 (12%) events did not show evidence suggesting increased post-mutational
preference for using the alternative site. These cases are a good illustration of the fact
that many other genomic splicing features are also relevant, including exonic splicing
enhancers (ESE), polypyrimidine tract, branch point, and RNA-binding proteins. They are
also consistent with the general view that splice score is not definitive (Jian et al., 2014).
We emphasize that all 1,790 alternative splice sites demonstrated usage based on patient
RNA-Seq data and that 10 out of 11 (>90%) identified splice site-creating mutations were
validated experimentally (see below).
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EXPRESSIVITY AND PENETRANCE OF SPLICE-SITE-CREATING MUTATIONS
In the presence of the mutation, alternative splice junctions exhibited a wide range of
expression. To quantify this effect, we measured alternative junction expression as the
fraction of alternatively spliced junction spanning reads over the total number of reads at
the genomic location, what we refer to as the Junction Allele Fraction (JAF). Fig. 3.3A
shows the distribution of JAF’s for all high confidence MiSplice predicted alternative
junctions, separated by conventional mutation annotations (Fig. 3.3A). Currently, we use
a JAF cut-off of 5% for reporting the final high-confidence sites. However, there are some
potential alternative sites excluded by this cut-off. Our analysis revealed alternative
junction expression varies widely. As expected, DNA variant allele fraction (VAF) and JAF
have a generally positive correlation (Fig. 3.3B), with SCMs in KDM6A and FGFR2 having
>75% DNA VAF and JAF. However, a SCM in ARID1A has a DNA VAF of 23% and JAF
of 67%. Such large ranges have been noted for mutations outside of the splice site
(Broeks et al., 2003; Clarke et al., 2000; Venables, 2004). Both the truncated and normal
spliced products can be observed for many variants, either due to the wild type allele or
leaky splicing, for example as observed in RNASEH2A, NFU1, SMN1, CFTR, and
NF2 (Boerkoel et al., 1995; Caminsky et al., 2014; Ferrer-Cortes et al., 2016; Lohmann
and Gallie, 2004; Mautner et al., 1996; Pagani et al., 2003; Rice et al., 2013; Svenson et
al., 2001; Vezain et al., 2011) .
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Figure 3.3. Junction allele fraction of splice site-creating mutations. (A) The junction allele fraction
(JAF) is defined as the number of reads supporting the alternative spliced junction relative to total
junction spanning reads. Distribution of JAF values separated by conventional annotation type. (B) JAF
vs. DNA Variant Allele Fraction (VAF) comparison by conventional annotation type. Most mutation
types show a generally positive correlation between JAF and VAF values. (C) Splice site-creating
mutations expressed in the newly created exon of the alternative splice junction. Comparison of
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mutation position relative to the percent of reads supporting the alternative junction and mutation
(Spliced-In JAF). The mean of each position is highlighted by the black point. For all positions, there is
a strong correlation between the presence of the splice site-creating mutation and the alternative splice
junction.

We next considered the expression of mutations that are spliced-in, i.e. mutations located
within the exon of the alternatively spliced product. To this end, we determined the ratio
of the number of alternative junction reads containing the mutation versus total number
of reads supporting the alternative junction (Fig. 3.3C). Overall, most of the reads
supporting the alternative junction also support the mutation, which suggests a strong
association between the mutation and alternative splice junction. Regarding the 5’ splice
site, mutations within the first 6 bp of the new exon junction have a much higher fraction
of alternative junction reads supporting them; and we see an inverse correlation between
the mutation and the junction as the distance between them increases. For the 3’ splice
site, we observe a similar trend, although with a higher variability as a function of the
distance from the alternative junction.

SPLICE SITE-CREATING MUTATIONS ACROSS GENES AND CANCER TYPES
A total of 1,607 unique genes harbored SCMs, with 85% (1,359) having one mutation and
15% (248) having two or more. TP53 contained the greatest number (26), followed by
GATA3 (18). While most SCMs were found outside the current cancer gene compendium
(Table S1), Fig. 3.4A shows that a remarkable number of cancer genes harbor splice
altering variants, a phenomenon supported in the literature (Sebestyen et al., 2016). A
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pan-cancer view reveals that TP53 was the most mutated across cancer types, while 18
GATA3 mutations and 6 ATRX mutations were specific to breast cancer (BRCA) and low
grade glioma (LGG), respectively.

Figure 3.4. Splice site-creating mutations across genes and cancer types. (A) Distribution of splice
site-creating mutations in each gene separated by total number of mutations in each gene. TP53 has the
largest number of splice site-creating mutations, followed by GATA3 and ATRX. (B) Genes with the
highest number of pancancer splice site-creating mutations. Circle size correlates with total number of
mutations for each gene (labeled inside circle), and colored by cancer type. Splice site-creating mutations
in TP53 are present in many cancer types, while mutations in ATRX and GATA3 are specific to LGG and
BRCA, respectively. (C) Proteins Timeless (PAB domain) and PARP1 (Chain A) are colored green and
pink, respectively. Originally annotated p.S939S mutation (red) and spliced-out sequence (blue) are
highlighted on PARP1 (Chain A). (D) 3D protein structure of PARP1 in complex with an inhibitor (PDB
ID: 5WRQ). Drug inhibitor and PARP1 (Chain A) are indicated with green and pink, respectively.
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We observed 137 mutations nearby to one another (+/- 5 bp) which lead to the creation
of the same recurrent splice site-creating events, not only in TP53, but also GATA3,
DDX5, KDM6A, SETD2, PTEN, SPOP, and BAP1. While some mutations did not occur
at the same position, 14 mutations creating the same alternative splice junction were
found in the same exon, including 2 mutations in the third exon of BAK1. While most
mutations in close proximity created the same alternative splice junction, two adjacent
splice site-creating mutations in CTNND1 and 2 nearby exonic mutations in ACP2 and
GMPPB created different alternative junctions.
SCMs can impact protein structure and have potential therapeutic implications. Poly ADPribose polymerase 1 (PARP1) is an enzyme involved in recruiting protein members of
DNA repair pathways including Timeless PAB (PARP1 binding domain) (Fig. 3.4C) (Xie
et al., 2015). Since PARP1 is essential to many cellular processes, including DNA repair,
it is commonly targeted by antitumor agents (Malyuchenko et al., 2015). PARP1 inhibitors
targeting the catalytic domain disrupt DNA repair mechanisms thereby increasing the
effectiveness of chemotherapeutic agents (Fig. 3.4D). Identifying mutations that disrupt
inhibitor binding are essential to properly evaluate treatment options. MiSplice identified
a conventionally annotated silent PARP1 mutation (p.S939S) in a lung squamous cell
carcinoma (LUSC) patient that acts as a splice site-creating variant by creating a de novo
donor site (Fig. 5A). 82 reads supported the de novo donor site, which results in a 10
amino acid deletion (p.940-p.950) that falls within the catalytic domain (Fig. 3.4D). Out of
173 LUSC control samples, none contained reads supporting the alternative junction,
providing strong evidence that the annotated “silent” mutation is actually a SCM. Previous
reports of missense mutations at p.940 are predicted to reduce PARP1 enzymatic activity
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by disrupting the binding affinity of PARP1 to its substrate NAD+ (Alshammari et al.,
2014). The in-frame SCM is likely disturbing the local structure of PARP1 and thereby
disrupting the interactions between PARP1, its protein binding partners, and drugs
binding within the pocket (Figs. 3.4C and 3.4D).

Figure S1. BAP1 gene and protein expression. Related to Figure 3.5. Violin plot of RSEM and
RPPA data for control samples (grey) and novel splice creating mutant samples (red).
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We identified two kidney renal clear cell carcinoma (KIRC) samples having the same
conventionally annotated missense mutation (c.233A>G, p.N78S) in BAP1, a nuclear
deubiquitinase, that created the same spliced-out alternative splicing product (Fig. 3.5B).
Inactivation of BAP1 is prevalent among renal cell carcinomas (Pena-Llopis et al., 2012)
and an annotated missense mutation (p.L570V) has been reported to create a cryptic
splice site in melanoma (Wadt et al., 2012). At the transcriptional level, the expressions
of the case and control samples are relatively comparable, but at the translational level,
one case with available protein data (RPPA) showed significantly lower expression
(p=0.044, permutation test) relative to the controls (Table S2). This result suggests the
conventionally annotated missense mutations in BAP1 are likely creating an alternatively
spliced transcript that is not readily expressed at the protein level.
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Figure 3.5. Minigene functional assay of splice site-creating mutations. (A) Integrative genomics
viewer (IGV) screenshot of the conventionally annotated synonymous mutation in PARP1 in exon 21.
RNA-Seq reads of the candidate splice site-creating mutation reveals the creation of an alternative
splice site (red reads) created by the conventionally annotated synonymous mutation. (B) Candidate
recurrent splice site-creating mutations in BAP1. Conventionally annotated as synonymous variants,
BAP1 mutated region shows alternatively spliced reads (red reads) in the IGV screenshot for each
sample with the splice site-creating mutation. (C) IGV screenshot of a conventionally annotated
synonymous mutation in RAD51C in exon 2. (D) Maximum entropy score of the splice site-creating
variant before (purple) and after (red) the introduced mutation for each variant functionally validated in
the mini-gene splicing assay. In silico predictions suggest all mutations strengthen the alternative splice
site. (E) Candidate splice site-creating mutations validated by the mini-gene splicing assay. Exons of
interest were cloned into the pCAS2.1 vector and mutant (red) and wildtype (purple) plasmids were
transfected into 293T cells and total RNA was extracted to identify mutation induced alternatively
spliced products.

We used a pCAS2.1 splicing reporter mini-gene functional assay, adapted from previous
publications (Bonnet et al., 2008; Gaildrat et al., 2010; Malone et al., 2016; Tournier et
al., 2008; Vreeswijk and van der Klift, 2012), to validate SCMs in eleven cancer genes,
including two originally annotated silent mutations in PARP1, RAD51C, two splice site
mutations in TP53 and BRCA1, and several missense mutations in ARID2, BAP1, BCOR,
CDH1, KMT2A, PTEN, and TSC2. Wild-type and mutant exons were cloned into a
pCAS2.1 vector (Gaildrat et al., 2010) and transiently transfected into HEK293T cells.
Total RNA was extracted to evaluate alternatively spliced products by RT-PCR.
Examining the change in the MaxEntScan score for the 11 genes revealed mutations in
ARID2, BAP1, BCOR, CDH1, PARP1, RAD51C, PTEN, and TSC2 having dramatically
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stronger splice scores in the presence of the mutation, while mutations in BRCA1,
KMT2A, and TP53 did not (Fig. 3.5D). Except for PTEN, variants with stronger splice
scores showed higher levels of the alternatively spliced product in the mini-gene assay
when compared to the wild-type. Variants with moderate changes in splice score still
showed evidence of alternatively spliced transcripts, revealing the importance of utilizing
functional assays to evaluate the effect of mutations in a splicing context in addition to insilico predictions. The mini-gene assay confirmed 91% (10/11 genes) splicing alterations
in all tested genes and sequencing confirmed the alternatively spliced products (Fig. 3.5E,
Methods), suggesting a strong concordance between MiSplice predicted splice sitecreating mutations and the functional assay.

NEO-ANTIGENS INTRODUCED BY SPLICE SITE-CREATING MUTATIONS

We have further investigated neoantigens produced by splice site-creating mutations. By
using the RefSeq transcript database, a total of 2,993 protein sequences were translated
for transcripts containing mutation-induced alternative splice forms (Table S3). In the
translation, we allowed for different transcripts from each SCM. The HLA types for each
sample were adopted from the TCGA pancan immune working group (Synapse ID:
syn5974636). NetMHC4 and NetMHCpan-3.0 (Andreatta and Nielsen, 2016) were used
to predict the binding affinity between epitopes and the major histocompatibility complex
(MHC) and showed a high concordance in total predicted neoantigens (Pearson = 0.94,
Supplementary Figure S2). We found that alternative splice forms for some important
genes related to tumorigenesis, including SMARC1, KDM6A, and NOTCH1, are highly
immunogenic and can contain 40 or more unique neoantigens (Fig. 3.6A) (Dalgliesh et
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al., 2010; Papadakis et al., 2015). In addition, the mean number of neoantigens across
SCMs from NetMHCpan-4.0 and NetMHCpan-3.0 are 2.0 and 2.5, respectively, which
are both higher than the average number of around 1 for non-synonymous mutations.
Furthermore, 28 genes contain recurrent neoantigen events (more than or equal to three)
across samples (Fig. 3.6B). In particular, GATA3 has the highest recurrence and GATA3
SCMs were mutually exclusive with other mutation types (Fig. 3.6C). The CA deletion at
chr8:8111433 disrupts the canonical splice site and an alternative splice site is used for
creating the alternative splice form, which results in a frame shifted protein product
spanning the Zinc-finger domain (Figs. 3.6D and 3.6E). 19 unique neoantigen peptide
sequences were mapped to the frameshifted protein product for the 16 samples (Fig.
3.6F). We were further able to validate one alternative peptide sequence using mass
spectrometry data from a recent proteogenomics study on 77 TCGA breast cancer
patients (Mertins et al., 2016). For one sample with the highly recurrent and expressed
GATA3 SCM, we used MSGF+ to search publicly available mass spectrometry data for
evidence of alternative GATA3 peptides. Fig. 3.6G shows one identified mass spectrum
supporting one alternative GATA3 peptide, which covers two immunogenic peptides
(KPKRRLPG and LIKPKRRLPG ) predicted in TCGA-AR-A1AP.

81

Figure 3.6. Schematic of GATA3 splice site-creating mutations and neoantigen predictions. (A)
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Distribution of neoantigens predicted by NetMHCpan and NetMHC4. Genes with highest number of
neoantigens labeled. Mean value for each tool indicated by X and labeled. (B) Genes with the largest
recurrence of predicted neoantigens across the dataset. GATA3 shows the highest recurrence. (C)
Mutual exclusivity of protein-affecting mutation (PAM), frame-shifting indel (FS), in-frame indel (IF) and
splice site-creating mutations (SCM) in GATA3. (D) IGV screenshot of GATA3 splice site-creating
mutation which disrupts the canonical splice site and utilizes a cryptic splice site 7 bp downstream.
Mutant reads highlighted in red and normal reads in purple. CA deletion indicated in figure. (E)
Predicted functional domains disrupted due to the recurrent splice site-creating mutation in GATA3. (F)
Predicted neoantigen peptide sequences mapped to the frameshifted protein product for samples with
GATA3 splice site-creating mutations. (G) Mass spectrum of GATA3 peptide in TCGA-AR-A1AP.
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Figure 3.7. PD-L1, PD-L2, PD-1, CD8A and CD8B expression. (A) Expression comparison of PD-L1,
PD-L2, and T cell markers: PD-1, CD8A, CD8B between samples with (case) and without (control)
splice site-creating mutations across 6 cancer types. Symbols: * is p-value less than 0.05, ** is p-value
<0.01, *** is p-value <0.001, n.s. is not significant.

High neoantigen burden is associated with an elevated immune response (Turajlic et al.,
2017). To test whether SCMs affect immune response, we compared the expression of
T-Cell markers PD-1, CD8A and CD8B and PD1 immune checkpoint blockades PD-L1
and PD-L2 (Fig. 3.7). We selected 6 cancer types (BRCA, BLCA, HNSC, LUAD, LUSC
and SKCM) with sufficient samples containing SCMs for adequate statistical power. Both
T-Cell markers (PD-1, CD8A and CD8B) and immune checkpoint blockade PD-L1 show
increased expression in samples with SCMs compared to samples without SCMs (Fig.
3.7), indicating alternative splice forms induced by SCMs increase the overall
immunogenicity of these cancers. The highly expressed PD-L1 suggests PD-L1
immunotherapy as potential treatments for samples containing SCMs.

3.3 Methods
DATASET DESCRIPTION

Aligned RNA-Seq bam files were analyzed using the ISB google. These cancer types are
Acute Myeloid Leukemia [LAML], Adrenocortical carcinoma [ACC], Bladder Urothelial
Carcinoma [BLCA], Brain Lower Grade Glioma [LGG], Breast invasive carcinoma
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[BRCA], Cervical squamous cell carcinoma and endocervical adenocarcinoma [CESC],
Cholangiocarcinoma [CHOL], Colon adenocarcinoma [COAD], Esophageal carcinoma
[ESCA], Glioblastoma multiforme [GBM], Head and Neck squamous cell carcinoma
[HNSC], Kidney Chromophobe [KICH], Kidney renal clear cell carcinoma [KIRC], Kidney
renal papillary cell carcinoma [KIRP], Liver hepatocellular carcinoma [LIHC], Lung
adenocarcinoma [LUAD], Lung squamous cell carcinoma [LUSC], Lymphoid Neoplasm
Diffuse Large B-cell Lymphoma [DLBC], Mesothelioma [MESO], Ovarian serous
cystadenocarcinoma [OV], Pancreatic adenocarcinoma [PAAD], Pheochromocytoma and
Paraganglioma [PCPG], Prostate adenocarcinoma [PRAD], Rectum adenocarcinoma
[READ],

Sarcoma

[SARC],

Skin

Cutaneous

Melanoma

[SKCM],

Stomach

adenocarcinoma [STAD], Testicular Germ Cell Tumors [TGCT], Thymoma [THYM],
Thyroid carcinoma [THCA], Uterine Carcinosarcoma [UCS], Uterine Corpus Endometrial
Carcinoma [UCEC], Uveal Melanoma [UVM]

MISPLICE PIPELINE

The MiSplice pipeline was developed to detect mutation-induced splicing events from
RNA-Seq data. It is written in Perl and incorporates two standard tools, samtools and
MaxEntScan. The pipeline is fully automated and can run multiple jobs in parallel on LSF
cluster. It executes the following steps:

1)

Splitting large maf file into multiple smaller files with less mutations (currently, the

default setting is 200).
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2)

Discovering splicing junctions within 20bps of the mutation with at least 5

supporting reads with mapping quality Q20 and then filtering canonical junctions by using
the Ensembl 37.75 database. We selected 20bp as a cut-off since it is the farthest
distance from the splice junction in a splice region.

3)

Computing the number of supporting reads of above cryptic splice sites for control

samples without mutations (Table S1).

4)

Calculating the splicing scores for the cryptic splice sites via MaxEntScan.

5)

Reporting the depth of each cryptic splice site via Samtools.

6)

Filtering cryptic sites which fall in HLA loci or less than 5% of reads at the genomic

location supporting the alternative junction of interest.

7)

Further filtering cryptic sites by comparing the supporting reads in control samples.

The final reported cryptic sites must stand as top 5% for the number of supporting reads
in the case (with mutation).

SPLICE SITE SCORE ESTIMATION

For each cryptic splice site and nearby canonical splice site, the corresponding nucleotide
sequences were first extracted for both the mutant and reference sequences (9-mer and
23-mer for donor and acceptor, respectively). Their splice scores as potential donor or
acceptor sites were then estimated using MaxEntScan.

NEOANTIGEN PREDICTION
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For each predicted SCM, we use a curated RefSeq transcript database (version
20130722) to obtain the translated protein sequences for transcript containing alternative
splice forms induced by SCMs. Different length of epitopes (8mer, 9mer, 10mer and
11mer)

are

constructed

from

the

translated

protein

sequence.

We

use

NetMHC3pan(Nielsen and Andreatta, 2016) and NetMHC4(Andreatta and Nielsen, 2016)
to predict the binding affinity between epitopes and MHC. Epitopes with binding affinity
<=500nM which are also not present in the wild-type transcript are extracted from the
following neoantigen analysis.

MANUAL REVIEW

All splice site-creating mutations were manually reviewed using the integrative genomics
viewer (http://software.broadinstitute.org/software/igv/). Mutations were placed into one
of three categories: Pass, Complex, and No Support. Mutations were classified as
complex if more than one alternatively spliced product was observed for the mutated
sample.

CODE AVAILABILITY

MiSplice is written in Perl and is freely available from GitHub at https://github.com/dinglab/misplice under the GNU general public license. MiSplice uses several independent
tools and packages, including SamTools and MaxEntScan, all of which are likewise freely
available, but which must be obtained from their respective developers. The MiSplice
documentation contains complete instructions for obtaining and linking these applications
into MiSplice.
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MINI GENE SPLICING ASSAY

Exons of interest and approximately 150 bp of their flanking intron sequences were PCR
amplified from HEK293T genomic DNA using primers carrying restriction enzyme sites
for BamH1 and MluI. PCR products were cleaned up using NucleoSpin PCR Cleanup
(Macherey-Nagel) or DNA Clean and Concentrator-5 Kit (Zymo Research) and digested
with BamHI and MluI. The digested pCAS2.1 vector and PCR products were ligated using
T4 DNA Ligase (NEB). Mutations were introduced via Q5 Site-Directed Mutagenesis
(NEB). WT and MUT constructs were confirmed by sequencing of the insert region. The
plasmids were transiently transfected into HEK293T cells using Lipofectamine 2000
(ThermoFisher Scientific). 24 hours post transfection, cDNA was synthesized using 2 to
3 ug of total RNA with the Superscript III First-Strand Synthesis System (ThermoFisher
Scientific) and priming with Oligo(dT)20. Finally, cDNA was amplified using pCAS-KO1(5′-TGACGTCGCCGCCCATCAC-3′) and pCAS-R (5′-ATTGGTTGTTGAGTTGGTTGTC3′) and the alternative splicing patterns were evaluated on a 2.5% agarose gel with
ethidium bromide. Qiaquick Gel Extraction Kit (Qiagen) was used to purify bands for
sequencing (Table S3.1-3.2, Figure S3-S6).
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Figure S2: Mini-gene splicing assay.

Table 3.1: Mutation information for splice site-creating mutations validated in minigene
assay.
Gene

Sample

Position

Refere

Muta

Coding

Amino

nce

nt

Change

Acid

Transcript

Change
ARID2

TCGA-FS-A1Z3

12:

T

A

46243434

89

c.1787T

p.Val596

ENST00000334

>A

Glu

344

TSC2

TCGA-EE-A17Y

16:209870

C

A

c.89C>A

p.Ser30Ty

ENST00000219

r

476

c.2392C

p.Leu798

ENST00000219

>G

Val

476

c.783-

p.X261_s

ENST00000269

2A>C

plice

305

c.234A>

p.Thr78Th

ENST00000337

G

r

432

c.4123C

p.Arg1375

ENST00000378

>T

Trp

444.4

c.233A>

p.Asn78S

ENST00000460

G

er

680

c.2817C

p.Ser939

ENST00000366

>T

Ser

794

c.301+2

p.X101_s

ENST00000471

T>G

plice

181

c.477G>

p.Arg159

ENST00000371

T

Ser

953

c.5423G

p.Trp1808

ENST00000534

>T

Leu

358

5
CDH1

TCGA-GC-A3I6

16:688636

C

G

53
TP53

TCGA-FG-A60J

17:757715

T

G

7
RAD5

TCGA-32-1982

1C
BCOR

17:567723

A

G

80
TCGA-DM-A1HA

X:399220

A

G

49
BAP1

TCGA-CJ-4637

3:

and TCGA-B0-

52442512

T

C

5107
PARP

TCGA-66-2791

1
BRCA

G

A

31
TCGA-D6-6823

1
PTEN

1:2265508

17:412568

A

C

83
TCGA-06-2559

10:896929

G

T

93
KMT2

TCGA-55-7994

A

11:118366

G

T

474

Table 3.2: Predicted alternative and wild-type RT-PCR splice products from mini-gene
splicing assay.
Type

RT-PCR Sequence

pCAS2.1

TGACGTCGCCGCCCATCACGCCTCCAGGCTGACCCTGCTGACCCTCCTGCTG
CTGCTGCTGGCTGGGGATAGAGCCTCCTCAAATCCAAATGCTACCAGCTCCAG
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CAGCCAAGATCCAGAGAGTTTGCAAGACAGAGGCGAAGGGAAGGTCGCAACA
ACAGTTATCTCCAAGATGCTATTCGTTGAACCCATCCTGGAGGTTTCCAGCTTG
CCGACAACCAACTCAACAACCAAT
BAP1 Wild Type

CCCTGTATATGGATTTATCTTCCTGTTCAAATGGATCGAAGAGCGCCGGTCCC
GGCGAAAGGTCTCTACCTTGGTGGATGATACGTCCGTGATTGATGATGATATT
GTGAATAACATGTTCTTTGCCCACCAG

BAP1 Mutant

CCCTGTATATGGATTTATCTTCCTGTTCAAATGGATCGAAGAGCGCCGGTCCC
GGCGAAAGGTCTCTACCTTGGTGGATGATACGTCCGTGATTGATGATGATATT

TP53 Wild Type

CTCGCTTAGTGCTCCCTGGGGGCAGCTCGTGGTGAGGCTCCCCTTTCTTGCG
GAGATTCTCTTCCTCTGTGCGCCGGTCTCTCCCAGGACAGGCACAAACACGCA
CCTCAAAGCTGTTCCGTCCCAGTAGATTACCA

TP53 Mutant

CTCGCTTAGTGCTCCCTGGGGGCAGCTCGTGGTGAGGCTCCCCTTTCTTGCG
GAGATTCTCTTCCTCTGTGCGCCGGTCTCTCCCAGGACAGGCACAAACACGCA
CCTCAAAGCTGTTCCGTCCCAGTAGATTACCACGA

BCOR Wild

CTTGCCATCGGCATTCTCCACGTAGTATTCCCCTGTCAGTGGCAATCCCCGCC

Type

TGGACTCCTGAGGGATCAAGTGTTTGGTTTTGCACAGTCTCTTCCCGGATGGC
TTCTCGCTGTTGTCGGTGTATTTCTGCAGCAGGGAGGCAGCCTGGCAATCCTC
TTCTTCGTCTGCACACAGCACATCTGTCTTCTGGTTTTCTTTAATTTTCTGCTGT
TTGGCAGGCGGCCTGGAGGCTGGTGCGCAGCTTGGCTGAGCCTGCTTTTTGC
CGCCTGCACTGGTGGATGAAAGACTCTTCATGGGCGGAGAGCCGGAGAACAC
AGGCAAGC

BCOR Mutant

CTGGACTCCTGAGGGATCAAGTGTTTGGTTTTGCACAGTCTCTTCCCGGATGG
CTTCTCGCTGTTGTCGGTGTATTTCTGCAGCAGGGAGGCAGCCTGGCAATCCT
CTTCTTCGTCTGCACACAGCACATCTGTCTTCTGGTTTTCTTTAATTTTCTGCTG
TTTGGCAGGCGGCCTGGAGGCTGGTGCGCAGCTTGGCTGAGCCTGCTTTTTG
CCGCCTGCACTGGTGGATGAAAGACTCTTCATGGGCGGAGAGCCGGAGAACA
CAGGCAAGC
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RAD51C Wild

AAGTTGGGATATCTAAAGCAGAAGCCTTAGAAACTCTGCAAATTATCAGAAGAG

Type

AATGTCTCACAAATAAACCAAGATATGCTGGTACATCTGAGTCACACAAGAAGT
GTACAGCACTGGAACTTCTTGAGCAGGAGCATACCCAGGGCTTCATAATCACC
TTCTGTTCAGCACTAGATGATATTCTTGGGGGTGGAGTGCCCTTAATGAAAACA
ACAGAAATTTGTGGTGCACCAGGTGTTGGAAAAACACAATTATG

RAD51C Mutant

AAGTTGGGATATCTAAAGCAGAAGCCTTAGAAACTCTGCAAATTATCAGAAGAG
AATGTCTCACAAATAAACCAAGATATGCTG

KMT2A Wild

CAGTGGGATGTTACCAAACGCAGTGCTTCCACCTTCACTTGACCATAATTATGC

Type

TCAGTGGCAGGAGCGAGAGGAAAACAGCCACACTGAGCAGCCTCCTTTAATG
AAGAAAATCATTCCAGCTCCCAAACCCAAAGGTCCTGGAGAACCAGACTCACC
AACTCCTCTGCATCCTCCTACACCACCAATTTTGA

KMT2A Mutant

TTGCAGGAGCGAGAGGAAAACAGCCACACTGAGCAGCCTCCTTTAATGAAGAA
AATCATTCCAGCTCCCAAACCCAAAGGTCCTGGAGAACCAGACTCACCAACTC
CTCTGCATCCTCCTACACCACCAATTTTGA

PARP1 Wild

CTTTGACACTGTGCTTGCCCTTGGGTAACTTGCTGATATGTGAAGCGTGCTTCA

Type

GTTCATAC

PARP1 Mutant

TGATATGTGAAGCGTGCTTCAGTTCATAC

BRCA1 Wild

ACTCCAAACCTGTGTCAAGCTGAAAAGCACAAATGATTTTCAATAGCTCTTCAA

Type

CAAGTTGACTAAATCTCGTACTTTCTTGTAGGCTC

BRCA1 Mutant

CTGTGTCAAGCTGAAAAGCACAAATGATTTTCAATAGCTCTTCAACAAGTTGAC
TAAATCTCGTACTTTCTTGTAGGCTC

ARID2 Wild

AACGGTCTTTCCAAATCATACAGTGAAGAGAGTGGAGGATTCCAGTAGCAATG

Type

GGCAGGCACATATTCATGTGGTAGGAGTAAAACGGAGGGCTATACCACTTCCC
ATTCAGATGTACTATCAGCAGCAACCAGTTTCTACTTCTGTTGTTCGTGTTGATT
CTGTTCCTGATGTATCTCCTGCTCCTTCACCTGCAG

ARID2 Mutant

AACGGTCTTTCCAAATCATACAGTGAAGAGAGTGGAGGATTCCAGTAGCAATG
GGCAGGCACATATTCATGAG
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PTEN Wild Type

TTGCACAATATCCTTTTGAAGACCATAACCCACCACAGCTAGAACTTATCAAAC
CCTTTTGTGAAGATCTTGACCAATGGCTAAGTGAAGATGACAATCATGTTGCAG
CAATTCACTGTAAAGCTGGAAAGGGACGAACTGGTGTAATGATATGTGCATATT
TATTACATCGGGGCAAATTTTTAAAGGCACAAGAGGCCCTAGATTTCTATGGG
GAAGTAAGGACCAGAGACAAAAAG

PTEN Mutant

TTGCACAATATCCTTTTGAAGACCATAACCCACCACAGCTAGAACTTATCAAAC
CCTTTTGTGAAGATCTTGACCAATGGCTAAGTGAAGATGACAATCATGTTGCAG
CAATTCACTGTAAAGCTGGAAAGGGACGAACTGGTGTAATGATATGTGCATATT
TATTACATCGGGGCAAATTTTTAAAGGCACAAGAGGCCCTAGATTTCTATGGG
GAA

CDH1 Wild

GACTTTGACTTGAGCCAGCTGCACAGGGGCCTGGACGCTCGGCCTGAAGTGA

Type

CTCGTAACGACGTTGCACCAACCCTCATGAGTGTCCCCCGGTATCTTCCCCGC
CCTGCCAATCCCGATGAAATTGGAAATTTTATTGATGAA

CDH1 Mutant

GACTTTGACTTGAGCCAGCTGCACAGGGGCCTGGACGCTCGGCCTGAAGTGA
CTCGTAACGACGTTGCACCAACCCTCATGAGTGTCCCCCG

TSC2 Wild Type

AGGGGTTTTCTGGTGCGTCCTGGTCCACCATGGCCAAACCAACAAGCAAAGAT
TCAGGCTTGAAGGAGAAGTTTAAGATTCTGTTGGGACTGGGAACACCGAGGCC
AAATCCCAGGTCTGCAGAGGGTAAACAGACGGAGTTTATCATCACCGCGGAAA
TACTGAGA

TSC2 Mutant

AGGGGTTTTCTGGTGCGTCCTGGTCCACCATGGCCAAACCAACAAGCAAAGAT
TCAGGCTTGAAGGAGAAGTTTAAGATTCTGTTGGGACTGGGAACACCGAGGCC
AAATCCCAG
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Figure S3. ARID2, BCOR, BRCA1 Mini-Gene results. Related to Figure 3.5. (A,D,G) DNA
chromatograms verifying ARID2, BCOR, and BRCA1 wildtype and mutant sequencing results,
respectively. Mutation position is highlighted. (B,E,H) Reverse transcriptase PCR (RT-PCR) with
wild type and mutant plasmids, results in triplicate. Numbered bands are sequenced for
confirmation. (C,F,I) DNA chromatograms of RT-PCR bands sequenced. Highlighted sequence
indicates boundary of pCAS2.1 plasmid.
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Figure S4. PTEN, PARP1, KMT2A Mini-Gene results. Related to Figure 3.5. (A,D,G) DNA
chromatograms verifying PTEN, PARP1, and KMT2A wildtype and mutant sequencing results,
respectively. Mutation position is highlighted. (B,E,H) Reverse transcriptase PCR (RT-PCR) with wild type
and mutant plasmids, results in triplicate. Numbered bands are sequenced for confirmation. (C,F,I) DNA
chromatograms of RT-PCR bands sequenced. Highlighted sequence indicates boundary of pCAS2.1
plasmid.
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Figure S5. RAD51C, TP53, TSC2 Mini-Gene results. Related to Figure 3.5. (A,D,G) DNA
chromatograms verifying RAD51C, TP53, and TSC2 wildtype and mutant sequencing results,
respectively. Mutation position is highlighted. (B,E,H) Reverse transcriptase PCR (RT-PCR) with wild
type and mutant plasmids, results in triplicate. Numbered bands are sequenced for confirmation. (C,F,I)
DNA chromatograms of RT-PCR bands sequenced. Highlighted sequence indicates boundary of
pCAS2.1 plasmid.
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Figure S6. BAP1 and CDH1 Mini-Gene results. Related to Figure 3.5. (A,D) DNA chromatograms
verifying BAP1 and CDH1 wildtype and mutant sequencing results, respectively. Mutation position is
highlighted. (B,E) Reverse transcriptase PCR (RT-PCR) with wild type and mutant plasmids, results in
triplicate. Numbered bands are sequenced for confirmation. (C,F) DNA chromatograms of RT-PCR
bands sequenced. Highlighted sequence indicates boundary of pCAS2.1 plasmid.

CELL CULTURE

HEK293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM)
supplemented with fetal bovine serum (FBS) and penicillin streptomycin.
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STATISTICAL ANALYSES

MiSplice assesses the significance of the number of reads supporting the predicted
alternative splice junction by comparing to read counts from a control cohort. Specifically,
a frequency distribution is constructed from the control cohort, from which threshold
values for 5% and 95% tails on the left and right, respectively, are determined. A series
of logic tests is then conducted to discern the best explanation of the data. Possible
verdicts are low or high expression if the datum is outside the 5% or 95% thresholds,
respectively, average expression if no thresholds are exceeded, or no expression in this
tissue if the thresholds are zero.

3.4 Discussion
In this study, we applied our newly developed bioinformatics tool called MiSplice
(Mutation Induced Splicing) to systematically analyze splice site-creating events that arise
from somatic mutations. Our analysis shows MiSplice reliably identifies SCMs across
multiple cancer types. Existing studies have largely focused on splice-disrupting events
in known splice sites, but the current study substantially extends our knowledge into the
realm of splice site-creating mutations in human cancer. For instance, we found 1,016
splice site mutations not only disrupt the canonical splice site, but also create an
alternative splice site. We also found that hundreds of mutations that would traditionally
be classified as missense, silent, indel, and nonsense are really acting as SCMs. Many
important cancer-related genes harbor these mutations, such as TP53, ATRX, BAP1,
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CTNNB1, RB1, etc. It is noteworthy that we found five splice site-creating mutations in
ATRX among 288 lower grade glioma cases, likely leading to the disruption of ATRX
function. A previous study has shown that loss of wild-type ATRX is associated with
tumor growth in glioma (Koschmann et al., 2016).

Characterization of these alternative splice events show that most SCMs have a higher
splice score, as measured by MaxEntScan, in the post-mutation alternative splice site as
compared to the reference. These results are consistent with the preferential selection of
these alternative sites as new splicing forms. For the splice-site mutation, the splice score
associated with the canonical junction is coincidently decreased after mutation. However,
while there is no difference in splice scores of canonical junctions before and after
missense and silent mutations, the alternative splice site was often strengthened after
mutation. This suggests silent and missense mutations instead act as modifiers of splicing
by creating or strengthening cryptic sites within the exon as opposed to disrupting the
canonical splice site. In addition, we found a significant enrichment of mutations at the -3
position in the 3’ splice site, the two dominant sequence contexts being aGag and agGag,
where G is at the -3 position.

In cases where the mutation is retained in the alternative splice junction, we distinguish
mutations with two further categories, splice-in and splice-out. For splice-in mutations,
we can characterize the association between mutations and cryptic splicing forms. For
example, we found high concordance for RNA-seq reads supporting alternatively spliced
junctions and mutations, suggesting the association between mutations and cryptic
splicing forms.
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The current study has greatly extended the insight into the transcriptional ramifications of
genomic alterations by identifying nearly 1,964 alternative splice sites introduced by
somatic mutations and functionally validating ten of eleven variants in a mini-gene splicing
assay. These events were conventionally annotated as missense, silent, splice site,
nonsense, or other mutations when, in fact, we have shown that they often create cryptic
splice sites. The relative abundance of the alternative and wild-type product suggests
varying levels of junction usage, depending on the context of the mutation, and
emphasizes the importance of validating predictions using a functional assay to
understand the full biological consequence. The alternative products may be
therapeutically targetable in some cancer patients. For example, the targeting of
neoantigens shows promising result in treating melanoma patients (Carreno et al., 2015).
By further evaluating human leukocyte antigen (HLA) genotypes and binding affinities to
the major histocompatibility complex (MHC), it is likely that new neoantigens from cryptic
splice sites may be discovered. The current study reveals that alternative splice forms
induced by splice site-creating mutations are highly immunogenic and correlated with a
high T-Cell immune response and an elevated PD-L1 expression, suggesting potential
for immunotherapy in these samples. Further investigation of the cryptic splice sites by
mass spectra
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Chapter 4: Rare germline and somatic
splice-site-creating mutations disrupt
exon definition in cancer genomes
Contribution: I developed the entire code for translation of MiSplice variants. I manually
reviewed many variants validated by our computational tool, performed all downstream
analyses, wrote the entire text, created all Figures, and performed entire mini-gene
splicing assay for 7 variants tested.

4.1 Introduction

Mutations can be germline or somatic in nature. Germline mutations are inherited from
parents or acquired de novo. Somatic mutations are acquired throughout an organism’s
lifetime in individual cells due to genetic and environmental factors such as chemicals
and radiation. Most of the damage in the DNA is repaired, but sometimes the alterations
are fixed. Mutations in genic and regulatory regions can affect gene function in several
ways by causing loss or gain of function, altering transcript splicing, and increasing or
decreasing gene expression level. In combination, such variations can disrupt normal
gene function and alter cellular response to regulation giving the cell a selective
advantage to proliferate autonomously.
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The underlying genomic architecture of individual species alters the resulting phenotypic
variability. Understanding how differences to gene architecture can alter a genes function
is essential to understanding many biological questions including disease diagnosis,
progression and treatment. Current studies suggest that between 70-95% of human
genes harbor multiple mRNA transcripts (Johnson et al.; Matlin et al.; Modrek and Lee).
Different mRNA transcripts are created by the process of alternative splicing which
expands the complexity and information content of the eukaryotic genome and allows for
tissue, developmental, or temporally expressed isoforms which can perform alternate
functions. Understanding how genomic variation in tumors can contribute to alternative
splicing defects is an actively expanding field.

For the past decade, cancer genomics studies have focused on identifying and validating
germline and somatic mutations by comparing patients tumor samples to their normal
tissue. The integration of transcriptomic and proteomic data provides valuable insight as
to the biological factors contributing to the cancer genome (Cieslik and Chinnaiyan). A
database to explore splice-junction usage across TCGA (Sun et al.) as well as a global
analysis of splicing across the TCGA cohort (Kahles et al.) were recently published
expanding the current paradigm about the exceptions and rules by which splicing is
dysregulated in cancer. While this recent publication analyzed the global landscape of
alternative splicing across the TCGA pan-cancer cohort, they limited their analysis to
germline mutations that are known to also be somatic in origin, greatly limiting their
prediction power (Kahles et al.).
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Earlier this year, we published a bioinformatic tool that systematically predicts somatic
splice-site-creating mutations across 33 cancer types (Jayasinghe et al.). We identified
nearly 2,000 somatic splice-site-creating mutations with 26% and 11% of mutations being
initially mis-classified as missense and silent mutations, respectively. This novel finding
lead us to question the burden of similar mutations in the germline of cancer patients, as
this is an underexplored question in the field. Recently, The Cancer Genome Atlas
consortium published a curated mutation profile of germline (Huang et al.) and somatic
(Bailey et al.; Ellrott et al.) mutations across cancer genomes. These timely and thorough
scientific publications have provided a sound basis for exploring the splice-site-creating
landscape in both a somatic and germline context.

Here we developed additional modules for MiSplice to facilitate accurate identification of
thousands of rare germline and somatic splice-site-creating events while providing
necessary supplemental scripts to infer the resulting transcriptional and translational
effects. Using our stringent pipeline we identified 2,888 rare germline and somatic SCMs
which were initially inaccurately annotated. We observed interesting patterns in genomic
sequence contexts surrounding SCM containing exons (SCM+ exons) including
increased nucleosome occupancy and an overall decrease in the novel splice form
relative to the original exon size. The discovery of rgSCMs genome wide facilitated the
proper annotation of hundreds of variants that could have direct implications in cancer.
For example, one recurrent synonymous variant was identified in RAD54L, generally
characterized as a DNA repair gene, suggesting this variant could be a novel pathogenic
germline variant that has been missed in previous studies. Finally, we validated 6 rare
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germline SCMs (rgSCMs) in cancer associated genes, including the RAD54L silent
variant, and one common germline SCM (cgSCM) validating our computational pipeline
and workflow for proper and efficient SCM identification.

4.2 Results
DATASET DESCRIPTION

To further explore the germline and somatic splice-site-creating landscape across cancer
samples, we collected somatic and germline mutations calls from the MC3 working group
(Ellrott et al.) and the Cancer Genome Atlas (TCGA) germline working group (Huang et
al.). We sought to evaluate the splice-creating potential of variants conventionally
annotated

as

SpliceDonorSNV,

SpliceAcceptorSNV,

Missense,

Synonymous,

IntronicSNV (near the splice site) and Nonsense mutations (Figure 4.1A). With stringent
filtering (Methods) we evaluated >3,000,000 somatic mutations, > 10,000,000 rare
germline mutations and >20,000,000 common germline variants in a splicing context
using the MiSplice pipeline (Jayasinghe et al.) (Figure 4.1C). For rare germline mutations
and somatic mutations, we defined a set of control samples in the same cancer type that
lacked the same mutation of interest. With respect to common germline mutations,
samples were placed in a case group or control group depending on their mutation status
for each mutation of interest. We conducted the splice-site-creating mutation analysis
using the ISB google cloud using MiSplice (mutation-induced splicing) that systematically
evaluates mutations in a splicing context using RNA-seq data. MiSplice manages large
analyses using parallel computation to search for alternative splice junctions within
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windows of ±20 bp from the mutation of interest. We identified high confidence rare and
common germline splice-site-creating mutations (rgSCMs, cgSCMs) and somatic splicesite-creating mutations (sSCMs).

Figure 4.1. Somatic and Germline splice-site-creating variant discovery. (A) Examples of splicesite-creating mutations (SCM) for different annotated mutation types. (B) Breakdown of rare germline
SCMs and somatic SCMs, plotted by conventional annotation type. Cancer associated genes are
highlighted in black. (C) The updated MiSplice workflow can process millions of somatic and germline
variants on the ISB-Google Cloud or on a local compute cluster. Mutation calls and RNA-Sequencing
bams are provided as input, and variants in close proximity to a detected splice junction are maintained
for additional filtering. Canonical junctions, low coverage, novel junction presence in the controls, large
predicted exon sizes and certain genes including HLA are filtered out. Finally an added annotation
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module determines allele frequency for each variant in the gnomAD database, predicts the mutation
effect using TransVar and predicts the resulting wildtype and novel protein isoforms

GERMLINE AND SOMATIC SPLICE-SITE-CREATING MUTATION DISCOVERY
The expanded discovery of somatic splice-site-creating mutations across 33 cancer types
identified 1,782 sSCMs (Figure 4.1B). 237 SCMs are annotated to genes commonly
associated with either adult or pediatric cancer. Some of the most highly recurrent events
were reported in our previous publication (Jayasinghe et al.) but novel sSCMs were
identified by expanding our analysis to this larger MC3 dataset (Table 1). Newly identified
sSCMs in cancer associated genes were manually reviewed for accuracy.

In expanding our analysis of splice-site-creating mutations to the germline, we identified
mis-annotated germline mutations that show evidence of creating new splice sites. After
processing rare variants from 33 cancer types a total of 14,709 cancer specific unique
variants were identified as having splice-creating-potential. Additional filters included
removing sites with more than 5% of controls containing the alternative splicing event (>2
reads), samples with less than 20 controls, and finally filtered out splicing events identified
in highly homologous genes including MUC*, AHNAK* and CRIPAK (Methods) leaving
4,295 potential splice-site-creating variants. Of the 4,295 variants, 1,121 variants had a
maximum allele frequency across populations in the controls subset less than 0.05% as
derived from gnomAD browser - version 2.1 (Lek et al.). Finally after peptide translation
and additional filtering, we were left with 1,106 high confidence single nucleotide variants
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classified as rgSCM events encompassing 995 unique variants from 852 genes, and 63
in cancer associated genes.

Additional filters were incorporated into MiSplice to filter out novel splice isoforms present
at a higher frequency in the cancer cohort population. Finally all variants underwent
additional annotation post filtering to capture filter out events present at a high frequency
in the population, and we incorporated TransVar to provide the most up to date annotation
and predict the resulting peptide change. For the entirety of this analysis we will focus on
single nucleotide variants.

A majority of SCMs were conventionally annotated as SpliceAcceptorSNVs followed by
Missense, Synonymous, SpliceDonorSNVs, Nonsense and a handful IntronicSNVs
(Figure 4.1B). This distribution held true for both rare germline and somatic events.
Interestingly, our expanded analysis identified 170 novel rare germline SCMs
conventionally annotated as synonymous variants and an additional X somatic SCMs not
identified in our previous work. A remarkable number of SCMs were annotated to cancer
associated genes (Table 1) including 63 rare germline SCMs and 237 somatic SCMs. We
will take a closer look at the biological relevance of these events in a later section.

COMPARATIVE SEQUENCE CONTEXTS AND CHARACTERISTICS
With this large and high confidence list of somatic and germline splice-site-creating
mutations across thousands of exons, we have the unique opportunity to collect relevant
genomic information to characterize SCM positive exons. First we looked to determine
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the location of the novel splice junction relative to the canonical splice site (Figure 4.2A).
In knowing that the strongest splicing enhancer elements are located near the canonical
splice site, we predicted many SCMs would cluster near the canonical site and taper off
with increasing distance from the canonical site. As expected splice acceptor and splice
donor variants are densely populated near the canonical splice site while synonymous
and missense mutations are found deeper within the exonic region. After the mutation is
introduced, the largest differences in transcript size post mutation (here on in referred to
as effect size) are shared by conventionally annotated missense, synonymous and
nonsense mutations, while smaller alterations are observed for mutations in close
proximity to the splice site (Supplementary Figure 4.1A). Due to our restricted search
window for identifying novel splice sites in proximity to mutations, we anticipated and
gladly observed a direct correlation between the effect size and distance from the
mutation to the canonical splice site (Supplementary Figure 1B).

116

Figure 4.2. Sequence contexts and characteristics of splice-site-creating mutations. (A) Cartoon
of donor and acceptor splice-site-creating mutations (SCM). Example mutation is plotted in red relative
to the novel splice site and canonical splice site. (B) Distribution of rgSCM and sSCM events relative to
the distance from the canoncial splice site. Proportion of variants at each position is colored by
conventional annotation type. (C) Comparison of the novel splice site score before and after mutation for
rgSCM and sSCM broken down by the creation of a novel donor or acceptor splice site. Each point is
colored by conventional annotation type. (D) Contrast the overall change in splice score before and after
mutation for the novel and canoncial junctions. Positive values indicate a stronger novel splice score
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change post mutation relative to canonical splice site. (E) For variants conventionally annotated as
SpliceDonorSNV and SpliceAcceptorSNV, compare the difference in splice score pre and post mutation
for the novel and canonical splice site.

To confirm the mutation is indeed a splice-site-creating mutation, we compared the novel
splice score of the genomic sequence before and after mutagenesis (Figure 4.2A). Rare
germline and somatic SCMs alike globally exhibited an increase in the novel splice score
after mutation (deviating in the positive direction above the xy line), with few exceptions
(Figure 4.2C). While strengthening a novel or cryptic splice site is necessary to induce
alternative isoform usage, we wanted to determine if the canonical splice site was also
disrupted due to the mutation. To characterize an overall splice score change, the
difference in the splice score was calculated for both the novel (ΔN) and canonical
(ΔC) splice site. The difference between ΔN-ΔC would be positive under conditions
where the novel splice score change post mutation was stronger than the canonical site
in the presence of the mutation, capturing the overall mutations effect on both sites. Figure
4.2D displays the distribution of the overall combined splice score change for each site
by conventional annotation type. While all values trend in the positive direction,
suggesting a stronger novel site change relative to canonical site change, conventionally
annotated splice donor variants are densely clustered together. By taking a step back we
can compare ΔN and ΔC separately. In Figure 4.2E, the difference in the novel score
(ΔN) increases dramatically, while the canonical site (ΔC) is completely disrupted. On the
other hand, for the donor site, the novel splice site doesn’t change in the presence of the
mutation, but the canonical site is disrupted.
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This interesting phenomenon for the donor splice site holds true for the 294 conventionally
annotated donor mutations and suggests that by simply disrupting the donor splice site,
it’s usage can be completely ablated and becomes unrecognizable, placing a stronger
emphasis on the donor site relative to the acceptor splice site. Supporting this hypothesis,
recently Wong et al. performed a massively parallel splicing assay on the introns of three
genes to monitor the effects of all predicted changes to the 9 nucleotide 5’ splice site,
surveying a total of 32,768 unique donor sites (Wong et al.). From the assay, they
determined disruption of the 5’ splice site alone was enough to disrupt splicing, despite
mutating nearby genomic regions.

The average exon in our dataset containing a splice-site-creating mutation is 289 bp long
with a standard deviation of 668 bp. By comparing the relative exon sizes between each
of the conventionally annotated mutation types, an increased canonical exon size was
observed for missense (p=2.1e-08,1.9e-13) and synonymous sites (2.9e-05,9.8e-11) in
comparison to the acceptor and donor splice sites, respectively. Nonsense mutations also
showed evidence of increased exon size relative to the donor splice site (p=0.033)
(Supplementary Figure 1A).

Next we chose to explore beyond the exon to determine if introns adjacent to the SCM
positive exon contained additional information for SCM classification. Interestingly, splice
acceptor mutations were more likely to be situated downstream of a larger intron relative
to the intron upstream of the synonymous mutation (p=5.4e-05, Figure 4.1C). Similarly
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the downstream intron size was larger for splice acceptor SNVs relative to introns
downstream of missense (p=3.4e-05), synonymous (p=2.5e-09) and splice donor
mutations (Supplementary Figure 1D). These initial observations suggest that while
evaluating the splicing score in the presence and absence of the mutation is very
informative, with a large enough dataset, we may be able to glean new information from
the adjacent genomic sequences to strengthen the identification of putative SCM
containing exons.

TRANSLATIONAL AND TRANSCRIPTIONAL IMPLICATIONS OF SCMS
Each variant was annotated according to their resulting translational consequence to
interrogate overall trends in splicing dysregulation (Methods). For both somatic and rare
germline SCMs, exon shrinkage events were observed at a higher frequency than exon
extension. 91% and 89% of translated sites resulted in exon shrinkage trending towards
an overall decrease in the novel exon size relative to the canonical exon (Figure 4.3A).
The novel exon size decreased by an average of 21 and 33 bp for sSCM and rgSCM,
respectively. From an evolutionary standpoint, exon size tends to be far more
constrained than intron size. One hypothesis for this constraint is due to the intricate
dance between chromatin remodeling and alternative splicing.

Within the nucleus, DNA is wrapped around histones in segments of <150 nucleotides.
Nucleosomes are made up of eight core histones and are conveniently positioned on
exons. The size of the average exon is ~150 nucleotides long providing strong evidence
as to the evolutionary pressure selecting for exons around this length(Amit et al.;
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Schwartz et al.). Since splicing is a co-transcriptional process, splicing factors and histone
marks work together to properly facilitate the splicing process(Jeong). With the
aforementioned evidence suggesting a link between nucleosome occupancy and splicing,
we performed a nucleosome occupancy enrichment analysis for the rgSCM and sSCMs
using NucMap (Zhao et al.). The enrichment scores were much stronger at regions
overlapping the exons containing splice-site-creating mutations relative to a 2kb window
surrounding the exon of interest (Figure 4.3B). Additional studies have revealed stronger
nucleosome enrichment for exons that are adjacent to long introns or have weaker splice
sites (Spies et al.). To explore this phenomenon in our dataset, SCMs were binned by
the canonical splice site score, and nucleosome enrichment was compared among the
four binned groups by quartile, but no correlation was observed in our dataset
(Supplemental Figure S7).
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Figure 4.3. Novel spliced isoform exon expression and predicted translation. (A) Contrasting
overall novel exon size relative to canonical exon size for rgSCM and sSCM events. Each point is colored
by the predicted reading frame of the novel spliced isoform. (B) Enrichment analysis of nucleosome
occupancy by NucMap on four different cell lines for all 2,888 predicted SCM containing-exons. Each
plot is centered on the exon containing the novel splice-site-creating mutation. (C) Junction allele fraction
(JAF) distribution by predicted reading frame. P-value reported by wilcox test comparing in frame and
off-frame events within each SCM group. (D) Based on the location of the premature termination codon,
each predicted protein product was classified as eliciting or escaping nonsense mediated decay based
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on the 50 bp rule. P-value reported by wilcox test comparing both groups within each SCM group. Each
point is colored by the predicted reading frame of the novel spliced isoform.

The resulting reading frame of the novel splice isoform was annotated as off-frame or inframe based on the size of the exon shrinkage or extension event. As expected, the
junction allele fraction, or fraction of reads supporting the alternative splice form, was
significantly lower for predicted off-frame SCMs compared to in-frame SCMs (wilcox test,
sSCM:p=1.281e-12, rgSCM:p=5.617e-15) (Figure 4.3C). The expression of the resulting
off-frame events is predicted to be lower at the RNA level because aberrantly spliced
transcripts are often degraded by nonsense mediated decay (NMD), a process that
identifies and degrades transcripts containing premature termination codons (PTCs). The
general rule of thumb is PTCs located at least 50 bp upstream of the last exon-exon
junction drive strong degradation, whereas those outside of this criteria are predicted to
escape the degradation process(Brogna and Wen; Lewis et al.; Maquat et al.; Nagy and
Maquat; Popp and Maquat; Venables; Weischenfeldt et al.). When applying the 50 bp
rule to to our set, 97% of the off-frame spliced products are predicted to elicit-NMD (990
off-frame, 33 in-frame) while 79% of in-frame events are expected to escape-NMD (1465
in-frame, 400 off-frame) (Supplemental Figure S7). For escapee transcripts, we would
expect to observe a higher expression of the novel splice form. Indeed, expression as
measured by the junction allele fraction supported NMD-escaping transcripts maintaining
a higher expression relative to the non-escapee group (wilcox, rgSCM:p=9.078e-15,
sSCM:p=8.129e-16) (Figure 4.3D).
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Even though some sites are predicted to undergo degradation, all SCMs were identified
due to their expression in the RNA-Sequencing data. Most sites have JAF’s lower than
50% suggesting some post transcriptional mechanisms by which the transcript is being
degraded, although not to completion. It is important to note that it is very likely we are
not capturing the full landscape of SCMs due to efficient degradation of mutation induced
alternative transcripts.

LANDSCAPE OF SOMATIC AND GERMLINE SCMS GENOME-WIDE

We next explored the landscape of SCMs genome-wide. Figure 4.4A highlights the most
highly recurrent genes in our dataset with TP53 harboring somatic SCMs spanning
several cancer types while CBWD5 has many SCMs predominantly derived from BRCA.
For the subset of highly recurrent SCM containing genes, rgSCM and sSCM almost
always do not co-occur in the same gene with the exception of: LZTR1 and PTPN13. Out
of 2,163 unique genes harboring at least one SCM, 161 genes encompassing 417
variants had both a germline and somatic SCM reported. Several shared SCM positive
genes overlap cancer associated genes including CHEK2, CHD8, CASP8, FANCL,
MUTYH, RAD51C, RPA1, BRCA1, EML4, FANCI, PARP3, and PARP4. Interestingly,
only CHEK2 shared a mutation at the same splice donor site, but both events produced
different transcriptional effects. Additionally, a conventionally annotated missense variant
in MLLT10 contained both an rgSCM and sSCM resulting in the same 251 bp exon
shrinkage, and was validated in our minigene splicing assay (Figure 4.5D).
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gene expression data from the UCSC XenaBrowser, we compared transcripts per million

(tpm) values between the SCM mutants, TCGA Cancer Cohort and associated GTEX
tissue cohort, when available. By comparing the expression of the SCM mutant to the
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cancer type cohort, several SCMs exhibited differential expression including those in
cancer associated genes (Figure 4.4B) (Wilcox test). The biological implications of the
altered expression will need to formally evaluated in follow up studies.

HYPERMUTATOR PHENOTYPE OF RAD54L RGSCM

RAD54L is involved in DNA repair via homologous recombination and frequently
undergoes copy number alterations depending on the tissue type of interest. For example,
loss of heterozygosity in RAD54L is common in breast cancer and lower-grade
gliomas(Nowacka-Zawisza et al.) and associates with longer progression free survival
and chemosensitivity(Tang et al.), respectively, suggesting a tumor suppressor
phenotype. More recently, the mechanism of cell proliferation and radio-resistance in
glioblastoma was linked to CDC7 expression, a gene directly regulated by RAD54L(Li et
al.). In contrast, in choroid plexus carcinomas the DNA repair gene was often amplified in
tumors and necessary for proliferation (Tong et al.) in murine models, suggesting an
oncogenic phenotype.
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Figure 4.5. RAD54L and mini-gene splicing assay. (A) Splice junction quantification of te novel and
canonical splice sites for two samples containing the RAD54L silent mutation and one normal sample.
Genomic sequence of the novel and canonical splice site are highted below the exon pictogram. The
novel change in novel and canonical splice score are indicated next to the genomic segments. (B)
Mutational signature for RAD54L HNSC Mutant sample. (C) Mutational signature for overall HNSC cohort
(D) Candidate splice creating variants validated by the mini-gene splicing assay. Exons of interest were
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cloned into the pCAS2.1 vector and mutant (red) and wildtype (purple) plamids were transfected into
293T cells and total RNA was extracted to identify mutation induced alternatively spliced products.

In our sample set two conventionally annotated silent (p.G659G) mutations in RAD54L
were identified more appropriately as an rgSCM and associated with a slightly higher
overall expression relative to the head and neck squamous cell carcinoma (HNSC) cohort
(wilcox p=0.099) but not in the testicular germ cell tumor (TGCT) (wilcox p=0.343). The
rare germline mutation creates a new splice site (GC>GT) leading to a 58 bp exon
shrinkage, frameshifting the remainder of the protein at exon 17 containing a Snf2 specific
helical domain (HD2) domain and the C terminal Domain (CTD) (Heyer et al.) (Figure
4.5A). The novel splice junction is located within 55 bp of the last exon-exon junction and
is thus predicted to escape NMD. The splicing score post-mutation increases dramatically
from 0.98 to 8.73 and the variant allele fractions in the tumor and normal sample are
comparable, 49% and 46% for the HNSC sample and 44% and 52% in the TGCT sample,
respectively.

We next sought to evaluate whether the predicted rgSCM event in RAD54L can induce
genomic changes relative to the associated cancer cohort. Both samples exhibit higher
mutation rate relative to the rest of their cancer type cohort, with the TGCT sample being
the highest mutated sample and the HNSC sample being one of the top 10 mutated
samples. To evaluate whether the potentially pathogenic rare germline SCM mimics a
hypermutator like phenotype, we evaluated the mutational signatures of each patient.
After inspecting the mutational signature of the HNSC sample, signature 2 and signature
13 are the most prevalent followed by 1, 7 and 10 (Methods). In contrast, the HNSC
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cancer type cohort did not exhibit a similar mutation signature, suggesting this sample is
under a different evolutionary pressure relative to the cancer cohort. The joint signatures
of 2, 10 and 13 in the HNSC sample are commonly found in patients undergoing local
hypermutator phenotypes and with this sample being one of the 5 top mutated samples
in HNSC (lacking mutations in other DNA-repair related genes) (Alexandrov et
al.) suggests the RAD54L rgSCM variant may be indicative of the observed phenotype.

Finally, to functionally confirm the predicted alternatively spliced product in the lab, we
performed a mini-gene splicing assay to validate rgSCMs in 6 cancer-associated genes
and 1 common germline SCM (Figure 4.5D). Briefly, we used a pCAS2.1 splicing reporter
mini-gene functional assay by cloning mutant exons into the pCAS2.1 vector (Gaildrat et
al.) and transiently transfected into HEK293T cells. RNA is extracted after 24 hours and
after generating cDNA synthesis, RT-PCR is performed to evaluate the presence of the
novel splice isoform relative to the wild-type vector. RAD54L rgSCM was one of the seven
germline SCMs confirmed in the assay (Figure 4.5D). Taken together, MiSplice was able
to predict a recurrent putative rare germline SCM event improperly annotated as a
synonymous mutation. While mutations disrupting DNA repair have been identified in
another member of the RAD family RAD51D (Pelttari et al.), to date no pathogenic
mutations have been identified in RAD54L.

4.4 Methods
DATASET DESCRIPTION
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Aligned RNA-Seq bam files were analyzed using the ISB google. These cancer types are
Acute Myeloid Leukemia [LAML], Adrenocortical carcinoma [ACC], Bladder Urothelial
Carcinoma [BLCA], Brain Lower Grade Glioma [LGG], Breast invasive carcinoma
[BRCA], Cervical squamous cell carcinoma and endocervical adenocarcinoma [CESC],
Cholangiocarcinoma [CHOL], Colon adenocarcinoma [COAD], Esophageal carcinoma
[ESCA], Glioblastoma multiforme [GBM], Head and Neck squamous cell carcinoma
[HNSC], Kidney Chromophobe [KICH], Kidney renal clear cell carcinoma [KIRC], Kidney
renal papillary cell carcinoma [KIRP], Liver hepatocellular carcinoma [LIHC], Lung
adenocarcinoma [LUAD], Lung squamous cell carcinoma [LUSC], Lymphoid Neoplasm
Diffuse Large B-cell Lymphoma [DLBC], Mesothelioma [MESO], Ovarian serous
cystadenocarcinoma [OV], Pancreatic adenocarcinoma [PAAD], Pheochromocytoma and
Paraganglioma [PCPG], Prostate adenocarcinoma [PRAD], Rectum adenocarcinoma
[READ],

Sarcoma

[SARC],

Skin

Cutaneous

Melanoma

[SKCM],

Stomach

adenocarcinoma [STAD], Testicular Germ Cell Tumors [TGCT], Thymoma [THYM],
Thyroid carcinoma [THCA], Uterine Carcinosarcoma [UCS], Uterine Corpus Endometrial
Carcinoma [UCEC], Uveal Melanoma [UVM].
MUTATION FILE DESCRIPTION

To evaluate somatic mutations we started with the mc3.v0.2.8.CONTROLLED.maf and
filtered out mutations with the following MAF Filter Flags: StrandBias, pcadontuse,
common_in_exac, oxog, contest, nonpreferredpair, ndp, badseq, broad_PoN_v2, leaving
a total of 10,573,839 variants. With respect to mutation callers, single nucleotide
polymorphisms and insertions and deletions were only maintained if there was agreement
from two or more callers. Finally mutations with a variant allele fraction of less than 5%
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were filtered out. Description of MC3 MAF file and filter flags found here:
https://www.synapse.org/#!Synapse:syn7214402/wiki/405297. Final filtered somatic
mutation

file

used

for

analysis

found

here:

https://www.synapse.org/#!Synapse:syn12074532.

To evaluate germline mutations, individual VCFs were downloaded from Huang et al.,
2018 (Huang et al.) encompassing TCGA cancer types listed in the Dataset Description.
All

variants

were

annotated

using

steps

6

and

7

of

germline

wrapper

(https://github.com/ding-lab/germlinewrapper) against hg19 Homo Sapiens fasta file.
After annotation, variants were maintained in a common germline MAF if allele frequency
is greater than 0.01 and filtered into a rare MAF if allele frequency is less than 0.01 or if
not reported. Common variants were only evaluated for BRCA. All rare variants were
evaluated for splice-site-creating function using MiSplice. Furthermore, total reads
supporting the alternatively spliced product were lowered for genes identified as
significant in Huang et al., 2018 (Huang et al.) and re-run through MiSplice. After filtering,
any variants with more than 10% of controls samples containing the alternatively spliced
product were further filtered out leaving high confidence variants. For the 20,205,168
common variants in BRCA, in an initial screen only 72,245 unique variants were evaluated
for splice-creating function. Of the 72,245 unique variants, 287 were shown to have
splice-creating function in at least one sample. The variants with splice-creating function
were then evaluated in the remaining samples. In total 74,383 variants were evaluated
for splice-creating function. 29 variants with less than 10% of control samples exhibiting
the alternatively spliced isoform were manually reviewed, resulting in 6 high confidence
common germline splice altering variants.
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Finally germline mutations were finally filtered as being rare if the allele frequency derived
from

the

Genome

Aggregation

Database

(gnomAD

browser;

http://gnomad.broadinstitute.org/; release 2.0.2) is less than 0.0005 AF (0.05%).
MISPLICE PIPELINE (SPLICE-SITE-CREATING MUTATION)

The MiSplice pipeline was developed to detect mutation-induced splicing events from
RNA-Seq data. It is written in Perl and incorporates two standard tools, samtools and
MaxEntScan. The pipeline is fully automated and can run multiple jobs in parallel on LSF
cluster. It executes the following steps:

1)

Splitting large maf file into multiple smaller files with less mutations (currently, the

default setting is 200).

2)

Discovering splicing junctions within 20bps of the mutation with at least 5

supporting reads with mapping quality Q20 and then filtering canonical junctions by using
the Ensembl 37.75 database. We selected 20bp as a cut-off since it is the farthest
distance from the splice junction in a splice region.

3)

Computing the number of supporting reads of above cryptic splice sites for control

samples without mutations.

4)

Calculating the splicing scores for the cryptic splice sites via MaxEntScan.

5)

Reporting the depth of each cryptic splice site via Samtools.
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6)

Filtering cryptic sites which fall in HLA loci or less than 5% of reads at the genomic

location supporting the novel junction of interest.
MISPLICE GERMLINE FILTERING

All relevant scripts for filtering germline splice-site-creating mutations can be found:
https://github.com/reykajayasinghe/MiSplice_Supplemental/.

1) Gene filter: Large exons with a high affinity for alternatively spliced products were
filtered out including: AHNAK, AHNAK2, HLA family, FMN2, CRIPAK, IGH*, MUCIN
family, RP11*, orf genes (Table X)

2) Remove events with less than 20 supporting controls.

3) Remove sites with greater than 5% of control samples having the same reported
alternative splicing event.

4) Nearby Mutations and combining mutations in the same gene by cancer type: Combing
the same splice-site-creating event into one entry when there are multiple mutations
nearby one another for the same sample set. Combining the same SCM event across
multiple patients into the same entry.

5) All sites are annotated with TransVar (Zhou et al.). Only variants with annotated
variants in protein_coding transcripts that were classified by uniprot as TSL=1 were
maintained for further analysis.
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6) Finally, all single nucleotide variants were annotated with population frequencies
derived

from

the

genome

aggregation

database

(gnomAD,http://gnomad.broadinstitute.org/).
SPLICE SITE SCORE ESTIMATION

For each cryptic splice site and nearby canonical splice site, the corresponding nucleotide
sequences were first extracted for both the mutant and reference sequences (9-mer and
23-mer for donor and acceptor, respectively). Their splice scores as potential donor or
acceptor sites were then estimated using MaxEntScan for single nucleotide
polymorphisms.
MUTATIONAL SIGNATURE

For determining the mutation signatures of a the subset of samples, mutations were
extracted from the MC3 public mutation file for the HNSC sample while mutations were
extracted

from

the

controlled

mutation

file

for

the

TGCT

sample

(https://www.synapse.org/#!Synapse:syn7214402). Different mutation files were needed
because all the mutations for the TGCT sample were removed from the public mutation
file due to filter flags mostly considered “NonExonic.” All mutations were run through
Mutational Signatures in Cancer (MuSiCa) to evaluate mutation signatures for each
patient.
NUCLEOSOME POSITIONING ANALYSIS

For determining the nucleosome positioning of the alternatively spliced exons, all exons
containing a rare germline or somatic SCM were collected and converted to bed format.
134

Coordinates

were

lifted

over

to

hg38

from

hg19

using

ucsc

hgLiftOver

(https://genome.ucsc.edu/cgi-bin/hgLiftOver) and coordinates were modified to match the
input for NucMap (http://bigd.big.ac.cn/nucmap/Faq.php#q9) to extract enrichment
scores of nucleosome binding sites across several cell lines including: hsNuc0270101,
hsnuc0260501, hsNuc0390101, hsNuc0320101, hsNuc0070101, and hsNuc0020101.
Using the browser analysis software normalized reads (RPM, reads per million) were
extracted from the aforementioned cell lines and an enrichment score was calculated
using the online software.
MANUAL REVIEW

All novel splice creating mutations were manually reviewed using the integrative
genomics viewer (http://software.broadinstitute.org/software/igv/). Mutations were placed
into one of three categories: Pass, Complex, and No Support. Mutations were classified
as complex if more than one novel alternatively spliced product was observed for the
mutated sample. After annotation, sites with large effect size (>100 bp) were manually
reviewed for confirmation. Many events with very large new exons were recharacterized
as ultra-short-introns.
TRANSLATION

All

MiSplice

Supplemental

scripts

are

written

in

python

(https://github.com/reykajayasinghe/MiSplice_Supplemental). Translation.py takes in the
TransVar annotated matrix and defines important characteristics surrounding the SCM
including: determining size of the upstream and downstream intron, size of the current
exon, size of the novel splice isoform, overall change in size of the spliced product,
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mutation position relative to the start and end of the exon, determines the resulting
wildtype and mutant amino acid predictions for the SCMs, and finally predicts degradation
by NMD. Some sites may be lost during this translation script due to improper annotation
by transvar to a protein coding transcript or the lack of a known transcriptional start site
in the input coding sequence file.
CODE AVAILABILITY

MiSplice is written in Perl and is freely available from GitHub at https://github.com/dinglab/misplice_gsSCM under the GNU general public license. MiSplice uses several
independent tools and packages, including SamTools and MaxEntScan, all of which are
likewise freely available, but which must be obtained from their respective developers.
The MiSplice documentation contains complete instructions for obtaining and linking
these applications into MiSplice.
MINI GENE SPLICING ASSAY

Exons of interest and approximately 150 bp of their flanking intron sequences were PCR
amplified from HEK293T genomic DNA using primers carrying restriction enzyme sites
for BamH1 and MluI. PCR products were cleaned up using NucleoSpin PCR Cleanup
(Macherey-Nagel) or DNA Clean and Concentrator-5 Kit (Zymo Research) and digested
with BamHI and MluI. The digested pCAS2.1 vector and PCR products were ligated using
T4 DNA Ligase (NEB). Mutations were introduced via Q5 Site-Directed Mutagenesis
(NEB). WT and MUT constructs were confirmed by sequencing of the insert region. The
plasmids were transiently transfected into HEK293T cells using Lipofectamine 2000
(ThermoFisher Scientific). 24 hours post transfection, cDNA was synthesized using 2 ug
136

of total RNA with the Superscript III First-Strand Synthesis System (ThermoFisher
Scientific) or igScript Reverse Transcriptase (Intact Genomics) and priming with
Oligo(dT)20.

Finally,

cDNA

was

amplified

using

pCAS-KO1-(5′-

TGACGTCGCCGCCCATCAC-3′) and pCAS-R (5′-ATTGGTTGTTGAGTTGGTTGTC-3′)
and the alternative splicing patterns were evaluated on a 2.5% agarose gel with ethidium
bromide. Qiaquick Gel Extraction Kit (Qiagen) was used to purify bands for sequencing.
CELL CULTURE

HEK293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM)
supplemented with fetal bovine serum (FBS) and penicillin streptomycin.
SELECTION OF VARIANTS FOR VALIDATION

In selecting variants to validate, we focused on mutations in cancer associated genes and
known cancer predisposition genes. After selected gSCMs from cancer predisposition
genes, we then filtered sites in 1) low complexity regions to avoid creating non-specific
primers; 2) exons containing variants with restriction enzyme cut sites in BamHI and MluI;
3) exons containing variants in the first or last exon of a gene. In these cases signals from
the UTR regions may disrupt the mini-gene splicing assay; 4) complex splicing events
that couldn’t be properly captured in a mini-gene splicing assay; 5) exons with small
introns. For the mini-gene splicing assay, we selected exons of interest that were located
far enough away from adjacent exons with specific enough primers to amplify 150 bp of
the intronic region on either side of the exon of interest.
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4.5 Discussion
Accurate and quick validation of somatic and germline variation is tantamount to
personalized medicine. Our MiSplice pipeline has proven to properly classify and
characterize splice-site-creating mutations and can help to improve our genomic
annotation pipelines when RNA-sequencing and DNA-sequencing data is integrated to
predict transcriptional consequences. Our findings also highlight the benefits of taking
advantage of the selective mutagenesis that occurs in cancer genomes to evaluate
splicing modulation across a given cohort. With our large and high confidence set of 2,888
SCMs we can effectively compare the landscape of rare and germline SCMs while
grouping both sets together to evaluate overall trends in SCM+ exons. We were able to
accurately determine that mutations overlapping the splice donor and splice acceptor
splice site commonly undergo different selective pressures when mutated.

Specifically, mutations overlapping the splice donor site were sufficient to disrupt the
canonical splice site usage but this phenomenon doesn’t hold true for acceptor splice site
mutations in our dataset. Alternatively acceptor SCMs needed to not only strengthen the
novel splice site to facilitate the novel site usage, but also disrupt the canonical splice
site. Furthermore, exons containing splice acceptor SCMs trended towards having a large
upstream intron and downstream intron relative to other SCM+ exons. By surveying
additional mutation induced alternative splicing events, we can continue to learn from the
surrounding genomic context to tease apart the intricacies of the splicing code as it
pertains to SCM+ exons. For example, we observed an enrichment of nucleosome
occupancy overlapping SCM+ exons, suggesting active splicing of these exons across at
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least the 33 tissue types surveyed in our analysis. Overall, the size of the novel exon
tended to decrease post mutation, mimicking a natural evolutionary selective pressure
but exploited in the cancer genome to maintain proper alternative splicing. With respect
to degradation of the novel isoform, regardless of whether or not the resulting protein
product was expected to undergo degradation, we still actively see expression of the
novel isoform, although significantly lower for the transcripts predicted to elicit NMD.

To date, this is the first analysis comparing rare germline SCMs and somatic SCMs
revealing their comparable dysregulation to the splicing code in cancer. Evaluating
mutation induced events separately from patient specific de novo events can provide a
focused analysis on the genomic features selecting for SCM+ exons relative to leaky
splicing or mutation independent cryptic splice site activation. As tissue type specific
datasets continue to increase, developing novel tissue specific signatures will help inform
the tissue type specific relevance of mutation induced SCMs. For example

Understanding how splice-altering variants can lead to alternative isoforms in tumor
samples and determining protein domains that are disrupted or created is still an open
area of study. In order to better characterize events specific to a tissue type, developing
modules of MiSplice that have known tissue specific transcripts will strengthen annotation
and mutation calling. Furthermore, there is room to expand outside of the single
nucleotide variant landscape to evaluate insertions, deletions and more complex events
that are potentially also contributing to the disease state. Finally, MiSplice is a very
stringent algorithm. There are many seemingly tissue type specific events that are present
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at a low level in some tissue types that have the potential to be exploited in other tissue
types especially under direct mutagenesis. While we did not report on these cases in this
analysis, the intermediate MiSplice outputs will provide very fruitful datasets for inferring
novel biological mechanisms exploited in the cell.

Supplemental Figure S7. (A) Distribution of overall effect size of novel isoform broken
down by conventional annotation and SCM type. (B) Comparing change in size of novel
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spliced isoform to the distance from the canonical splice site. Both values were
generated from different steps in the pipeline, further confirming our annotation pipeline.
(C) Distribution of upstream intron sizes by conventional annotation. (D) Distribution of
upstream intron sizes by conventional annotation.

Supplemental Figure S8. NMD Prediction Overview . (A) Comparing overall JAF
distribution by conventional annotation type and colored by NMD prediction. (B)
Based on the location of the premature termination codon, each predicted protein
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product was classified as eliciting or escaping nonsense mediated decay based on
the 50 bp rule.

Supplemental Figure S9. Nucleosome Occupancy by Canoncical Splice Site
Score . (A) Exons containing SCMs were grouped into bins by strength of canonical
splice site and nucleosome occupancy was evaluated by group using NucMap. Low [17.58,6.39], Medium [6.40,8.21], Higher[8.22,9.77], Highest [9.78,15.07].
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Chapter 5: Conclusion and Future
Directions

CANCER SPECIFIC EXON DEFINITION

From studying differential alternative splicing across species, it is understood the
appearance of alternatively spliced exons has manifested through three different
mechanisms: (1) the transition of a constitutive exon to an alternatively spliced exon, (2)
exon shuffling and (3) exonization of intronic sequences.

When a new or duplicated exon is inserted into an existing gene it is known as exon
shuffling. This process is facilitated by the repetitive elements in introns leading to
recombination events and thereby exon shuffling. The model of exon creation through
exonization was initially thought to occur from nothing. While many exon creation events
are due to repetitive elements (Alu elements) which can undergo exonization, there are
two well accepted methods of exonization including: intron-mutation induced splice signal
creation events and RNA editing. Alu elements belong to the short interspersed element
family (SINE), consist of a 300 nucleotide sequence, and are inserted into various regions
of the genome via retrotransposition. The regions of an Alu element strongly resemble a
canonical splice site in that they contain a poly-pyrimidine tract and splice-site like signals
nearby that can be inaccurately identified by the splicing machinery. The use of a new
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exon is further encouraged by strong alternatively spliced exons flanking the inserted
sequence along with splicing enhancer and silencer elements. Interestingly, Alu exons
have been found to be enriched for enhancer elements and depleted of silencer elements,
encouraging the exonization event. In addition to the primary sequence, secondary
structure can also affect exonization by means of adenosine deaminase acting on RNA
(ADAR) editing. Adenosine to Inosine editing is common in Alu elements due to the
secondary structure created when two inverted Alu elements are inserted near one
another. During this process, the ADAR family of enzymes alters Adenosine residues to
Inosine.

Since Inosine is recognized by the biological machinery as Guanosine, a

functional splice site can be created in an Alu element by altering AA to AG. There have
been several cases of exon gain due to Alu insertions in exons (Sela et al.) and introns
(unpublished).

Evolutionary conservation or depletion of a splice site provides strong evidence as to the
biological function of the alternatively spliced product.

Understanding how exon creation or modification can generate a novel protein isoform is
vital to understanding the evolution of canonical gene function. New exon events that
arise in cancer or in natural selection in various species allows for the new exon event to
be “tested”, since the new event is almost always alternatively spliced the wildtype form
is also present in the organism as well (Sorek, 2007). If the alternative isoform is
detrimental it will be selected against, and if beneficial we should see evidence of
selection in the form of expression of the alternatively spliced product. It has been
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suggested that exonization events are ways to test out new gene modules with a generally
small effect on the overall evolution of the species.

The findings from my thesis work suggests that evolutionary constraints on the tumor has
selected for these splice-site-creating mutants and conferred some combination of the
following criteria: (1) modify protein structure and/or (2) shift mRNA usage away from the
wild type.

Although many of the predicted splice-site-creating events are predicted to escape
nonsense mediated decay, about half of the sites should be degraded but are still present
in the total RNA population, signifying a novel means of escaping degradation. In this
thesis we propose an additional classification of “exonization” through the lens of cancer
evolution. We have identified thousands of somatic and germline coding mutations,
inducing the use of a novel or cryptic splice site functionally altering the reading frame of
the mutant isoform and diversifying the landscape of the cancer genome. In the following
sections, I will discuss additional analyses that can be performed on this compendium of
splice-site-creating mutants to evaluate selection of SCMs across the TCGA dataset.

Allelic Imbalance of SCMs
Over evolutionary time during the birth of a new exon, while undergoing various selective
pressures, newly created exons tend to exhibit increased expression and eventually
become fixed over the previous wild-type form (Sorek, 2007). Similarly with our splicecreating mutants, we see varying levels of selection by the tumor, and in some cases the
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mutant induced splice form is selected at a higher frequency than the wild type suggesting
preference for the alternatively spliced product (Sorek, 2007).

In thinking about cancer from an evolutionary standpoint, we have a unique opportunity
to evaluate changes to overall exon definition and determine their potential for purifying
selection over a relatively short time scale. When interrogating mutational signatures in
cancer, we predict genomic changes will lead to changing expression of the resulting
gene product. The clonal heterogeneity of a tumor exemplifies the theory of selective
pressures on growing populations of cells in a microenvironment. Selective pressures
(including treatment, microenviroment, tissue etc.) alter the clonal architecture and the
clone with the most beneficial fitness is maintained until treated (Gerlinger et al.). By
looking at the overall variant allele fraction of the DNA and RNA, we can evaluate the
transcriptional dynamics that could be exploited by the cancer cell. When exons are newly
created, some might fix over time and we can evaluate this by comparing expression of
the newly created exons relative to the wildtype sequence (Sorek, 2007). When
comparing the different Alu element insertions between mouse and humans, Sela et al.,
found increased levels of the newly created exons in humans relative to mouse (Sela et
al.) suggesting selection for the Alu created exons over evolutionary time.

For approximately 80 rare germline splice-site-creating events in our dataset, we have
access to DNA-Sequencing and RNA-Sequencing for both the tumor and normal
samples. With these data we can assess the comparative Variant Allele Fractions (VAF)
for DNA-seq and Junction Allele Fraction (JAF) in the RNA-Seq between the tumor and
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normal data. Understanding allelic imbalance will aid us in understanding the difference
in expression between the mutant and wild type allele, a selection of one allele over
another in the tumor would suggest either cis or trans factors that affect expression of the
associated gene thereby altering the tumor biology.

Protein Support from Mass Spectrometry
Support of the novel splice-site-creating event could be significantly strengthened by
peptide support. The Clinical Proteomic Tumor Analysis Consortium (CPTAC) has
performed mass spectrometry for a subset of samples from the cancer genome atlas
project to further interrogate how mutations can manifest on the translational level. To
evaluate the translational potential of the splice-site-creating mutants, for a handful of
samples in our dataset we have mass spectrometry data to evaluate if the novel isoform
is translated (Table 5.1). In Table 5.1 I have highlighted all the sample and gene pairs for
which we have associated mass spectrometry data and can validate the novel splice
isoform if it is expressed. Specifically, MSGF+ (https://omics.pnl.gov/software/ms-gf) can
be utilized to identify peptides specific to our novel splice isoforms. Although we have
evidence of the mutant isoforms in the RNA-Sequencing data, support by mass spec will
provide very strong evidence that the mRNA is translated to a protein whose functions
could be altered due to the alternatively spliced product.

Table 5.1. rgSCM and sSCM events with mass spectrometry data
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Oncogenic Function of SCMs
MiSplice identified two kidney renal clear cell carcinoma (KIRC) samples having the same
conventionally annotated missense mutation (c.233A>G, p.N78S) in BAP1, a nuclear
deubiquitinase, that created the same novel spliced-out alternative splicing product.
Inactivation of BAP1 is prevalent among renal cell carcinomas (Wadt et al., 2012) and an
annotated missense mutation (p.L570V) has been reported to create a cryptic splice site
in melanoma. At the transcriptional level, the expression of the case and control samples
are relatively comparable, but at the translational level, one case with available protein
data (RPPA) showed significantly lower expression relative to the controls. This result
suggests the conventionally annotated missense mutations in BAP1 likely create an
alternatively spliced transcript that is not readily expressed at the protein level. With this
evidence it would be interesting to determine the in vitro function of BAP1 splice-creating
variant in a cell line of interest. Using the established cell lines with our splice-site-creating
variants of interest, downstream assays can be performed to determine if the SCMs have
the potential to contribute to oncogenesis.
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Mutation Induced Ultra Short Introns
With the birth of a new intron, we see cases of intronization or the alternative splicing of
an internal exon (Irimia et al., 2008). With certain events we also see the alternative
splicing of internal introns that look to be facilitated by selected mutation induced splicing
events. Small intron-creation events in exons were observed in approximately ~150
unique gene-cancer type events. While introns are commonly spliced out by the major
and minor spliceosome, several alternative mechanisms can facilitate the splicing of very
short introns, typically less than 65 nucleotides in length. For example a U2 snRNP SF3b
excises short introns ranging from 43 to 56 bp in NDOR1, HNRNPH1 and ESRP2 (SasakiHaraguchi et al.). While introns in humans are quite long, introns in invertebrates are
much shorter. With this knowledge, Lim et al. assessed genomic features of short introns
across organisms to determine the minimum amount of information required to define an
intron (Lim and Burge). While there is ample evidence in the literature supporting ultra
short introns (USI), genomic deletions can arise due to repetitive sequences. To filter out
common genomic deletions, we overlapped our predicted USI’s with computationally
predicted USI’s in a recent publication by Abebrese et al (Abebrese et al.). In total, 29
USI’s were filtered leaving less than 20 putative mutation induced USI’s. Furthermore, 3
USI’s in KMT2D, CBLN3 and PRRC2C overlapped with Abebrese et al. and PRRC2C
had evidence of splice junction usage across several cell lines after screening A549, Bj,
H1 hESC, HeLa, HepG2, Hsmm, K562, Mcf7, Nhek, and Nhlf.

To date, mutation induced USI’s have not been systematically evaluated in cancer. In
general for all the USI’s identified, all but one are in frame and generally do not change
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the splice site score but are recurrent and span cancer types. While the splicing score
doesn't change, it has been reported that short introns generally have non-canonical
splice sites such as those observed in IRE1alpha-dependent Xbp1 mRNA splicing known
for splicing out 26 nucleotide sequences in various genes including itself (Bai et al.). The
predicted mutation induced USIs identified in the TCGA dataset provides additional
evidence regarding the mechanisms by which the splicing code can be dysregulated in
the human population and potentially exploited in cancer.

Common Germline Splice-Site-Creating Variants
As a proof concept, we wanted to explore common germline splice-site-creating events
in one cancer type to determine ancestry specific events. For the 20,205,168 common
variants in Breast Invasive Carcinoma (BRCA), in an initial screen only 72,245 unique
variants were evaluated for splice-site-creating function. Of the 72,245 unique variants,
287 had evidence of splice-creating function in at least one sample. The variants with
splice-site-creating function were then evaluated in the remaining samples. In total 74,383
variants derived from 287 unique sites were evaluated for splice-site-creating function. 29
variants with less than 10% of control samples exhibiting the alternatively spliced isoform
were manually reviewed, resulting in 6 high confidence common germline splice-sitecreating variants (Table 5.2).

Table 5.2. Common SCMs
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Gene

Mutation

#

% of

Cases

Controls

# reads in case samples

with event
Neurolysin,

5:6508410

mitochondrial

1 A>G

22

0%

15,14,18,11,8,7,12,13,5,7,11,
13,6,5,10,13,6,7,18,27,9,10

(NLN)
Leukocyte

19:550986

Immunoglobulin

67 G>A

20

0.39 %

11,5,7,5,15,6,7,7,5,8,13,10,15
,5,17,9,8,10,9,10

Like Receptor
A2 (LILRA2)
Glutaminyl-

19:462062

Peptide

62 G>A

4

1.07 %

7,5,5,7

17

2.25 %

6,6,6,6,6,5,8,6,6,7,5,8,5,8,7,6,

Cyclotransferase
Like (QPCTL)
TatD DNase

1:2129855

Domain

92 G>A

12

Containing 3
(TATDN3)
Calpain 13

2:3098597

(CAPN13)

7 G>A

4

2.64 %
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9,11,8,16

NAD kinase 2,

5:3621971

mitochondrial

0 C>T

22

6.01 %

13,6,18,9,8,5,17,8,25,18,11,7,
8,19,12,35,17,34,16,6,6,7

(NADK2)

The NLN common germline variant has a population frequency of 0.19 in the african
american community. 20 of the 22 samples with the germline variant are black or african
american in the TCGA dataset and have a slightly higher expression of the NLN gene
relative to non-mutated controls in breast cancer, although not significant (wilcox test =
0.09). Our initial findings of the NLN gene and other common variants suggest a subset
could be mis-annotated when evaluating both RNA and DNA sequencing. Interestingly
a few variants created ultra-short-intron events described in the previous section.

Non-Canonical Splice Sites and Minor Spliceosome Alterations

For both splice-site-creating papers, we only focused on sites creating canonical GT or
AG splice sites. Several interesting SCMs created non-canonical splice sites (deviating
from GT and AG genomic context) suggesting usage of non-canonical splice sites by the
major spliceosome or minor spliceosome.

The splicing code is made up of cis-acting elements that help the splicing complex
distinguish between non-coding (intron) and coding (exon) regions. There are two known
distinct ribonucleoprotein complexes known as the major and minor spliceosomes that
are responsible for joining exons and splicing out two types of introns, U2 and U12. For
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U2 type introns, the consensus intronic dinucleotide GT splice donor and AG splice
acceptor flank the exons at the 3’ and 5’ ends respectively, and can be found in 99% of
all introns. The remaining 1% are U12 type introns and were initially recognized due to
their non-consensus splice site sequences AT and AC at the 3’ and 5’ splice sites,
respectively (Hall and Padgett; Jackson). Interestingly, some introns with the canonical
GT-AG splice sites are also spliced by the minor spliceosome. While the consensus
sequence alone cannot differentiate between the two groups, several other cissequences including lacking a polyprimidine tract upstream of the 3’ splice site,
polypyrimidine tract and branch point (Dietrich et al.) can help differentiate between the
two groups. The major and minor spliceosome share the U5 snRNP and many
spliceosomal proteins.

While only 1% of U12 type introns are present in the genome, they are highly conserved
across eukaryotes suggesting a potential functional role in the genome. For example, U12
type introns are shown to be removed at a much slower rate than U2 type introns (Patel
et al.), and the minor spliceosomal proteins are present at a much lower abundance than
the major spliceosome (Tarn and Steitz). This evidence suggests that minor introns are
likely a rate limiting step in the expression of various mRNAs that contain U12 type
introns. Despite this evidence, the current compendium of minor introns is still expanding.

The benefit of coupling U12 intron containing genes and U12 spliceosome abundance
allows the cell a regulatory mechanism by which only a subset of genes can be
differentially regulated in response to stimuli. Younis et al., determined the U6atac snRNA
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minor spliceosomal gene expression could be increased by cell stress activated kinases
leading to increased expression of U12 intron containing genes that regulate cell stress
physiology (Younis et al.). RNA-seq analysis revealed a down-regulation of 2,088 genes
including 429 minor intron genes. Together, these results show that altering expression
of minor spliceosomal genes can alter a distinct subset of genes with overarching
changes at the transcriptome level.

With the large dataset provided by The Cancer Genome Atlas mechanisms of U12
dysregulation across cancer genomes can be more effectively evaluated. Furthermore,
our analysis of splice-site-creating mutants identified the usage of many non-canonical
GT-AG splice sites, suggesting a potential dysregulation of spliceosomal usage.

As with aberrations in major spliceosome related genes, mutations in minor spliceosomal
genes lead to different disease phenotypes ranging from brain to skeletal irregularities.
Recently, Madan et al., evaluated alternatively spliced junctions in 8 Myelodysplastic
syndrome (MDS) patients with ZRSR2 mutations and identified 689 mis-spliced junctions
in all 8 cases (Madan et al.). The mispliced junctions are specific to ZRSR2 mutants.
Additionally, a conditional knockdown of Rnu11 in mice resulted in microcephaly and
upregulated intron retention of minor intron containing genes (Baumgartner et al.). Many
of the minor intron containing genes were not differentially expressed but 178 introns were
detained at higher levels in the mutant relative to the wildtype while one was
downregulated. Finally a family of three sisters were found to have biallelic mutations in
RNPC3 and when downstream U12 intron retention rates were compared, 21 genes out
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of 522 tested had decreased U12/U2 ratios in the patient cells(Argente et al.).
Interestingly the subset of aberrant U12 introns were relevant to the disease phenotype
and some U2 cryptic splice sites were activated instead of the U12 intron. Mutations in
U12 spliceosomal proteins have been linked to several other diseases including RNU12
(Elsaid et al.), RNU4ATAC (Edery et al.; He et al.; Heremans et al.; Merico et al.),
TRAPPC2 (Shaw et al.), FUS (Reber et al.), and SMN1 (Zhang et al.). The previous
studies provide strong evidence that minor splicing factors regulate subsets of minor
introns. By evaluating differential expression of related minor introns, novel functional
mutations in minor spliceosome genes or U12 minor introns themselves can be identified
to determine if minor intron splicing is altered globally in cancer.

As with mutations in spliceosomal genes, mutations in cis can also alter minor intron
splicing. LKB1 encodes a serine threonine protein kinase involved in major cellular
processes including cell cycle arrest, p53 mediated apoptosis among others. The second
intron of LKB1 is a minor intron and a mutation that affects the 5’ splice site causes PeutzJeghers syndrome (Hastings et al.). Interestingly, the 5’ splice site mutation changes the
splice sites of intron 2 from AT-AC to GT-AC. One would expect that a 5’ splice site
mutation would cause skipping of the subsequent exon or use of an alternative 5’ splice
site, but the authors found instead that a cryptic 3’ splice site was utilized, thereby altering
the frame of the final transcript, which induced a premature termination codon and
degraded by nonsense mediated decay.
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In a related manner, a mutation in SCN8A has been shown to inactivate the 5’ splice site
thereby resulting in an exon skipping event associated with an X-linked recessive disorder
(Shaw et al.). While this exon skipping event doesn’t occur in the minor intron itself, it
does lead to altering the usage of minor intron contained within the gene, suggesting a
strong interplay between splice site usage.

In 2018, our lab published a comprehensive analysis of gene fusions identified in RNASeq across the TCGA compendium (Gao et al.). From this publication, several gene
fusions were identified involving minor spliceosomal related genes (Table 5.3). All of
these resulting fusion products in the associated samples have the potential to
dysregulate a large subset of downstream minor introns, but their current consequence
is unknown. A case control comparison evaluating overall expression of the fusion genes
with wild type counterparts will determine if the expression of the fusion itself or
downstream targets are affected due to the predicted fusion product.

Table 5.3. U12 and U12 associated genes with detected Fusions in TCGA
Cance

Sample

Fusion

r
HNSC

PRAD

TCGA-CV-7090-01A-

DHX15--

11R-2016-07

RBPJ

TCGA-G9-6339-01A-

DHX15--ETV1

Juncti

Spanni

Breakpoin

on

ng

t1

6

21

chr4:24548

chr4:2638635

855:-

3:+

chr4:24584

chr7:1393589

323:-

6:-

chr4:24541

chr6:4194058

873:-

5:-

9

35

12R-A311-07
SARC

TCGA-DX-A3LU-01A-

DHX15--

11R-A21T-07

CCND3

1

164

12

Breakpoint2

COAD

ESCA

TCGA-F4-6809-01A-

FUS--

11R-1839-07

PYCARD

TCGA-IG-A51D-01A-

FUS--IL9R

2

6

116

7

11R-A36D-31
HNSC

OV

TCGA-CV-6941-01A-

FUS--

11R-1915-07

PRSS36

TCGA-13-1481-01A-

FUS--KAT8

1

22

11

22

01R-1565-13
STAD

BRCA

BRCA

BRCA

SARC

SKCM

BLCA

GBM

HNSC

TCGA-HU-A4HB-01A-

FUS--

12R-A251-31

TMEM114

TCGA-LD-A7W5-01A-

PDCD7--

22R-A352-07

TAF15

TCGA-E2-A14Z-01A-

RNPC3--

11R-A115-07

KIAA0825

TCGA-E2-A10A-01A-

SNRNP48--

21R-A115-07

NISCH

TCGA-IW-A3M4-01A-

ZCRB1--

11R-A21T-07

YAF2

TCGA-D9-A6E9-06A-

ZCRB1--

12R-A311-07

LIMA1

TCGA-G2-AA3B-01A-

ZMAT5--

11R-A39I-07

ASCC2

TCGA-41-2572-01A-

ZMAT5--

01R-1850-01

ASCC2

TCGA-T3-A92M-01A-

ZMAT5--

31R-A39I-07

NIPSNAP1

71

3

3

2

1

18

4

110

5

165

35

16

5

1

8

64

15

32

11

chr16:3118

chr16:312022

2422:+

03:-

chr16:3118

chrY:5718942

2664:+

6:+

chr16:3118

chr16:311497

4396:+

31:-

chr16:3118

chr16:311270

0227:+

35:+

chr16:3118

chr16:857222

5179:+

4:-

chr15:6512

chr17:358177

9032:-

16:+

chr1:10352

chr5:9441738

6262:+

0:-

chr6:75951

chr3:5248451

01:+

3:+

chr12:4232

chr12:422106

5924:-

19:-

chr12:4232

chr12:502224

4019:-

85:-

chr22:2976

chr22:297936

6949:-

76:-

chr22:2976

chr22:297905

6872:-

48:-

chr22:2976

chr22:295618

6872:-

62:-

LUAD

LUSC

TCGA-05-4426-01A-

ZMAT5--

1

01R-1206-07

KIAA1671

TCGA-85-8048-01A-

ZMAT5--HIRA

2

3

7

11R-2247-07
SARC

TCGA-Z4-A9VC-01A-

DDIT3--FUS

3

23

11R-A37L-07
BRCA

LUAD

LUSC

SKCM

SKCM

BRCA

STAD

OV

PAAD

TCGA-E2-A1IO-01A-

CLPX--

1000

11R-A144-07

PDCD7

TCGA-97-A4M7-01A-

MPG--

11R-A24X-07

SNRNP25

TCGA-21-1070-01A-

ARHGAP17--

01R-0692-07

SNRNP25

TCGA-D3-A8GC-06A-

FAM129B--

11R-A37K-07

SNRNP25

TCGA-EB-A44Q-06A-

KDM2B--

11R-A266-07

SNRNP35

TCGA-E2-A14T-01A-

TMEM117--

11R-A115-07

ZCRB1

TCGA-BR-8077-01A-

YAF2--

11R-2343-13

ZCRB1

TCGA-24-1425-01A-

ST6GALNAC

02R-1566-13

1--ZMAT5

TCGA-3A-A9IH-01A-

NF2--ZMAT5

32

1000

116

chr22:2976

chr22:250144

6949:-

30:+

chr22:2973

chr22:193315

8330:-

56:-

chr12:5752

chr16:311896

0418:-

65:+

chr15:6516

chr15:651331

6642:-

83:-

chr16:8325

chr16:57086:+

6:+
1

7

chr16:2496

chr16:56539:+

4197:6

35

chr9:12751

chr16:55777:+

6857:5

18

9

12R-A39D-07

7

3

24

26

8

8

5

chr12:1215

chr12:123458

32806:-

021:+

chr12:4384

chr12:423241

4928:+

04:-

chr12:4221

chr12:423139

0355:-

86:-

chr17:7664

chr22:297424

3508:-

80:-

chr22:2967

chr22:297424

8323:+

80:-

In evaluating disruptions of minor introns, several experiments can validate the in silico
predictions. If the minor intron is retained due to mutation or disruption of U12 or U12166

associated splicing factor we would expect to see either expression of the retained intron
in RNA-Seq or decreased expression of the associated gene. If the minor intron has an
associated premature termination codon, one would predict the resulting transcript would
be degraded by nonsense mediated decay. If effectively degraded, no reads supporting
the transcript would be identified in the RNA-Seq. To confirm this, the transcript containing
the mutation can be transfected into the cell line of interest and puromycin treated to
inactivate the NMD pathway thereby allowing us to evaluate the full repertoire of
transcripts produced by the mutant transcript. If the transcript is alternatively spliced due
to the mutation in the minor intron and is normally degraded by NMD, in this experiment
we should see evidence of the minor intron retained due to the knockdown of NMD factors
by puromycin. Alternatively, if we do not see the transcript even after NMD knockdown,
then the mutation in the minor intron is likely not disrupting this particular intron retention
event.

If the minor intron is retained as suggested by evidence in the RNA-Sequencing data and
it isn’t degraded efficiently, we can next try and determine if the major and minor
spilceosomal machinery is responsible for removal of the minor intron of interest. Since
the U2 spliceosome is known to be degenerate and can identify multiple sequences, it is
possible that the U12 spliceosome isn’t playing a role in removing the minor intron of
interest. To test this experimentally(Hastings et al.), a mini-gene derived with our exon,
intron and exon of interest can be can be incubated in nuclear extract. When incubated
in the presence of ATP, we can evaluate mRNA products that are derived from ATP
dependent splicing reactions. Then in this same experimental condition, U2 and U12
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dependent spliceosomes can be inactivated using antisense oligonucleotides directed at
the U2 small nuclear RNA, U12 snRNA or both. Finally, RNA is extracted from all
conditions and alternatively spliced products can be evaluated via RT-PCR. Outcome 1:
If U12 spliceosome is important for this particular minor intron splicing then you will see
a decrease or absence in the spliced product when associated spliceosomal RNA is
knocked down. And when U2 spliceosome is knocked down there should be no change
in spliced product. Outcome 2: If the U2 spliceosome is important for the splicing of this
transcript then you will see a decrease or absence in the spliced product when associated
spliceosomal RNA is knocked down. And when U12 is knocked down there should be no
change in spliced product. Outcome 3: Both spliceosomes may be important for this
process thereby resulting in differences in the spliced products under both knockdown
conditions.
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Appendix: Additional Projects
5.1 Complex Insertions and Deletions in Cancer
Genomes

Systematic Discovery of Complex Indels in Human Cancers (Nature Medicine, 2016)
(Ye et al., 2016)
Contribution: I lead the development and scripted several scripts that were used to
develop a variant quality control pipeline for filtering complex insertions and deletions. I
manually reviewed many complex indels and helped with writing and submission. I helped
to validate complex insertions and deletions identified in a COLO829 cell line by sanger
sequencing.
Refer to Supplementary Note 2: Sanger Sequencing of Validated Complex Indels from
COLO829.

173

5.2 Analysis of Somatic Complex Insertions and
Deletions in Pediatric Hematopoietic Malignancies

Identification of Complex Indels in Pediatric Cancer Genomes
Complex indels are formed by deleting and inserting DNA fragments of different sizes at
a common genomic location. Application of the publicly available Pindel-C suite
(https://github.com/genome/pindel) to 545 whole genome Pediatric Cancer Genome
Project (PCGP) samples uncovered 21 somatic complex insertions and deletions among
20 pediatric hematopoietic cancer samples listed in Table below. Our analysis was
restricted to the following genes commonly mutated in hematopoietic diseases including:
TP53, CBL, CREBBP, FLT3, KMT2D (MLL2), PAX5, SETD2, IKZF1, PMS2, RAD51,
NCOR1, TBL1XR1 and KMT2C (MLL3). Nine of the 21 complex insertions and deletions
identified differed from those reported in the original studies as follows:
•

2 complex events in TBL1XR1 and SETD2 were not reported;

•

6 complex events in MLL2, SETD2, IKZF1, and CREBBP were classified as simple
indels;

•

1 complex event in TP53 was classified as both a SNV and an INDEL separately.

The remaining 12 events occurring among several key genes are found among samples
that are currently not publicly available. These samples are among the following cancer
types: Hyperdiploid Acute Lymphoblastic Leukemia (SJHYPER), E2A-PBX Acute
Lymphoblastic Leukemia

(SJE2A),

and ETS-Related
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Gene

Associated

Acute

Lymphoblastic Leukemia (SJERG). A handful of somatic and germline complex indels
have also been identified in non-coding regions of the genome, but our initial analysis
focuses on coding somatic mutations in cancer genes.
This preliminary analysis demonstrates the importance of using the most updated
form of Pindel-C to identify complex events that may be absent or classified as other
variant types in current cancer genomics studies.

Table A.1. Complex indels identified for PCGP Samples
Sample

Gene

Chromosome Start

End

SJE2A043

PAX5

9

37002647

37002649

SJERG031

MLL2

12

49444452

49444454

SJERG020052

MLL3

7

151842335 151842365

SJERG020306

SETD2

3

47059133

SJERG020307

TBL1XR1 3

176756153 176756179

SJERG020309

MLL2

49444958

SJETV001

TBL1XR1 3

176769294 176769299

SJETV024

SETD2

3

47059194

47059204

SJHYPER005

NCOR1

17

15952238

15952243

SJHYPER007

FLT3

13

28608280

28608286

12

175

47059166

49444960

SJHYPER051

TP53

17

7577595

7577601

SJHYPER097

SETD2

3

47162194

47162195

SJHYPER104

PAX5

9

37002675

37002676

SJHYPER108

MLL2

12

49443861

49443863

SJHYPER111

CBL

11

119148875 119148900

SJHYPER111

FLT3

13

28608305

28608309

SJHYPER227

IKZF1

7

50367310

50367314

SJHYPO002

CREBBP

16

3843416

3843439

SJHYPO040

CREBBP

16

3799606

3799632

SJINF013

TP53

17

7577093

7577111

3

47147487

47147488

SJPHALL020043 SETD2

Complex indel discovery
1. Read Extraction
2. Pattern Growth-Based Alignment
3. Distinguishing Complex Indels from Simple Indels
4. Remove False Predictions and Variant Allele Frequency Analysis
Filtering procedure
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1. Coverage: All sites with at least 20 reads supporting the site of interest in both the
tumor and normal sample were maintained for further analysis.
2. Coding Region Selection: Identified all complex indels overlapping an exon as
defined by ensembl 75 including flanking 2 bp splice sites.
3. Repetitive Regions: Removed any variants falling in repetitive regions as defined
by MSI Sensor. Reptitive regions are defined as areas having more than 6 or more
repeat unit bases in a segment of the genome.
4. Manual Review: Finally all sites were manually reviewed in the integrative
genomics viewer to finally confirm all complex indels.
The screenshots below from the Integrative Genomics Viewer show the events described
in the table above (tumor sample on top, normal sample on bottom).

Sample

Gene

Chromosome

SJE2A043

PAX5

9

177

Start

End

37002647

37002649

Sample

Gene

Chromosome
178

Start

End

SJERG031

MLL2

12

179

49444452

49444454

Sample

Gene

Chromosome

SJERG020052

MLL3

7

180

Start

End

151842335 151842365

Sample

Gene

Chromosome
181

Start

End

SJERG020306

SETD2

3

182

47059133

47059166

Sample

Gene

Chromosome

SJERG020307

TBL1XR1

3

183

Start

End

176756153 176756179

Sample

Gene

Chromosome
184

Start

End

SJERG020309

MLL2

12

185

49444958

49444960

Sample

Gene

Chromosome

SJETV001

TBL1XR1

3

186

Start

End

176769294 176769299

Sample

Gene

Chromosome

SJETV024

SETD2

3

187

Start

End

47059194

47059204

Sample

Gene

Chromosome
188

Start

End

SJHYPER005

NCOR1

17

189

15952238

15952243

Sample

Gene

Chromosome

SJHYPER007

FLT3

13

190

Start

End

28608280

28608286

Sample

Gene

Chromosome
191

Start

End

SJHYPER051

TP53

17

192

7577595

7577601

Sample

Gene

Chromosome

SJHYPER097

SETD2

3

193

Start

End

47162194

47162195

Sample

Gene

Chromosome

SJHYPER104

PAX5

9

194

Start

End

37002675

37002676

Sample

Gene

Chromosome

SJHYPER108

MLL2

12

195

Start

End

49443861

49443863

Sample

Gene

Chromosome
196

Start

End

SJHYPER111

CBL

11

197

119148875 119148900

Sample

Gene

Chromosome

SJHYPER111

FLT3

13

198

Start

End

28608305

28608309

Sample

Gene

Chromosome
199

Start

End

SJHYPER227

IKZF1

7

200

50367310

50367314

Sample

Gene

Chromosome

SJHYPO002

CREBBP

16

201

Start

End

3843416

3843439

Sample

Gene

Chromosome
202

Start

End

SJHYPO040

CREBBP

16

203

3799606

3799632

Sample

Gene

Chromosome

SJINF013

TP53

17

204

Start

End

7577093

7577111

Sample

Gene

Chromosome

SJPHALL020043

SETD2

3

205

Start

End

47147487

47147488

5.3 Children’s Discovery Institute: Utilizing CharGer
to determine novel variants in undiagnosed pediatric
cases

There is an urgent need for improved and quick diagnosis of birth defects. To address
this concern our lab has developed CharGer (unpublished) to assess the pathogenicity
of variants using and automated query of public data sources (example: Clinvar). Using
patient mutation files (example: VCFs) derived from the mother, father and child, we can
derive both de novo and compound heterozygous mutations.

When focusing on de novo variants we are interested in identifying spontaneous
mutations in developmental genes compared to inherited mutations that are derived from
both parents. We also require that mutations have a low frequency in the population
(PM2). In this partial blind study we ran mutation files through the CharGer pipeline
without knowing the associated phenotype. Variants of interest reported through the
pipeline were reported to a physician at Washington University to determine the overlap
between mutations called by an orthogonal gene sequencing service, GeneDx, and those
that were missed.
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To validate our automatic classification, we applied CharGer on a data set of 7 families
with various birth defects in infants and children. For 6 families, CharGer confirmed a
predicted “likely pathogenic” variant reported from GeneDx or followup functional studies
from collaborators. Using variant call format (VCF) from GeneDx we derived mutations
inherited from the mother, father and de novo variants in the child. Variants were filtered
by high population allele frequency (>0.05) derived from 1000 genomes (1KG), Exome
Aggregation Consortium (ExAC) and Exome Sequencing Project (ESP) and reported
variants in our predefined gene list made up of 597 developmental genes (Saunders et
al.,), 625 cancer genes and 11 additional genes identified in GeneDx positive analyses.
CharGer identified 3/6 families as having 'Likely Pathogenic 'candidate variants and the
remaining 3/6 as having 'Unknown Significance’. Furthermore, CharGer identified
additional candidate variants for all 6 families, along with candidate variants for the 7th
GeneDx negative family.
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5.4 Discovery of Novel Fusions in Cancer Genomes

Contribution: I helped oversee the overall development of this project including figure
development and writing.

Cell Rep. 2018 Apr 3;23(1):227-238.e3. doi: 10.1016/j.celrep.2018.03.050.
Driver Fusions and Their Implications in the Development and Treatment of Human
Cancers {(Gao et al., 2018)}.
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5.5 Evaluating Novel Germline Variants in Cancer
Genomes

Contribution: I helped to manually review many germline variants and helped significantly
with the BRCA1 homologous recombination assay for the below publication.

Patterns and functional implications of rare germline variants across 12 cancer types (Lu
et al., 2015).
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5.6 Effect of Blood Somatic Mutations in PPM1D on
TP53 and Cell Cycle Arrest

In 2014, our lab was one of the first to identify blood specific somatic mutations in elderly
patients without any adverse hematopoietic diseases (Xie et al., 2014). After, performing
a similar analysis on additional samples, we identified one novel recurrently mutated gene
with a significant enrichment of blood-somatic mutations. PPM1D is a phosphatase
involved in the dephosphorylation of DNA damage response genes including TP53.
While this gene has been associated with breast and ovarian cancer predisposition, it has
still not yet been reported in hematological malignancies. C-terminal truncating mutations
are predicted to hinder the activation of DNA damage response proteins by enhancing
the dephosphorylation activity of PPM1D. Figure X highlights blood specific mutations
identified across 2,278 patients.

Figure A.1: Blood specific somatic mutations identified in PPM1D
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We hypothesized blood specific mutations in PPM1D disrupt TP53 phosphorylation. To
evaluate this hypothesis, we determined the level of p53 Ser15 phosphorylation of
PPM1D Mutants after radiation treatment (Methods). Under conditions of DNA damage
(ex. Radiation) TP53 is phosphorylated and will activate downstream genes to initiate the
DNA damage response pathway. Normally PPM1D will dephosphorylate TP53, thereby
inactivating the DNA damage response pathway. Without UV treatment you would expect
to see low levels of TP53 phosphorylation. As shown previously in our lab, PPM1D
mutants further decreased Ser15 phosphorylation levels (stronger than WT), suggesting
PPM1D mutants are more “active” than the wild type. Under wild type conditions, we
expect to see a larger number of cells undergoing apoptosis after UV treatment. Under
normal conditions TP53 should be phosphorylated and activated thereby halting the cell
cycle process in response to DNA damage. To evaluate this, we can use propidium iodide
(PI) staining to evaluate cells in various stages of the cell cycle. PI dyes DNA and binds
to DNA in proportion to the amount of DNA present in the cell. Cells in S phase will
therefore have more DNA than cells in G1 and will take up proportionally more dye (more
fluorescence) with a higher amount of DNA content. Cells in G2 should be twice as bright
as cells in G1 phase. Using FACS and the PI dye, we can conditionally sort these cells
using fluorescence.
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Figure A.2. FACS sorted cells from mutant and wildtype treatments after UV
induction.

Table A.2. Predicted results for assay
Strain

TP53 Activity

Cell cycle changes after
UV treatment

BAF3/Null

ON

More cells undergoing
apoptosis

BAF3/WT-PPM1D

On-ish/Off-ish

Less cells undergoing
apoptosis (less dividing
cells)

BAF3/PPM1D-D314A

ON

More cells undergoing

(phosphate dead)

apoptosis
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BAF3/PPM1D-Q520*

More OFF-ish

(activating)

Less cells undergoing
apoptosis

The results from Figure A.2 suggest that blood-specific PPM1D mutants tend to have
higher phosphatase activity against TP53, and prevented the cells from apoptosis after
DNA damage, suggesting that PPM1D mutations were potentially involved in cell
proliferation regulation. Under conditions of BAF3/Null and the D314 phosphatase dead
cell line, we would expect to always see active TP53 which should successfully halt the
cell cycle process therefore more cells in S/G1. With the Q520 mutant, we expect to see
higher expression of PPM1D thereby inactivating TP53 and more cells in G2 phase
(mitotic cells-dividing). TP53 is unable to stop cells from entering the cell cycle even after
DNA damage.

Protocol for Cell Cycle Analysis
Day 1
Prior to starting make sure cells are confluent. Move media to water bath.
1. Transfer cells from flasks to 15 mL tubes. BAF3 cells are a cell suspension cell
line (so most cells are in the media floating around).
2. Spin down 200 rpm for 5 minutes
3. Remove supernatant.
4. Resuspend pellet in 1 mL of appropriate media.
5. Count Cells
a. 1:5 dilution
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b. Add 80 ul of Trypan blue to small tube.
c. Add 20 ul of sample to small tube.
d. Calculate # of cells using hematocytometer. Need to have 10^6 cells
6. Spin down resuspension one more time.
7. Remove supernatant.
8. Add 1000 ul media.
9. Label 6 well plates. One should be UV treated and the other should be no UV.
Set up experiments in duplicates or triplicates if possible.
a. BAF3
b. WT
c. D314A
d. Q520
10. Add 2 mL of media to each well.
11. Add calculated amount of each sample to the appropriate well.
12. Transfer remaining cells back to cell culture flask with 6 mL of media.
13. Incubate Errbody!
Day 2
Wait 24 hours and irradiate the cells with 6 Gy UV
Day 4
Wait 48 hours and harvest cells for fixation
Fixation
1. Remove cells from 6 well plate and move to 15 mL tubes.
2. Centrifuge at 500 rpm for 5 min
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3. Remove supernatant and resuspend cells in 1 mL of media.
4. Count cells.
5. Resuspend at 2x10^6 cells in 1 mL ice cold buffer.
6. Vortex gently, slowly adding the cell suspension dropwise to 9 mL of 70%
ethanol in a 15 mL polypropylene centrifuge tube.
7. Store at 4 degrees C for 24 hours.
Day 5
8. Centrifuge cells at 200 x g, 10 min, 4 degrees Celsius
9. Resuspend pellet in 3 mL cold PBS and transfer to tubes.
10. Wash cells with cold PBS.
11. Resuspend cells in 300-500 ul PI triton staining solution to 10 mL of 0.1 % (v/v)
Triton X-100 (Sigma) in PBS add 2 mg DNAse-free RNAse A.
12. Incubate 37 degrees Celsius for 15 min or for 30 min at 20 degrees Celsius.
13. Transfer tubes to ice or store at 4 degrees Celsius protected from light.
14. Acquire data on flow cytometer within 48 hours.
15. Perform FACS on department of pathology and immunology
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5.7 Discovery of Truncation Mutations Leading to
Protein Alterations

Studying the allele specific expression of nonsense mutations across genes genome wide
will broaden our understanding of rules by which nonsense mediated decay can
effectively degrade a transcript. To study mutation enrichment and degradation efficiency
across cancer types, we propose a novel scoring method using RNA-Sequencing and
whole exome sequencing variant allele fraction ratio as a proxy for allele specific
expression. By comparing case expression to a control dataset in each cancer type, our
analysis has uncovered an enrichment of nonsense mutations predicted to escape
nonsense mediated decay (NMD) and a subset showing evidence of N and C terminally
truncated proteins. Identifying variants that target a transcript for degradation via NMD or
produce a transcript that could be translated to a truncated protein are both clinically
pathogenic. We further expanded our investigation to consider enriched mutations across
mutation types, including missense, silent and splice site variants, to identify activating
and inactivating truncation mutations.

Of note our analysis identified a subset of mutations in a tumor suppressor, STK11, utilize
a downstream start codon to create N terminally truncated proteins lacking the N terminal
localization sequence in lung cancer samples. We propose a novel scoring method using
RNA and DNA variant allele fraction ratio as a proxy for allele specific expression to study
mutation enrichment and degradation efficiency across cancer types.
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Recurrent protein isoforms are shown to be present in prostate, lung, hepatocellular and
tumor samples, but only a small percentage of samples in a few cancer types are shown
to harbor mutations in splicing factors(Brooks et al.; Rajan et al.; Zhang et al.). Since the
dominant isoform present in many tumors are not attributed to mutations in splicing
factors, this directs us to focus on introduced genomic variants that are contributing to
altering splicing patterns. Furthermore, since one-third of alternative splicing events in
human genes are thought to cause NMD(Brogna and Wen; Lewis et al.; Ni et al.; Pan et
al.; Venables; Weischenfeldt et al.; Weischenfeldt et al.), it is vital that we can predict
nonsense mutations that will and won’t be degraded by the introduced mutation.
One-third of SAVs are estimated to introduce a premature termination codon
(PTC), which could lead to dominant negative or gain of function effects. Annotated
nonsense mutations are predicted to create premature termination codons (PTC) in the
resulting transcripts, which are predominantly degraded by the Nonsense Mediated
Decay (NMD) pathway. The general rule of thumb is that PTC’s located at least 50-55 bp
upstream of the last exon-exon junction drive strong NMD, whereas those outside of this
criteria are predicted to escape the degradation process. Finally, as noted in previous
studies, N terminally truncated proteins can lead to translation re-initiation at a
downstream codon, thereby bypassing NMD and creating a product with residual
function. This exception to NMD is known for few genes, but has yet to be characterized
in cancer and genome wide.
Understanding how SAVs can lead to alternative isoforms in tumor samples and
determining if the new transcripts become a target of NMD is still an open area of study.
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Identifying variants that target a transcript for degradation via NMD or produce a splicing
product that could be translated to a truncated protein are both clinically pathogenic. A
pan-cancer analysis of SAVs can expand the current paradigm about the exceptions and
rules by which NMD and splicing are altered in cancer.

Dataset and mutation distribution
Stringent filters (Supplementary Methods) were used to create high quality mutation calls
for 18 cancer types: breast adenocarcinoma (BRCA), bladder urothelial carcinoma
(BLCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC),
colon and rectum adenocarcinoma (COADREAD), glioblastoma multiforme (GBM), head
and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal
clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid
leukemia (LAML), low grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung
adenocarcinoma

(LUAD),

lung

squamous

cell

carcinoma

(LUSC),

Stomach

adenocarcinoma (STAD), thyroid carcinoma (THCA), uterine carcinosarcoma (UCS) and
uterine corpus endometrioid carcinoma (UCEC).
Filters: We collected nonsense mutations predicted to introduce termination codons into
a transcript of interest. We performed RNA-Seq and DNA-Seq readcount analysis to
determine sites that had at least 20X coverage. From the high coverage nonsense
mutation gene set, we collected silent and missense mutations, performed readcount
analysis and filtered out sites with less than 20X coverage. Finally sites with both copy
number and gene expression data available through the Broad GDAC Firehose were
collected for further analysis.
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Our final mutation dataset consisted of 88,845 silent, nonsense and missense mutations
in 5,023 genes across 16 cancer types from 3,129 samples.

Dataset and mutation distribution
Stringent filters (Supplementary Methods) were used to create high quality mutation calls
for 18 cancer types: breast adenocarcinoma (BRCA), bladder urothelial carcinoma
(BLCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC),
colon and rectum adenocarcinoma (COADREAD), glioblastoma multiforme (GBM), head
and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal
clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid
leukemia (LAML), low grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung
adenocarcinoma

(LUAD),

lung

squamous

cell

carcinoma

(LUSC),

Stomach

adenocarcinoma (STAD), thyroid carcinoma (THCA), uterine carcinosarcoma (UCS) and
uterine corpus endometrioid carcinoma (UCEC). We collected 11,952 nonsense
mutations predicted to introduce a premature termination codon into the transcript of
interest. We additionally collected silent and missense mutations in all genes with
nonsense mutations for comparison. Our final mutation dataset consisted of silent,
nonsense and missense mutations in 6,107 genes across 18 cancer types in 3,863
samples. All mutations were collected in copy number neutral sites with at least 20 reads
spanning the site of interest in RNA-Sequencing data and DNA-Sequencing.

Identification of activating nonsense mutations in copy number neutral data
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To evaluate the effect of nonsense mutations on stability, we used a novel method to differentiate
between nonsense mutations degraded and escaping degradation as measured by next
generation sequencing data. We chose to leverage variant allele fractions (VAFs) measured by
DNA and RNA sequencing of the tumor samples to define the relationship between the genomic
position and transcriptome effect. One would expect a comparative relationship between RNA
and DNA VAF if allelic content and transcription were directly proportional. But in practice there
are a number of variables that can cause a deviation from this proportional relationship including
post transcriptional modifications such as RNA degradation.

By comparing the RNA to DNA VAF ratio across exons for nonsense, missense and silent
mutations in copy number neutral regions we can evaluate the positional effect of nonsense
mutations. This comparison between mutation types across exons and genes will highlight exons
of interest that have a higher than expected RNA VAF when compared to DNA VAF and can
potentially be used as a proxy to measure sites that escape nonsense mediated decay.
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Figure A.3. Bar plot of total sites with RNA/DNA VAF Ratio greater than (top) and
less than one (bottom) separated by gene.
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Figure A.3 highlights the top 14 exons found to have the largest number of nonsense mutations
and their RNA/DNA VAF Ratios. Many exons predicted to contain nonsense mutations that
escape NMD are present in the last exon of the gene including ARID1A, AHNAK, APC, SMAD2,
as expected. Of the 2,538 exons from 2,194 genes with at least one nonsense mutation with an
RNA/DNA VAF greater than one, 1,069 of the exons are classified as the last exon of the gene of
interest. This confirmed our first main finding that many nonsense mutations in cancer act as
expected and are degraded effectively by the NMD pathway. Interestingly, there are still a large
number of nonsense mutations that are present at a high variant frequency in RNA and DNA,
suggesting evasion of the degradation pathway. We focused on a set of tumor suppressor genes
that contained a large number of nonsense mutations with high RNA VAF including CDKN2A,
TP53, SMAD2, CREBBP, ARID1A, PTEN, MAP3K1, KMT2C and KMT2D.

A subset of our mutations had available normalized RSEM gene expression data to compare the
gene expression of the case to associated controls. For each of the genes mentioned above, we
compared the case expression of the gene of interest to control samples in the same cancer type,
and also compared genes within the same pathway to identify downstream genes with altered
expression due to the activating truncation mutation. After identifying potential activating
mutations, each mutation was annotated using TransVar(Zhou et al.), a multilevel variant
annotator.

One sample had a mutation in exon 1 of CDKN2A in HNSC and was found to have much higher
expression than control samples. CDKN2A expression leads to activation of INK4A and ARF
which in turn inhibits MDM2, CDK4 and CDK6. Gene expression of the downstream genes
showed significantly decreased expression of MDM2 and CDK6 but lower expression of TP53
and RB1 which should have increased expression with decreased expression of MDM2 and
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CDK6. A closer look at the mutations present in this sample revealed a frame shift insertion in
TP53 and upon inspection of the RNA-Seq showed very few reads spanning TP53 exons and
present in a copy number neutral region and similar findings for RB1 (but without a mutation).

For each gene of interest we identified missense, silent, nonsense and splice site variants
deemed to be activating mutations by our gene expression permutation test. We used a lolliplot
to visualize the predicted activating mutations within each functional domain. Our findings
identified a number of “hotspots” where mutations cluster that create similar truncating activating
mutations.

We defined genes as expressed if they had a RSEM value greater than the lower quartile of the
distribution of RSEM control values. Furthermore, we focused on sites that have RNA and DNA
VAF ratio greater than 1 and RSEM value greater than the lower quartile for the distributed RSEM
control values.

Measuring allele specific expression by integrating RNA and DNA variant allele
fractions
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Figure A.4. Comparison of RNA Variant Allele Fraction and DNA allele fraction by
conventional annotation type. Top panels indicate all sites and bottom panels are only
expressed.
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Figure A.5. Normalized gene expression (RSEM) and variant allele fraction for all
sites.
Table A.3. Total number of variants in each RNA/DNA VAF ratio category
No Filter
Mutation Type

Ratio >=

Ratio < 1 Fisher

1
Missense

Expressed
Ratio >= 1 Ratio < 1 Fisher

(Silent)
33304

24727

8.863e-

Mutation

15
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(Silent)
24632

17556

2.143e12

Nonsense

2219

6329

<2.2e-16

1556

3623

<2.2e-16

11960

10049

-

8793

7150

-

Mutation
Silent Mutation

76,501 mutations fall into copy number neutral sites and 63,489 mutations have case
RSEM greater than the lower quartile of matched cancer control samples lacking
mutations in the gene of interest. We classify these mutations as expressed relative to
their control samples.

We chose to leverage variant allele fractions (VAFs) measured by DNA and RNA
sequencing of the tumor samples to define the relationship between the genomic position
and transcriptome effect. One would expect a comparative relationship between RNA and
DNA VAF if allelic content and transcription were directly proportional. But in practice
there are a number of variables that can cause a deviation from this proportional
relationship including post-transcriptional modifications such as RNA degradation. Figure
A.4 highlights the relationship between DNA and RNA VAF across missense, nonsense
and silent mutations while table 1 gives a numerical representation of the number of
mutations falling above a slope of 1. Nonsense mutations show an increased number of
mutations with higher DNA VAF than RNA VAF, suggesting a higher level of degradation
efficiency compared to missense and silent mutations. Overall we can see a higher level
of RNA VAF enrichment of missense mutations (positive selection) compared to silent
mutations while nonsense mutations show on overall negative selection.
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Using the silent mutation RNA and DNA VAF distribution, we can make the assumption
silent mutations follow a null distribution. We used fishers exact test to compare the
proportion of mutations greater than and less than a RNA DNA VAF Ratio of 1 to
determine if the difference in proportions is significant between both missense and
nonsense with silent mutations as the null distribution.

Novel inactivation of STK11

Figure A.6. Lolliplot of novel inactivating mutations in STK11. Statistics of STK11 variants
below.

227

Figure A.7. All Alternative isoforms of indicated STK11 mutants.

We identified 7 mutations in the canonical transcript of exon in ensembl transcript
ENST00000326873. We used TransVar1 to perform equivalence annotation to map the
mutation of interest to all other transcripts defined by Ensembl based on the genomic
coordinates of the variant. To determine which transcript is readily expressed in the tissue
type, we determined the total number of reads supporting the first and last base of the
exon unique to each Ensembl transcripts. For the example of STK11 we determined
transcript X is expressed in LUAD by assessing number of reads supporting the unique
exon for that transcript.

Studies found that the subcellular localization of kinase deficient mutants were found in
the nucleus while mutants with disrupted NLS were localized in the cytoplasm.
Furthermore, the mutant with the disrupted NLS could still induce G1 cell cycle arrest
comparable to the wild type protein. We hypothesize a subset of nonsense mutations in
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the first exon of STK11 utilize a downstream start codon to create N terminally truncated
proteins lacking the N terminal localization sequence.

Identification of activating mutations using allele specific expression
Our analysis was able to pick up well known activating mutations in key cancer genes
including EGFR. Of the 28 EGFR mutations tested in our gene expression test comparing
case to control gene expression, 16 had RNA VAF greater than 10% suggesting some
level of transcription supporting the variant allele. 9 of the 16 mutations are functionally
characterized activating mutations in EGFR including: L858R4 (4 - LUAD), L861Q (1 LUSC), G719A4 (1 - LUAD), G598A,V (2 –LGG), R108K5 (1 - GBM). Furthermore, a tool
using protein structure guided discovery identified R252C/P (2 – LGG), S768I (1 – LUAD)
and L833V (1 – LUAD) as potential activating mutations due to their proximity to known
activating mutations6.

Kelch-like erythroid cell derived protein with CNC homology (ECH)-associated protein 1
(Keap1) is essential in the regulation of cytoprotective and detoxifying defense systems.
Keap1 is responsible for sequestering nuclear factor erythroid 2-related factor 2 (Nrf2 or
NFE2L2) in the cytoplasm and interacts with Cul3-E3 ubiquitin ligase complex to target
Nrf2 for ubiquitination and degradation by the proteosome. Many mutations in lung cancer
disrupt the binding of Keap1 to Nrf2, thereby increasing the presence of free active Nrf2,
or the degradation efficiency of Nrf2 by disrupting binding to Cul37. In 2014, several
“superbinder” mutants were found to increase the levels of Nrf2 within the nucleus without
disrupting the interaction between KEAP1 and Nrf28. To evaluate how this could be the
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case, the authors looked at protein turnover of Nrf2 and found the superbinder mutants
R320Q and R470C dramatically stabilized Nrf2 more so than the wild-type Keap1 but
maintained successful ubiquitination. This surprising result could suggest that the
increased affinity for Keap1 for Nrf2 suppresses substrate turnover by disrupting a
degradation step post ubiquitination.

Assessing degradation efficiency of nonsense mutations using allele specific
expression

Figure A.8. (A) Allele specific expression denoted by RNA/DNA VAF Ratio of
nonsense mutations across exons. Red corresponds to mutations found in the first
exon, green in middle exon and blue in last exon. Wilcox test was used to compare
groups of nonsense mutations located in the first, middle and last exons of a gene. (B)
RNA/DNA VAF Ratio distribution across all cancer types for mutations found in the
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first, middle and last exons. (C) RSEM distribution across all cancer types for
mutations found in first, middle and last exons.

Nonsense mutations in the last exon tend to have higher allele specific expression than
mutations in another exon, as expected. Interestingly, nonsense mutations in the first
exon show a similar trend as the last exon mutations (higher allele specific expression).
N terminally truncated proteins can lose their localization sequences, thereby altering
the cellular localization of the protein. Studies of β-globin show a very distinct transition
between nonsense mutations in the first exon that are able to bypass NMD and those
that are subject to degradation. The potential of the transcript to evade degradation is
dependent upon the presence of a downstream start codon to reinitiate translation.

All nonsense mutations from the first and last exon were annotated to all possible
transcripts using TransVar to determine mapping potential to alternative isoforms. 143 of
the 207 nonsense mutations annotated to the first exon maintained the nonsense
mutation prediction on alternative isoforms. Of the 143 variants annotated solely to the
first exon, 58 variants had an RNA VAF less than 10% suggesting selection against the
variant allele in the tumor or the presence of a subclonal mutation. The presence of the
remaining 85 variants with greater than 10% RNA VAF supporting the N-terminal
nonsense mutation could be explained by translation readthrough or reinitiation at a
downstream start codon. Two studies reported leak expression when nonsense mutations
were introduced up to residue 70 of the Shaker voltage-gated potassium (Kv) channel10
and residue 26 of B-globin9, suggesting a sharp divide between mutations susceptible
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and resistant to NMD. Both studies came to the conclusion that the likely mechanism is
due to reinitiation of translation at a downstream translation start site, and in the case of
the Kv channel, non-canonical start codons were used (AAG, AGG). Additionally,
translation isn’t limited to the next start codon, but alternative start sites farther
downstream can be used by a fraction of ribosomes.
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5.8 Viral integration
Contribution: I helped with gene expression figures related to discordant pair analysis. All
Figures

and

supplemental

documentation

can

be

seen

in

the

following

publication.

Divergent viral presentation among human tumors and adjacent normal tissues, Scientific
Reports, 2016 Jun. doi:10.1038/srep28294
Cao S., Wendl M., Wyczalkowski M.A., Wylie K., Ye K., Jayasinghe R.G. et al.
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5.9 DROSHA Mutation Analysis

Through this collaboration we identified novel mutations in DROSHA and Dicer and
evaluated RNA-Seq expression for associated downstream products that could be
altered. Of note, for one of the mutated samples, MDM2 expression was increased,
matching our collaborators findings in a patient of interest.

Figure A.9. DICER1_14_95556886_T_G_TCGA-EL-A3GO
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Figure A.10. DICER1_14_95556886_T_G_TCGA-EM-A2CT

Figure A.11. DICER1_14_95557629_T_C_TCGA-EL-AD35
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Figure A.12. Distribution of normalized expression for downstream genes and
DICER1 for mutants vs. control samples

Table A.4: Samples with DROSHA Mutations
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